NEUROPROTECTIVE AGENTS

  1. Neuroprotection by estradiol
  2. Neuroprotection by the inhibition of apoptosis
  3. The problem of assessing effective Neuroprotection in experimental cerebral ischemia
  4. Perinatal brain injury: from pathogenesis to Neuroprotection
  5. Nerve growth factor signaling, Neuroprotection , and neural repair
  6. Neuroprotection by the metabolic antioxidant α-lipoic acid
  7. Adenosine and Neuroprotection
  8. Estrogens and Neuroprotection
  9. Erythropoietin–a novel concept for Neuroprotection
  10. Antioxidant Neuroprotection in Alzheimer’s disease as preventive and therapeutic approach
  11. Neuroprotection against oxidative stress by estrogens: structure-activity relationship
  12. Innate immunity: the missing link in Neuroprotection and neurodegeneration?
  13. Estrogen-mediated Neuroprotection after experimental stroke in male rats
  14. Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of Neuroprotection
  15. Neuroprotection in relation to retinal ischemia and relevance to glaucoma
  16. Bilobalide and Neuroprotection
  17. Endocannabinoids and Neuroprotection
  18. Hibernation, a model of Neuroprotection
  19. Neuroprotection and the ischemic cascade
  20. Is Neuroprotection a viable therapy for glaucoma?
  21. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition
  22. Neuroprotection : heat shock proteins
  23. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation
  24. Endogenous Neuroprotection factors and traumatic brain injury: mechanisms of action and implications for therapy
  25. Drug-mediated Neuroprotection and antiepileptogenesis: animal data
  26. Neuroprotection mediated by changes in the endothelial actin cytoskeleton
  27. Glycine antagonist (gavestinel) in Neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial
  28. Experimental stroke and Neuroprotection in the aging rat brain
  29. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant
  30. Erythropoietin-mediated Neuroprotection involves cross-talk between Jak2 and NF-κ B signalling cascades
  31. Neuroprotection by a caspase inhibitor in acute bacterial meningitis
  32. Testosterone‐mediated Neuroprotection through the androgen receptor in human primary neurons
  33. Glycine antagonist in Neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial
  34. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies
  35. Nonproteolytic Neuroprotection by human recombinant tissue plasminogen activator
  36. Cannabinoids and Neuroprotection in global and focal cerebral ischemia and in neuronal cultures
  37. brain cooling during transient focal ischemia provides complete Neuroprotection
  38. Current status and perspectives of Neuroprotection in ischemic stroke treatment
  39. Neuroprotection with noninvasive neurotrophin delivery to the brain
  40. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat
  41. Cytokines in CNS disorders: neurotoxicity versus Neuroprotection
  42. Caspase inhibitor affords Neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury.
  43. Assessment of the retinal nerve fiber layer in clinical trials of glaucoma Neuroprotection
  44. Glaucoma, apoptosis, and Neuroprotection .
  45. Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep
  46. Neuroprotection by (−)-deprenyl and related compounds
  47. A new concept in the pharmacology of Neuroprotection
  48. Neuroprotection by memantine against neurodegeneration induced by β-amyloid (1–40)
  49. The mitogen-activated protein kinase pathway mediates estrogen Neuroprotection after glutamate toxicity in primary cortical neurons
  50. The role of the complement cascade in ischemia/reperfusion injury: implications for Neuroprotection
  51. Current status of Neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies
  52. Neuroprotection by a bile acid in an acute stroke model in the rat
  53. Neuroprotection and traumatic brain injury: the search continues
  54. Neuroprotection by brain -derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase
  55. Neuroprotection by bromocriptine against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurotoxicity in mice1
  56. Reaction of uric acid with peroxynitrite and implications for the mechanism of Neuroprotection by uric acid
  57. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia
  58. NOS knockouts and Neuroprotection
  59. Glycogen synthase kinase‐3β, mood stabilizers, and Neuroprotection
  60. The potential of Neuroprotection in glaucoma treatment
  61. The pharmacological manipulation of glutamate receptors and Neuroprotection
  62. Interactions of estrogens and insulin-like growth factor-I in the brain : implications for Neuroprotection
  63. Nuclear estrogen receptor-independent Neuroprotection by estratrienes: a novel interaction with glutathione
  64. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-β
  65. Pathways of neuron-astrocyte interactions and their possible role in Neuroprotection
  66. Role of sodium channel inhibition in Neuroprotection : effect of vinpocetine
  67. Neuroprotection for acute stroke: making clinical trials work
  68. Neurotrophins, Neuroprotection and the blood-brain barrier
  69. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt
  70. The future of Neuroprotection
  71. Evaluation of memantine for Neuroprotection in dementia
  72. Neuroprotection in cerebrovascular disease
  73. Subthalamic nucleus‐mediated excitotoxicity in Parkinson’s disease: a target for Neuroprotection
  74. Erythropoietin and the brain : from neurodevelopment to Neuroprotection
  75. Central nicotinic receptors, neurotrophic factors and Neuroprotection
  76. Potential treatment modalities for glaucomatous neuropathy: Neuroprotection and neuroregeneration.
  77. Hematopoietic factor erythropoietin fosters Neuroprotection through novel signal transduction cascades
  78. Hyperalgesia, anxiety, and decreased hypoxic Neuroprotection in mice lacking the adenosine A1 receptor
  79. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease
  80. RGC death in mice after optic nerve crush injury: oxidative stress and Neuroprotection
  81. Inhibition of p38 mitogen‐activated protein kinase provides Neuroprotection in cerebral focal ischemia
  82. Cannabinoids and Neuroprotection
  83. Impact of progestins on estrogen-induced Neuroprotection : synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate
  84. Glia-dependent neurotoxicity and Neuroprotection in mesencephalic cultures
  85. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson’s disease
  86. Dopamine agonists and Neuroprotection in Parkinson’s disease
  87. Caspase activation and Neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation
  88. New horizons in Neuroprotection
  89. Magnesium for Neuroprotection in ischaemic stroke
  90. GABA and Neuroprotection
  91. Vitamin D hormone confers Neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons
  92. Neuroprotection : is it already applicable to glaucoma therapy?
  93. Minocycline provides Neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia
  94. Neuroprotection by the α2-Adrenoreceptor Agonist Dexmedetomidine in a Focal Model of Cerebral Ischemia
  95. Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors
  96. Neuroprotection is unlikely to be effective in humans using current trial designs
  97. Neuroprotection of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients
  98. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers Neuroprotection during chemical ischemia
  99. Action of Glucocorticoids on Survival of Nerve Cells: Promoting Neurodegeneration or Neuroprotection ?1
  100. Detailed characterization of Neuroprotection by a rescue factor humanin against various Alzheimer’s disease-relevant insults
  101. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension
  102. Epilepsy and Neuroprotection : an illustrated review
  103. … system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and Neuroprotection
  104. Monosialogangliosides, Neuroprotection , and neuronal repair processes.
  105. Nuclear factor κB is a critical determinant in N‐methyl‐d‐aspartate receptor‐mediated Neuroprotection
  106. Melatoninergic Neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge
  107. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia.
  108. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for Neuroprotection
  109. Neuroprotection and dopamine agonists
  110. Vaccination for Neuroprotection in the mouse optic nerve: implications for optic neuropathies
  111. Vitamin E and other antioxidants in Neuroprotection
  112. Mechanisms of Neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein
  113. A putative role for platelet-derived growth factor in angiogenesis and Neuroprotection after ischemic stroke in humans
  114. Caspases and Neuroprotection .
  115. Preconditioning-induced Neuroprotection is mediated by reactive oxygen species
  116. Modeling of acute spinal cord injury in the rat: Neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673
  117. The therapeutic potential of the cannabinoids in Neuroprotection
  118. The protease thrombin is an endogenous mediator of hippocampal Neuroprotection against ischemia at low concentrations but causes degeneration at high …
  119. Apoptosis, Neuroprotection , and retinal ganglion cell death: an overview
  120. Endogenous mechanisms of Neuroprotection : role of zinc, copper, and carnosine
  121. The novel β-blocker, carvedilol, provides Neuroprotection in transient focal stroke
  122. Propofol Neuroprotection in a rat model of ischaemia reperfusion injury
  123. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes
  124. Glial cell survival is enhanced during melatonin‐induced Neuroprotection against cerebral ischemia
  125. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack
  126. Neuroprotection by dehydroepiandrosteronesulfate: role of an NFκB-like factor
  127. REVIEW■: Neuroprotection in brain Ischemia: An Update (Part I
  128. Differential mechanisms of Neuroprotection by 17 β-estradiol in apoptotic versus necrotic neurodegeneration
  129. On the mechanisms of Neuroprotection by creatine and phosphocreatine
  130. Current understanding of Neuroprotection in glaucoma
  131. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson’s disease
  132. Neuroprotection by S‐nitrosoglutathione of brain dopamine neurons from oxidative stress
  133. Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and Neuroprotection
  134. Cellular and molecular mechanisms of estrogen regulation of memory function and Neuroprotection against Alzheimer’s disease: recent insights and remaining …
  135. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons
  136. Estrogen provides Neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats
  137. Partial Neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats
  138. Molecular Pathology of Cerebral Ischemia: Delayed Gene Expression and Strategies for Neuroprotection a
  139. Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal
  140. Marked age‐dependent Neuroprotection by brain ‐derived neurotrophic factor against neonatal hypoxic—ischemic brain injury
  141. Modest hypothermia provides partial Neuroprotection for ischemic neonatal brain
  142. Stimulation of β-adrenoceptors activates astrocytes and provides Neuroprotection
  143. Indefatigable CA1 sector Neuroprotection with mild hypothermia induced 6 hours after severe forebrain ischemia in rats
  144. Differential Neuroprotection from human heat shock protein 70 overexpression in in vitro and in vivo models of ischemia and ischemia-like conditions
  145. Dopamine agonists and Neuroprotection in Parkinson’s disease
  146. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos
  147. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for Neuroprotection in stroke and trauma
  148. Inducible nitric oxide synthase expression after traumatic brain injury and Neuroprotection with aminoguanidine treatment in rats
  149. Dopaminergic Neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive …
  150. Medical treatment and Neuroprotection in traumatic brain injury
  151. Autoimmune maintenance and Neuroprotection of the central nervous system
  152. Cellular basis for progesterone Neuroprotection in the injured spinal cord
  153. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats
  154. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism
  155. Neuroprotection by selective nitric oxide synthase inhibition at 24 hours after perinatal hypoxia-ischemia
  156. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells
  157. Alpha-lipoic acid provides Neuroprotection from ischemia-reperfusion injury of peripheral nerve
  158. CDP‐choline: Neuroprotection in transient forebrain ischemia of gerbils
  159. Lithium induces brain -derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for Neuroprotection against glutamate excitotoxicity
  160. Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795
  161. Ca2+ channel antagonists and Neuroprotection from cerebral ischemia
  162. Recombinant human erythropoietin for Neuroprotection : what is the evidence?
  163. Association of serum estrogen level and ischemic Neuroprotection in female rats
  164. Antioxidant property of pramipexole independent of dopamine receptor activation in Neuroprotection
  165. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization
  166. Role of metallothionein and other antioxidants in scavenging superoxide radicals and their possible role in Neuroprotection
  167. Amphiphilic, tri‐block copolymers provide potent, membrane‐targeted Neuroprotection
  168. Neuroprotection by the α2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia
  169. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to Neuroprotection in Parkinson’s disease
  170. Does Neuroprotection improve stroke outcome?
  171. Preconditioning‐induced Neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factor‐κB
  172. Neuroprotection of glial cell line‐derived neurotrophic factor in damaged spinal cords following contusive injury
  173. Neuroprotection by both NMDA and non-NMDA receptor antagonists in in vitro ischemia
  174. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity
  175. Death and Neuroprotection of retinal ganglion cells after different types of injury
  176. Neuroprotection for ischaemic stroke
  177. Neuroprotection of acute ischemic stroke: where are we?
  178. Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and Neuroprotection
  179. Adenosine A2A Receptors and Neuroprotection
  180. Glaucomatous neurodegeneration and the concept of Neuroprotection .
  181. Neuroprotection of S (+) ketamine isomer in global forebrain ischemia
  182. Neuroprotection by melatonin from kainate‐induced excitotoxicity in rats
  183. Neuroprotection by T-cells depends on their subtype and activation state
  184. Neuroprotection at Drosophila synapses conferred by prior heat shock
  185. Prophylactic Neuroprotection for cerebral ischemia.
  186. Relationship between the increased cell surface α7 nicotinic receptor expression and Neuroprotection induced by several nicotinic receptor agonists
  187. brain -derived neurotrophic factor-mediated Neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3′-kinase …
  188. Neuroprotection after several days of mild, drug-induced hypothermia
  189. Estrogen‐mediated Neuroprotection against β‐amyloid toxicity requires expression of estrogen receptor α or β and activation of the MAPK pathway
  190. Progesterone Neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease
  191. Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity
  192. Cerebrolysin® reduces microglial activation in vivo and in vitro: a potential mechanism of Neuroprotection
  193. Lipid alterations in transient forebrain ischemia: Possible new mechanisms of CDP‐choline Neuroprotection
  194. σ Receptor-mediated Neuroprotection against glutamate toxicity in primary rat neuronal cultures
  195. Hyperbaric oxygen preconditioning induces Neuroprotection against ischemia in transient not permanent middle cerebral artery occlusion rat model.
  196. Dendritic spines for Neuroprotection : a hypothesis
  197. Ginkgo biloba Neuroprotection : Therapeutic implications in Alzheimer’s disease
  198. Discovery of endocannabinoids and some random thoughts on their possible roles in Neuroprotection and aggression
  199. brain damage due to episodic alcohol exposure in vivo and in vitro: furosemide Neuroprotection implicates edema‐based mechanism
  200. Neuroprotection
  201. Conjugation of brain -derived neurotrophic factor to a blood–brain barrier drug targeting system enables Neuroprotection in regional brain ischemia following …
  202. Physiological approaches to Neuroprotection : boosting of protective autoimmunity
  203. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein …
  204. Modest hypothermia provides partial Neuroprotection when used for immediate resuscitation after brain ischemia
  205. Differential damage to auditory neurons and hair cells by ototoxins and Neuroprotection by specific neurotrophins in rat cochlear organotypic cultures
  206. Persistent Neuroprotection with prolonged postischemic hypothermia in adult rats subjected to transient middle cerebral artery occlusion
  207. Drug-induced Neuroprotection from global ischemia is associated with prevention of persistent but not transient activation of nuclear factor-kappaB in rats
  208. Erythropoietin exerts Neuroprotection in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production
  209. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector
  210. Differential Neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability …
  211. Combination of intraischemic and postischemic hypothermia provides potent and persistent Neuroprotection against temporary focal ischemia in rats
  212. Accelerated functional recovery and Neuroprotection by agmatine after spinal cord ischemia in rats
  213. Valproate and Neuroprotection
  214. Neuroprotection in acute ischemic stroke
  215. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington’s disease
  216. Is pharmacological Neuroprotection dependent on reduced glutamate release?
  217. Neuroprotection against CA1 injury with metalloporphyrins.
  218. Neuroprotection by methanol extract of Uncaria rhynchophylla against global cerebral ischemia in rats
  219. Symposium overview: the role of glutathione in Neuroprotection and neurotoxicity.
  220. Survival signaling and selective Neuroprotection through glutamatergic transmission
  221. Future of Neuroprotection in Parkinson’s disease
  222. Caffeine’s Neuroprotection against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice
  223. Microglial reaction induced by noncytotoxic methylmercury treatment leads to Neuroprotection via interactions with astrocytes and IL‐6 release
  224. Selective mGluR5 receptor antagonist or agonist provides Neuroprotection in a rat model of focal cerebral ischemia
  225. Neuroprotection in ischemia–reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor
  226. Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia
  227. Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia
  228. Hypoxic-ischemic brain injury in the newborn: cellular mechanisms and potential strategies for Neuroprotection
  229. Oxidative changes in brain pyridine nucleotides and Neuroprotection using nicotinamide
  230. Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral …
  231. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex—a possible mechanism of Neuroprotection in major depression?
  232. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: Neuroprotection and local regeneration
  233. Neuroimmunophilin ligands exert neuroregeneration and Neuroprotection in midbrain dopaminergic neurons
  234. Quantitative assessment of Neuroprotection against NMDA-induced brain injury
  235. Retrograde cerebral perfusion as a method of Neuroprotection during thoracic aortic surgery
  236. Neuroprotection by pigment epithelial‐derived factor against glutamate toxicity in developing primary hippocampal neurons
  237. Group I and group III metabotropic glutamate receptor subtypes provide enhanced Neuroprotection
  238. Nimodipine Neuroprotection in cardiac valve replacement: report of an early terminated trial
  239. Electroencephalographic burst suppression is not required to elicit maximal Neuroprotection from pentobarbital in a rat model of focal cerebral ischemia
  240. Oxidative stress in the pathogenesis of Alzheimer’s disease and antioxidant Neuroprotection
  241. Treatment of acute ischemic stroke: Part II: Neuroprotection and medical management
  242. NMDA recepter-mediated Neuroprotection by essential oils from the rhizomes of Acorus gramineus
  243. Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-κB and Neuroprotection by antioxidants
  244. Nitric oxide is involved in anoxic preconditioning Neuroprotection in rat hippocampal slices
  245. The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo
  246. Mechanism of Action and Persistence of Neuroprotection by Cell-Permeant Ca2+ Chelators
  247. Neuroprotection in Alzheimer’s disease—new strategies for treatment
  248. KATP channel openers, adenosine agonists and epileptic preconditioning are stress signals inducing hippocampal Neuroprotection
  249. Neuroprotection by propofol in acute mechanical injury: role of GABAergic inhibition
  250. Neuroprotection by ketamine at the cellular level
  251. Preconditioning‐mediated Neuroprotection : role of nitric oxide, cGMP, and new protein expression
  252. A specific inhibitor of calcium/calmodulin-dependent protein kinase-II provides Neuroprotection against NMDA-and hypoxia/hypoglycemia-induced cell death
  253. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression: a prominent role in Neuroprotection against excitotoxicity
  254. Estrogen and Neuroprotection : from clinical observations to molecular mechanisms
  255. Pharmacologic Neuroprotection in experimental spinal cord ischemia: a systematic review
  256. Isoflurane Neuroprotection : a passing fantasy, again?
  257. Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity
  258. Estrogen-astrocyte interactions: implications for Neuroprotection
  259. Rapid preconditioning Neuroprotection following anoxia in hippocampal slices: role of the K+ ATP channel and protein kinase C
  260. The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers Neuroprotection
  261. Preconditioning-mediated Neuroprotection through erythropoietin?
  262. Nitric oxide in acute ischaemic stroke: a target for Neuroprotection
  263. Transient ischemia of the retina results in altered retrograde axoplasmic transport: Neuroprotection with brimonidine
  264. Delayed sclerosis, Neuroprotection , and limbic epileptogenesis after status epilepticus in the rat
  265. Animal and culture models of glaucoma for studying Neuroprotection
  266. Neuroprotection in acute ischaemic stroke
  267. Characterization of postischemic behavioral deficits in gerbils with and without hypothermic Neuroprotection
  268. Neuroprotection due to irrigation during bipolar cautery
  269. Corticotropin-releasing hormone-mediated Neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid β …
  270. Is there a rationale for Neuroprotection against dopamine toxicity in Parkinson’s disease?
  271. Dose‐ and time‐dependence of l‐NAME Neuroprotection in transient focal cerebral ischaemia in rats
  272. Nicotine blocks TNF‐α‐mediated Neuroprotection to NMDA by an α‐bungarotoxin‐sensitive pathway
  273. Retracted: Neuroprotection mediated by glial group‐II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol‐3 …
  274. Neuroprotection : a new treatment modality for glaucoma?
  275. Potential signalling pathways underlying corticotrophin‐releasing hormone‐mediated Neuroprotection from excitotoxicity in rat hippocampus
  276. New conceptual approaches for pharmacological Neuroprotection in glaucomatous neuronal degeneration
  277. Hypothermic Neuroprotection : a global ischemia study using 18-to 20-month-old gerbils
  278. Glucose deprivation and chemical hypoxia: Neuroprotection by P2 receptor antagonists
  279. Ischemic preconditioning acts upstream of GluR2 down-regulation to afford Neuroprotection in the hippocampal CA1
  280. N-methyl-D-aspartate receptor-mediated Neuroprotection in cerebellar granule cells requires new RNA and protein synthesis
  281. An improved survival model of hypoxia/ischaemia in the piglet suitable for Neuroprotection studies
  282. Intravenous agents and intraoperative Neuroprotection : beyond barbiturates
  283. p75-mediated Neuroprotection by NGF against glutamate cytotoxicity in cortical cultures
  284. Statins and Neuroprotection
  285. Group I metabotropic glutamate receptors in spinal cord injury: roles in Neuroprotection and the development of chronic central pain
  286. Neuroprotection after focal cerebral ischaemia in hyperglycaemic and diabetic rats
  287. Janus kinase 2, an early target of α7 nicotinic acetylcholine receptor-mediated Neuroprotection against Aβ-(1–42) amyloid
  288. Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco
  289. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis
  290. Anti-oxidative Neuroprotection by estrogens in mouse cortical cultures.
  291. Morphological aspects of spinal cord autoimmune Neuroprotection : colocalization of T cells with B7‐2 (CD86) and prevention of cyst formation
  292. Hypoxia and hypoxia-inducible factor modulated gene expression in brain : involvement in Neuroprotection and cell death
  293. Enoxaparin in experimental stroke: Neuroprotection and therapeutic window of opportunity
  294. Investigations of neurotoxicity and Neuroprotection within the nucleus basalis of the rat
  295. Insulin-like growth factor-1-mediated Neuroprotection against oxidative stress is associated with activation of nuclear factor κB
  296. Neuroprotection is associated with β-adrenergic receptor antagonists during cardiac surgery: evidence from 2,575 patients
  297. Neuroprotection . Models and basic principles
  298. Modulation of neuronal and glial cell function by adenosine and Neuroprotection in vascular demential
  299. Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-κB activation
  300. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B
  301. Where do we stand on Neuroprotection ? Where do we go from here?
  302. Neuroprotection from glutamate toxicity with ultra-low dose glutamate
  303. Estrogen attenuates tumor necrosis factor-α expression to provide ischemic Neuroprotection in female rats
  304. Cellular delivery of trophic factors for the treatment of Huntington’s disease: is Neuroprotection possible?
  305. Brief electrical stimulation of cerebellar fastigial nucleus conditions long-lasting salvage from focal cerebral ischemia: conditioned central neurogenic Neuroprotection
  306. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers Neuroprotection that exceeds the transduced population
  307. Inflammatory cytokines IL-1α, IL-1β, IL-6, and TNF-α impart Neuroprotection to an excitotoxin through distinct pathways
  308. Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil
  309. Hypoglycaemia-induced cell death: features of Neuroprotection by the P2 receptor antagonist basilen blue
  310. The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson’s Disease with Iron …
  311. Age‐and concentration‐dependent Neuroprotection and toxicity by TNF in cortical neurons from β‐amyloid
  312. Head trauma and Neuroprotection
  313. Neuroprotection by estrogen via extracellular signal‐regulated kinase against quinolinic acid‐induced cell death in the rat hippocampus
  314. Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion®)
  315. Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons
  316. Corticostriatopallidal Neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration
  317. Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-β
  318. The dopamine agonist cabergoline provides Neuroprotection by activation of the glutathione system and scavenging free radicals
  319. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides Neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma
  320. Improved Neuroprotection with hypothermia delayed by 6 hours following cerebral hypoxia-ischemia in the 14-day-old rat
  321. T cell immunity to copolymer 1 confers Neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies
  322. The estrogen receptor is not essential for all estrogen Neuroprotection : new evidence from a new analog
  323. Evidence that brain ‐derived neurotrophic factor Neuroprotection is linked to its ability to reverse the NMDA‐induced inactivation of protein kinase C in cortical neurons
  324. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide
  325. Attempts to obtain Neuroprotection in Parkinson’s disease
  326. Neuroprotection of spinal motoneurons following targeted transduction with an adenoviral vector carrying the gene for glial cell line-derived neurotrophic factor
  327. Stress‐inducible protein 1 is a cell surface ligand for cellular prion that triggers Neuroprotection
  328. Combined argatroban and edaravone caused additive Neuroprotection against 15 min of forebrain ischemia in gerbils
  329. Hypoxia, excitotoxicity, and Neuroprotection in the hippocampal slice preparation
  330. Advances in Neuroprotection trials
  331. Stimulus-dependent activation of NF-κB specifies apoptosis or Neuroprotection in cerebellar granule cells
  332. Traumatic Neuroprotection with inhibitors of nitric oxide and ADP-ribosylation
  333. … : an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in Neuroprotection
  334. Acute administration of Ginkgo biloba extract (EGb 761) affords Neuroprotection against permanent and transient focal cerebral ischemia in Sprague‐Dawley rats
  335. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members
  336. Estrogen Neuroprotection : the involvement of the Bcl-2 binding protein BNIP2
  337. Unexpected Neuroprotection observed with the adenosine A2A receptor agonist CGS 21680
  338. Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide Neuroprotection in the MPTP‐mouse model of Parkinson’s disease
  339. Phosphatidylinositol 3‐kinase mediates Neuroprotection by estrogen in cultured cortical neurons
  340. Long-term Neuroprotection by benzodiazepine: full versus partial agonists after transient cerebral ischemia in the gerbil
  341. Role of calcium in sigma-mediated Neuroprotection in rat primary cortical neurons
  342. Dose-dependent Neuroprotection with tiagabine in a focal cerebral ischemia model in rat
  343. Pharmacology of AMPA antagonists and their role in Neuroprotection
  344. Nitric-oxide synthase and neurodegeneration/Neuroprotection
  345. Comparative optic nerve physiology: implications for glaucoma, Neuroprotection , and neuroregeneration.
  346. Design and application of HSV vectors for Neuroprotection
  347. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA‐074: a novel strategy for Neuroprotection based on ‘calpain–cathepsin …
  348. Monitoring for Neuroprotection : new technologies for the new millennium
  349. Assessment of cannabinoid induced gene changes: tolerance and Neuroprotection
  350. Neuroprotection by ATP-dependent potassium channels in rat neocortical brain slices during hypoxia
  351. Neuroprotection with NBQX in rat focal cerebral ischemia. Effects on ADC probability distribution functions and diffusion-perfusion relationships.
  352. Opportunities for Neuroprotection in traumatic brain injury
  353. Strategies for Neuroprotection
  354. Prolonged induction of neuronal NOS expression and activity following cortical spreading depression (SD): implications for SD-and NO-mediated Neuroprotection
  355. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting Neuroprotection in cerebral ischemia through apoptosis reduction …
  356. Neuroprotection by the pyridoindole stobadine: a minireview
  357. Expectations in the treatment of retinal diseases: Neuroprotection
  358. Immortalized dopamine neurons: A model to study neurotoxicity and Neuroprotection
  359. Neuroprotection : the role of neuroglia.
  360. Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: a strategy for Neuroprotection
  361. Neuroprotection against nitric oxide injury with inhibitors of ADP-ribosylation.
  362. Strategies for Neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies.
  363. Neuroprotection in brain Ischemia: An Update (Part II
  364. Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity
  365. Felbamate Neuroprotection against CA1 traumatic neuronal injury
  366. BDNF and NGF afford in vitro Neuroprotection against ethanol combined with acute ischemia and chronic hypoglycemia
  367. Neuroprotection by scatter factor/hepatocyte growth factor and FGF‐1 in cerebellar granule neurons is phosphatidylinositol 3‐kinase/akt‐dependent and MAPK/CREB …
  368. A dose-response study of Neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
  369. Clinical trial update: Neuroprotection against acute ischaemic stroke
  370. Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation
  371. Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view
  372. Harnessing the immune system for Neuroprotection : therapeutic vaccines for acute and chronic neurodegenerative disorders
  373. Neuroprotection by glial cells through adult T cell leukemia-derived factor/human thioredoxin (ADF/TRX)
  374. Monitoring Neuroprotection and restorative therapies in Parkinson’s disease with PET
  375. Dose‐related Neuroprotective effects of chronic nicotine in 6‐hydroxydopamine treated rats, and loss of Neuroprotection in α4 nicotinic receptor subunit knockout mice
  376. Neuroprotection by corticotropin releasing factor during hypoxia in rat brain .
  377. Evaluation of Neuroprotection by lithium and valproic acid against ouabain‐induced cell damage
  378. Do statins afford Neuroprotection in patients with cerebral ischaemia and stroke?
  379. … audiogenic seizures (MDDASs) in adult mice: a nutritional model for discriminatory screening of anticonvulsant drugs and original assessment of Neuroprotection
  380. Multiple pathways of Neuroprotection against oxidative stress and excitotoxic injury in immature primary hippocampal neurons
  381. Optic nerve degeneration and potential Neuroprotection : implications for glaucoma
  382. Gene therapeutic strategies for Neuroprotection : implications for Parkinson’s disease
  383. Toxicity of CSF in motor neurone disease: a potential route to Neuroprotection
  384. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat
  385. AP-1 proteins in the adult brain : facts and fiction about effectors of Neuroprotection and neurodegeneration
  386. Intrinsic neurons of fastigial nucleus mediate neurogenic Neuroprotection against excitotoxic and ischemic neuronal injury in rat
  387. Lidocaine for Neuroprotection : more evidence of efficacy
  388. -Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl)-Piperidine Affords Neuroprotection From Focal Ischemia With Prolonged Reperfusion
  389. Neurotoxicity of polyamines and pharmacological Neuroprotection in cultures of rat cerebellar granule cells
  390. Feasibility and efficacy of balloon-based Neuroprotection during carotid artery stenting in a single-center setting
  391. Oestrogen and nerve growth factor–Neuroprotection and repair in Alzheimer’s disease
  392. brain antioxidant regulation in mammals and anoxia-tolerant reptiles: balanced for Neuroprotection and neuromodulation
  393. Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and Neuroprotection in the central nervous system
  394. Interactions between Hypothermia and the Latency to Ischemic Depolarization Implications for Neuroprotection
  395. Bone morphogenetic proteins are involved in fetal kidney tissue transplantation-induced Neuroprotection in stroke rats
  396. Neuroprotection with anaesthetic agents
  397. Enhanced Neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate
  398. Cellular basis of steroid Neuroprotection in the wobbler mouse, a genetic model of motoneuron disease
  399. Neuroprotection for Parkinson’s disease
  400. Diazepam-induced Neuroprotection : dissociating the effects of hypothermia following global ischemia
  401. Cyclic guanosine 3′, 5′-monophosphate-mediated Neuroprotection by nitric oxide in dissociated cultures of rat dorsal root ganglion neurones
  402. Neuroprotection for Parkinson’s disease: a new approach for a new millennium
  403. Hypothermic Neuroprotection of peripheral nerve of rats from ischaemia–reperfusion injury
  404. Conus peptides and Neuroprotection .
  405. Activation of σ1 receptor subtype leads to Neuroprotection in the rat primary neuronal cultures
  406. Review of clinical trials of Neuroprotection in acute spinal cord injury
  407. Postischemic hypothermia and IL-10 treatment provide long-lasting Neuroprotection of CA1 hippocampus following transient global ischemia in rats
  408. Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia
  409. Spectrin proteolysis in the hippocampus: a biochemical marker for neuronal injury and Neuroprotection
  410. Neuroprotection in acute ischaemic stroke
  411. Neuroprotection by 2-h postischemia administration of two free radical scavengers, α-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN …
  412. Neonatal ischemic Neuroprotection by modest hypothermia is associated with attenuated brain acidosis
  413. Neuroprotection by recombinant thrombomodulin
  414. Iron and neurodegeneration: prospects for Neuroprotection
  415. Neurodegeneration and Neuroprotection in Parkinson’s disease
  416. Neuroprotection in Parkinson’s disease: love story or mission impossible?
  417. Nitric oxide synthase expression in the transient ischemic rat retina: Neuroprotection of betaxolol
  418. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives
  419. Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment
  420. Injury mechanisms in the ischaemic penumbra–approaches to Neuroprotection in acute ischaemic stroke
  421. Calcium antagonists: their role in Neuroprotection
  422. Discovery of molecular mechanisms of Neuroprotection using cell-based bioassays and oligonucleotide arrays
  423. Neuroprotection by peptide growth factors against anoxia and nitric oxide toxicity requires modulation of protein kinase C
  424. Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat
  425. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats.
  426. Role of alpha-2 adrenergic receptors in Neuroprotection and glaucoma
  427. Increased calpain expression is associated with apoptosis in rat spinal cord injury: calpain inhibitor provides Neuroprotection
  428. Studies of damaged processes in the nervous system and possibilities of Neuroprotection
  429. NMDA antagonists: their role in Neuroprotection
  430. cDNA microarray to study gene expression of dopaminergic neurodegeneration and Neuroprotection in MPTP and 6-hydroxydopamine models: implications for …
  431. The rapid effects of estrogen are implicated in estrogen-mediated Neuroprotection
  432. Metallothionein induction in human CNS in vitro: Neuroprotection from ionizing radiation
  433. Neuroprotection and intracellular Ca2+ modulation with fructose-1, 6-bisphosphate during in vitro hypoxia–ischemia involves phospholipase C-dependent signaling
  434. Cerebral Neuroprotection and ketamine
  435. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia
  436. … 4-aryl-3-aminoquinolin-2-ones: a new class of calcium-Dependent, large conductance, potassium (maxi-K) channel openers targeted for post-stroke Neuroprotection
  437. Beneficial autoimmune T cells and posttraumatic Neuroprotection
  438. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model
  439. Neuronal cell death and strategies for Neuroprotection
  440. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3β pathway: Implications for Neuroprotection
  441. Neurogenesis and Neuroprotection in the Adult brain : A Putative Role for 5‐Lipoxygenase?
  442. … (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in Neuroprotection
  443. … precursor protein expression and serotonergic sprouting following excitotoxic lesion of the rat magnocellular nucleus basalis: Neuroprotection by Ca2+ antagonist …
  444. Neuroprotection with felbamate: a 7-and 28-day study in transient forebrain ischemia in gerbils
  445. Neuroprotection and antiepileptogenesis: overview, definitions, and context
  446. Neuroprotection in neuroanesthesia: current practices in Germany
  447. Selegiline: current perspectives on issues related to Neuroprotection and mortality
  448. Early and late molecular events in neurodegeneration and Neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron
  449. Usefulness of postischemic thrombolysis with or without Neuroprotection in a focal embolic model of cerebral ischemia
  450. Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile
  451. Role of potassium channels in the central neurogenic Neuroprotection elicited by cerebellar stimulation in rat
  452. Sodium and potassium channel modulators: their role in Neuroprotection
  453. Liposome-mediated transfer of the bcl-2 gene results in Neuroprotection after in vivo transient focal cerebral ischemia in an animal model
  454. Neuroprotection disappointment yet aGAIN
  455. Les leucomalacies périventriculaires. IL Diagnostic, séquelles et Neuroprotection
  456. Excitotoxicity and Neuroprotection
  457. Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N …
  458. Inhibition of glutamate release: a possible mechanism of hypothermic Neuroprotection
  459. Glutamate-induced excitotoxicity in retina: Neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers
  460. Neuroprotection by melatonin from glutamate‐induced excitotoxicity during development of the cerebellum in the chick embryo
  461. HU-211, a nonpsychotropic cannabinoid, produces short-and long-term Neuroprotection after optic nerve axotomy
  462. Neuroprotection —rationale for pharmacological modulation of Na+-channels
  463. The effect of oedema and tissue swelling on the measurement of Neuroprotection ; a study using chlormethiazole and permanent middle cerebral artery occlusion in …
  464. Neuroprotection : establishing proof of concept in human stroke
  465. Strategies for Neuroprotection against L‐trans‐2,4‐pyrrolidine dicarboxylate‐induced neuronal damage during energy impairment in vitro
  466. Is there Neuroprotection in Parkinson syndrome?
  467. Amyloid protein precursor stimulates excitatory amino acid transport: implications for roles in Neuroprotection and pathogenesis
  468. Neuroprotection failure in stroke
  469. Hypothermia and metabolic stress: narrowing the cellular site of early Neuroprotection .
  470. Neuroprotection with Bcl-220–34 peptide against trauma
  471. In glaucoma, should enthusiasm about Neuroprotection be tempered by the experience obtained in other neurodegenerative disorders?
  472. Therapeutic coma or Neuroprotection by anaesthetics
  473. Cellular and molecular basis of estrogen’s Neuroprotection
  474. VIP Neuroprotection against excitotoxic lesions of the developing mouse brain
  475. Combined Neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia.
  476. No additional Neuroprotection provided by barbiturate-induced burst suppression under mild hypothermic conditions in rats subjected to reversible focal ischemia
  477. … as a stressor in mice:: Against the dopaminergic neurotoxicity of d-mdma, low body weight mitigates restraint-induced hypothermia and consequent Neuroprotection
  478. Modeling pediatric head trauma: mechanisms of degeneration and potential strategies for Neuroprotection
  479. Characterization of Neuroprotection from excitotoxicity by moderate and profound hypothermia in cultured cortical neurons unmasks a temperature-insensitive …
  480. Imaging technologies for assessing Neuroprotection in glaucomatous optic neuropathy
  481. ATP-dependent potassium channel mediates Neuroprotection by chemical preconditioning with 3-nitropropionic acid in gerbil hippocampus
  482. Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia
  483. Neurotoxic action of veratridine in rat brain neuronal cultures: mechanism of Neuroprotection by Ca++ antagonists nonselective for slow Ca++ channels.
  484. Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)‐4‐phosphonophenylglycine
  485. A global hypoxia preconditioning model: Neuroprotection against seizure-induced specific gravity changes (edema) and brain damage in rats
  486. Do dopamine agonists provide Neuroprotection ?
  487. T cell-mediated Neuroprotection involves antithrombin activity
  488. Selective blockade of type-1 metabotropic glutamate receptors induces Neuroprotection by enhancing gabaergic transmission
  489. Transgenic glutathione peroxidase mouse models for Neuroprotection studies.
  490. Metallothionein, neurotrophins and selegiline in providing Neuroprotection in Parkinson’s disease
  491. Neuroprotection against N-methyl-D-aspartate-induced excitotoxicity in rat magnocellular nucleus basalis by the 5-HT1A receptor agonist 8-OH-DPAT
  492. Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats
  493. Retinal neuronal cell death: molecular mechanism and Neuroprotection
  494. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for Neuroprotection studies
  495. Neuroprotection during cardiac surgery: strategies to reduce cognitive decline
  496. Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in Neuroprotection
  497. Vasoprotection as Neuroprotection for the optic nerve
  498. Practical importance of Neuroprotection in Parkinson’s disease
  499. Structure/function in Neuroprotection and apoptosis
  500. Neuroprotection by a novel compound, NS521
  501. A model of ‘epileptic tolerance’for investigating Neuroprotection , epileptic susceptibility and gene expression-related plastic changes
  502. Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl (R) salsolinol, and Neuroprotection by propargylamines
  503. Ketamine racemate and S-(+)-ketamine. Cerebrovascular effects and Neuroprotection following focal ischemia
  504. Neuroprotection for Parkinson’s disease using viral vector-mediated delivery of GDNF
  505. Neuroprotection induced by stimulating A1 or blocking A2A adenosine receptors: an apparent paradox
  506. In vitro Neuroprotection against glutamate-induced toxicity by pGlu-Glu-Pro-NH2 (EEP)
  507. Ketamine and Neuroprotection . Clinical outlook
  508. Intravenous Magnesium for Neuroprotection in Acute Stroke: Clinical Hope Versus Basic
  509. Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity.
  510. Neuroprotection : past successes and future challenges
  511. T cell mediated Neuroprotection is a physiological response to central nervous system insults
  512. Neuroprotection in acute ischaemic stroke. II: Clinical potential
  513. Extradural compression of sensorimotor cortex: a useful model for studies on ischemic brain damage and Neuroprotection
  514. Neuroprotection and antiepileptogenesis: Where are we now?
  515. ACTH/MSH-derived peptides and peripheral nerve plasticity: neuropathies, Neuroprotection and repair
  516. Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke
  517. Neuroprotection by the N‐Methyl‐d‐Aspartate Receptor Antagonist CGP 40116: In Vivo and In Vitro Studies
  518. MCI-186: further histochemical and biochemical evidence of Neuroprotection
  519. Neuroprotection in aortic surgery
  520. Cocaine dependence. A clinical syndrome requiring Neuroprotection .
  521. The effect of reperfusion on Neuroprotection using an inhibitor of poly (ADP-ribose) polymerase
  522. Preclinical studies with modafinil. Evidence for vigilance enhancement and Neuroprotection .
  523. Deleterious effects of IL-9–activated mast cells and Neuroprotection by antihistamine drugs in the developing mouse brain
  524. Neuroprotection against ischemic brain injury conferred by a novel nitrate ester
  525. Hypothermic Neuroprotection of peripheral nerve of rats from ischemia–reperfusion injury: intraischemic vs. reperfusion hypothermia
  526. Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites
  527. Chemokines released from astroglia by vasoactive intestinal peptide. Mechanism of Neuroprotection from HIV envelope protein toxicity.
  528. Neuroprotection in HIV-positive drug users: implications for antioxidant therapy
  529. Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: in vivo model for drug-induced Neuroprotection ?
  530. Possible role of microglial prostanoids and free radicals in Neuroprotection and neurodegeneration
  531. Glutamate-mediated Neuroprotection against N-methyl-D-aspartate toxicity: a role for metabotropic glutamate receptors
  532. Neuroprotection by caspase inhibitors
  533. Opioids: Epilepsy and Neuroprotection
  534. Assessment of neurotoxicity and “Neuroprotection
  535. Evaluation of Neuroprotection and behavioral recovery by the kappa-opioid, PD117302 following transient forebrain ischemia
  536. Neuroprotection by selegiline and other MAO inhibitors
  537. Calcium channel blockers and Neuroprotection
  538. Transcriptional pharmacology of neurodegenerative disorders: novel venue towards Neuroprotection against excitotoxicity?
  539. NO-Related species: Neuroprotection verses neurodestruction
  540. Hydroxyl radicals and nitric oxide in neurotoxicity and Neuroprotection
  541. Neuroprotection in stroke: is it time to consider large-molecule drugs?
  542. Gene transfer for Neuroprotection in animal models of Parkinson’s disease and amyotrophic lateral sclerosis
  543. Neuroprotection of grafted neurons with a GDNF/caspase inhibitor cocktail
  544. Imidazole receptors and clonidine-displacing substance in relationship to control of blood pressure, Neuroprotection , and adrenomedullary secretion
  545. Clinical trials of Neuroprotection in Parkinson’s disease: long-term selegiline and alpha-tocopherol treatment.
  546. Neuroprotection by memantine as increased by hypothermia and nimodipine
  547. Immunosuppressant Analogs in Neuroprotection
  548. Prophylactic pharmacologic Neuroprotection against focal cerebral ischemia.
  549. The pursuit of effective Neuroprotection during infant cardiac surgery
  550. Correlates of delayed neuronal damage and Neuroprotection in a rat model of cardiac-arrest-induced cerebral ischemia
  551. In vitro Neuroprotection against glutamate toxicity provided by novel non‐competitive N‐methyl‐d‐aspartate antagonists
  552. Neuroprotection in idiopathic Parkinson’s disease
  553. Human retina contains polyamine sensitive [3H]-ifenprodil binding sites: implications for Neuroprotection ?
  554. Neuroprotection by dextromethorphan in acute experimental subdural hematoma in the rat
  555. Neuroprotection by anti-oxidant strategies in Parkinson’s disease
  556. Neuroprotection with herpes simplex vectors expressing virally derived anti-apoptotic agents
  557. Emerging strategies in Neuroprotection
  558. Neuroprotection in stroke: Analysis of failure, and alternative strategies
  559. Neuroprotection in ischemia of the retina in an animal model
  560. Neuroprotection by MK-801 in temperature maintained gerbils
  561. … class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and Neuroprotection
  562. Neuroprotection by A2A receptor antagonists
  563. Neuroprotection by R (−)-deprenyl and N-2-hexyl-N-methylpropargylamine on DSP-4, a neurotoxin, induced degeneration of noradrenergic neurons in the rat locus …
  564. Neuroprotection for the new millennium: matchmaking pharmacology and technology
  565. Corticosteroid hormones in Neuroprotection and brain damage
  566. Neuroprotection to the retina: relevance in glaucoma
  567. Quantitative and dynamic MRI of Neuroprotection in experimental stroke
  568. Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative …
  569. Azulenyl nitrones: Colorimetric detection of oxyradical end products and Neuroprotection in the gerbil transient forebrain ischemia/reperfusion model
  570. Delayed multidose treatment with nicotinamide extends the degree and duration of Neuroprotection by reducing infarction and improving behavioral scores up to two …
  571. Cell Death in Spinal Cord Injury (SCI) Requires de Novo Protein Synthesis: Calpain Inhibitor E‐64‐d Provides Neuroprotection in SCI Lesion and Penumbra
  572. Neuroprotection and stroke
  573. Basic neurobiochemical mechanisms of brain Neuroprotection
  574. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides Neuroprotection in the aged parkinsonian rat.
  575. Neuroprotection : fact or fantasy?
  576. Synthesis, brain antihypoxic activity and cell Neuroprotection of 1-substituted-3, 7-dimethylxanthines
  577. Neuroprotection of mild hypothermia: differential effects
  578. Mild hypothermia: an alternative to deep hypothermia for achieving Neuroprotection
  579. Temporal dependent Neuroprotection with propentofylline (HWA 285) in a temporary focal ischemia model
  580. Oxidation of N-methyl (R) salsolinol: involvement to neurotoxicity and Neuroprotection by endogenous catechol isoquinolines
  581. Stereoselective effects of 2, 3-benzodiazepines in vivo: electrophysiology and Neuroprotection studies
  582. The Role of the Metabolism of (−)-Deprenyl in Neuroprotection
  583. Grand prematurity, risk of neuropsychic handicaps and Neuroprotection
  584. Glycosaminoglycans boost insulin-like growth factor-I-promoted Neuroprotection : blockade of motor neuron death in the wobbler mouse
  585. Cell culture models of neuronal degeneration and Neuroprotection
  586. Neuroprotection role of adenosine under hypothermia in the rat global ischemia involves inhibition of not dopamine release but delayed postischemic hypoperfusion
  587. Neuroprotection during hypoxic insults: role of adenosine
  588. Neuroprotection in Parkinson’s disease; a commentary
  589. Neuroprotection (including hypothermia)
  590. Inflammation in stroke—a potential target for Neuroprotection ?
  591. Neuroprotection from focal ischemia by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats
  592. Alcohol Blocks TNFα but Not Other Cytokine‐Mediated Neuroprotection to NMDA
  593. Neuroprotection by LY341122, a novel inhibitor of lipid peroxidation, against focal ischemic brain damage in rats
  594. Unilateral Hypoxic-Ischemic Injury in the Neonatal Rat brain Evaluated by In Vivo MRI: Correlation with Histopathology and Neuroprotection by MK-801
  595. Cellular delivery of trophic factors for the treatment of Huntington’s disease: is Neuroprotection possible?
  596. The environmental estrogenic compound bisphenol A exerts estrogenic effects on mouse hippocampal (HT-22) cells: Neuroprotection against glutamate and amyloid …
  597. Neuroprotection in stroke. A critical overview
  598. Prophylactic Neuroprotection to improve stroke outcome
  599. Learning may provide Neuroprotection against dementia.
  600. Excitotoxicity and Neuroprotection
  601. … motor system: Analyses of motoneuron cell death, motility, and target trophic factor activity and in vitro analyses of neurotoxicity and trophic factor Neuroprotection
  602. Positive modulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors elicits Neuroprotection after trimethyltin exposure in …
  603. Dopamine receptor agonists mediate Neuroprotection in malonate-induced striatal lesion in the rat
  604. Participation of manganese-superoxide dismutase in the Neuroprotection exerted by copper sulfate against 1-methyl 4-phenylpyridinium neurotoxicity
  605. Neuroprotection against excitotoxicity by N-alkylglycines in rat hippocampal neurons
  606. European Stroke Prevention Study-2 results: serendipitous demonstration of Neuroprotection induced by endogenous adenosine accumulation?
  607. Clinical aspects of Neuroprotection in Parkinson’s disease.
  608. Mechanisms of 1S, 3R-ACPD-induced Neuroprotection in rat hippocampal slices subjected to oxygen and glucose deprivation
  609. Dual effect of cerebrolysin in children with attention deficit syndrome with hyperactivity: Neuroprotection and immunomodulation.
  610. Neuroprotection by N-methyl-D-aspartate antagonists in focal cerebral ischemia is dependent on continued maintenance dosing
  611. Metabolism of dehydroepiandrosterone by rat hippocampal cells in culture: possible role of aromatization and 7-hydroxylation in Neuroprotection
  612. The case for Neuroprotection with dopamine agonists
  613. Neuroprotection and perinatal brain care: the field of the future, currently going nowhere!?
  614. Introduction to the special issue on Neuroprotection by steroids: new perspectives
  615. Neurotrophin-mediated Neuroprotection by solid fetal telencephalic graft in middle cerebral artery occlusion: a preventive approach
  616. Hypothermic Neuroprotection in cerebral ischemia
  617. SOD‐1 Transgenic Mice as a Model for Studies of Neuroprotection in Stroke and brain Traumaa
  618. Neuroprotection as initial therapy in acute stroke
  619. Neuroprotection , neuroregeneration, and interaction with insulin‐like growth factor‐I: novel non‐anticoagulant action of glycosaminoglycans
  620. Neuroprotection against ischemia by metabolic inhibition revisited: A comparison of hypothermia, a pharmacologic cocktail and magnesium plus mexiletine
  621. Metallothionein provides ubiquinone-mediated Neuroprotection in Parkinson’s disease
  622. Correlation of CGS 19755 Neuroprotection against in vitro excitotoxicity and focal cerebral ischemia
  623. Immunohistochemical evidence of Neuroprotection by R(−)‐deprenyl and N‐(2‐hexyl)‐N‐methylpropargylamine on DSP‐4‐induced degeneration of rat brain
  624. Neuroprotection after cardiac arrest
  625. Neuroprotection of completely lacerated spinal cord of adult rats by homotopic and heterotopic transplantation
  626. Acidic fibroblast growth factor delays in vitro ischemia-induced intracellular calcium elevation in gerbil hippocampal slices: a sign of Neuroprotection
  627. Noise, Calpain, Calpain Inhibitors, and Neuroprotection : A Preliminary Report of Tinnitus Control.
  628. Current situation of Neuroprotection in stroke
  629. Peptidic endothelin-1 receptor antagonist, BQ-123, and Neuroprotection
  630. Neuroprotection by caffeine and pentoxifylline during experimental cerebral ischaemia.
  631. Neuroprotection against oxidative stress by serum from heat acclimated rats
  632. Central neurogenic Neuroprotection : Protection of brain from focal ischemia by cerebellar stimulation
  633. Stereoselective Neuroprotection by novel 2, 3-benzodiazepine non-competitive AMPA antagonists against non-NMDA receptor-mediated excitotoxicity in primary rat …
  634. Characterization of mianserin Neuroprotection in experimental spinal trauma: dose/route response and late treatment.
  635. Workshop II:“Neuroprotection ”–the Lugano consensus
  636. Neurotrophins and Neuroprotection improve axonal regeneration into Schwann cell transplants placed in transected adult rat spinal cord
  637. Neuroprotection afforded by some hindered phenols and α-tocopherol in guinea-pig detrusor strips subjected to anoxia-glucopenia and reperfusion-like conditions
  638. Increase of ATP levels by glutamate antagonists is unrelated to Neuroprotection .
  639. RS-100642-198, a novel sodium channel blocker, provides differential Neuroprotection against hypoxia/hypoglycemia, veratridine or glutamate-mediated neurotoxicity …
  640. Neuroprotection by aspirin in cerebrovascular pathology
  641. Failure of Neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy)
  642. Intraoperative Neuroprotection
  643. Motor, cytoarchitectural and biochemical assessment of pharmacological Neuroprotection against CNS damage induced by neonatal exposure to ionizing radiation
  644. Prospects for improved Neuroprotection trials in stroke
  645. In vitro Neuroprotection by substituted guanidines with varying affinities for the N-methyl-D-aspartate receptor ionophore and for sigma sites.
  646. Neuroprotection in Acute Stroke: Is there Still Hope?
  647. Heme oxygenase 1 transgenic mice as a model to study Neuroprotection .
  648. Neuroprotection in selective focal ischemia in rats by nitrates, an alternative redox manipulation on nitric oxide: experimental model
  649. Is MK-801 Neuroprotection mediated by systemic hypothermia in the immature rat?
  650. Pharmacological strategies for Neuroprotection and rehabilitation
  651. Blockade of voltage-sensitive Na+ channels by the 5-HT1A receptor agonist 8-OH-DPAT: possible significance for Neuroprotection
  652. Neuroprotection after spinal cord injury: state of the science.
  653. For ischemic brain damage, is preclinical evidence of Neuroprotection by presynaptic blockade of glutamate release enough?
  654. Mechanisms of the Neuroprotection of astrocyte during cerebral ischemic disease
  655. Nitric oxide-mediated mitochondrial impairment in neural cells: a role for glucose metabolism in Neuroprotection
  656. Neuroprotection in acute stroke
  657. Neuroprotection afforded by MK-801 against L-2-chloropropionic acid-induced cerebellar granule cell necrosis in the rat
  658. Neuroprotection , anaesthesia, and the brain
  659. Transforming Growth Factor-β Signaling and Neuroprotection
  660. Neuroprotection in vitro and in vivo by cell membrane-permeant Ca2+ chelators.
  661. Parkinson therapy yesterday, today, tomorrow. Neuroprotection gains in importance
  662. Acid–base management–is it relevant for the study design of hypothermic Neuroprotection ?
  663. Neuroprotection and selective vulnerability of neurons within the nucleus basalis magnocellularis
  664. Physiologic roles for the heme oxygenase products carbon monoxide, bilirubin and iron: links to Neuroprotection in stroke and Alzheimer’s disease
  665. Neuroprotection in acute ischemic stroke. Practicability of guidelines for treatment
  666. IGF-I in neuronal differentiation and Neuroprotection
  667. Periventricular leukomalacia and brain protection. II. Diagnosis, sequelae and Neuroprotection
  668. Primary dissociated cultures of human brain stem cells: a useful tool for their characterization and Neuroprotection study
  669. Excitatory amino acids and Neuroprotection
  670. The glycine binding site of the NMDA receptor: involvement in neurodegeneration and new approach for Neuroprotection .
  671. Membrane-derived lipid second messengers as targets for Neuroprotection : Platelet-activating factor
  672. Strategies and Techniques for Neuroprotection in Coronary Artery Surgery
  673. Neuroprotection for acute ischemic stroke: an overview
  674. Induced mild hypothermia: the spearhead strategy for effective neonatal Neuroprotection ?
  675. Neuroprotection by NMDA and non-NMDA glutamate antagonists
  676. β2‐Adrenoceptor Agonist Clenbuterol Causes NGF Expression and Neuroprotection
  677. ARL-15896, a NovelN-Methyl-D-aspartate Receptor Ion Channel Antagonist: Neuroprotection against Mitochondrial Metabolic Toxicity and Regional Pharmacology
  678. Isoflurane preconditioning induces Neuroprotection against middle cerebral artery occlusion damage in rat
  679. Cannabinoids and Neuroprotection in stroke
  680. Lipid peroxidation blockade: Neuroprotection from cell membranes to humans
  681. Studies on the interaction between 1, 2, 3, 4-tetrahydro-β-carboline and cigarette smoke: a potential mechanism of Neuroprotection for Parkinson’s disease
  682. Neuroprotection reduces the risk of peri-procedural major strokes and death in octogenarians
  683. Neuroprotection of mild hypothermia beginning at different time intervals on cerebral ischemia/reperfusion injury
  684. Pharmacological Characterization of [3H]-Ifenprodil Binding to Polyamine Binding Sites on Rabbit and Rat Retinal Homogenates: Role in Neuroprotection ?
  685. “Low-Tech” Neuroprotection for brain Injury
  686. Neurotrophic factors, Neuroprotection and hypothalamic function
  687. Excitatory and inhibitory pathways for anoxic preconditioning Neuroprotection in hippocampal slices
  688. CNS Neuroprotection
  689. Biomarkers of 3‐nitropropionic acid (3‐NPA)‐induced mitochondrial dysfunction as indicators of Neuroprotection
  690. … -Ischemic (HI) Hypothermia (Ht) Reduces Necrosis and Apoptosis Correspondingly in the Newborn Rat However Restraint Stress Ameliorates Neuroprotection
  691. Neuroprotection in neuro-ophthalmic disease
  692. Excitotoxic cascade and Neuroprotection in various stages of cerebral development
  693. Perioperative Neuroprotection
  694. Molecular mechanisms of Neuroprotection from neuronal death by trophic factor deprivation
  695. Neuroprotection by High Dose Magnesium in CABG Patients: Preliminary Data
  696. Neuroprotection as Initial Therapy in Acute Stroke: Third Report of an Ad Hoc Consensus Group Meeting
  697. Estrogens and other antioxidants in Neuroprotection : implications for Alzheimer’s disease
  698. Neuroprotection for ischemic stroke
  699. Theoretical aspects of Neuroprotection in acute ischaemic stroke. I: basic mechanisms
  700. Neuroprotection EFFECT OF TAURINE IN YOUNG RATS AND THE MECHANISM INVOLVED
  701. Neuroprotection by free radical scavengers and other antioxidants
  702. Neuroprotection during carotid endarterectomy
  703. Hydroxyl radical generation and post-ischemic reperfusion brain damage implications for Neuroprotection
  704. Mild hypothermia as a clinical strategy for Neuroprotection
  705. Neuroprotection by 21-aminosteroids: insights from latencies of anoxic terminal negativity in hippocampus slices of guinea pig
  706. Mitochondrial approaches to Neuroprotection
  707. Antiepileptics and Neuroprotection
  708. Neuroprotection and antiepileptogenesis
  709. Vaccination for T cell‐mediated Neuroprotection : Dream or reality?
  710. Sights set on Neuroprotection for glaucoma
  711. Future perspectives of gender hormones in Neuroprotection
  712. Hyperbaric oxygen preconditioning induces Neuroprotection against ischemia in transient not permanent middle cerebral artery occlusion rat model
  713. Results of two controlled studies on estrogen: avenue to Neuroprotection in schizophrenia
  714. Neuroprotection by neurotrophic factors in apoptosis
  715. Regulation of cyclic AMP synthesis in microglial cells and possible role of cyclic AMP in Neuroprotection
  716. Mild hypothermia provides Neuroprotection in an in vitro model of fetal cerebral ischemia.
  717. Current situation of experimental studies of glaucomatous optic Neuroprotection therapy [J]
  718. Mitochondria: Aspects for Neuroprotection
  719. No Naip: naff Neuroprotection
  720. gp120-Neuroprotection by mernantine
  721. Selective estrogen receptor modulator LY353381. HCl-mediated Neuroprotection and Bcl-2 expression after experimental stroke
  722. Monoamine oxidase inhibition and Neuroprotection by N1‐propargylphenelzine
  723. Plasma and CSF levels of dizocilplne (MK-801) required for Neuroprotection in the quinolinate-injected rat striatum
  724. Neuroprotection in glaucoma. Where is the clinical evidence?
  725. Modeling neurodegeneration and Neuroprotection in hippocampal slices
  726. Treatment of laser-induced retinal injuries by Neuroprotection
  727. Deleterious consequences of corticosteroid exposure: possible therapeutic Neuroprotection
  728. Neuroprotection in cerebral ischemia
  729. Pharmacological treatment of laser eye injuries by Neuroprotection
  730. HIGH PROSTAGLANDIN (PG) LEVELS IN THE PERINATAL PERIOD CONFER Neuroprotection .† 1218
  731. Free radical scavengers in Neuroprotection
  732. Rationale for the use of soy phytoestrogens for Neuroprotection
  733. Neuroprotection of cultured foetal rat hippocampal cells against glucose deprivation: are GABAergic neurons less vulnerable or more sensitive to TCP protection?
  734. Excitotoxicity, cerebral ischemia, and Neuroprotection by competitive NMDA receptor antagonists
  735. Neuroprotection IN ICU
  736. Effect of fractalkine on Neuroprotection
  737. Neuronal death mode switch and neurogenesis as in vivo Neuroprotection
  738. LONG-TERM Neuroprotection BY MATERNALLY-ADMINISTERED MAGNESIUM SULFATE (MgSO 4) IN PRETERM INFANTS IS RELATED TO INITIAL POST …
  739. Experimental and Clinical Neuroprotection : An Update
  740. KN-62 provides Neuroprotection against glutamate-induced excitotoxicity in neurons.
  741. Intraoperative Neuroprotection
  742. … inhibitors in Alzheimer’s disease: An experimental study on mechanisms of interatcion with muscarinic and nicotinic receptors and Neuroprotection
  743. A model of neonatal cerebral ischemia in rats (“levine”) to study Neuroprotection and neuroregeneration,”
  744. Beyond Neuroprotection : the protection of axons and oligodendrocytes in cerebral ischemia
  745. The approach of Neuroprotection for the new millennium
  746. Caroverine Depressesthe Activity of Cochlear Glutamate Receptors (in vivo Model for Drug-Induced Neuroprotection )
  747. Mitochondrial dysfunction in neurodegeneration: prospects for Neuroprotection
  748. Mild and moderate hypothermia for Neuroprotection
  749. Immune-mediated cell death and Neuroprotection in neurodegenerative diseases
  750. Molecular mechanism underlying Neuroprotection by rasagiline
  751. of Neuroprotection in the CNS
  752. Trophic factors, Neuroprotection and spinal cord repair
  753. The Pathophysiology of Stroke: Neuroprotection Following Stroke and Head Injury
  754. Neuroprotection in rabbit retina with N-acetyl-aspartylglutamate and 2-phosphonyl-methyl pentanedioic acid
  755. The role of estrogen receptor subtypes alpha and beta in developmental Neuroprotection and neurotrophism.
  756. Neuroprotection in Neuro-Ophthalmology-Introduction
  757. EARLY CEREBRAL Neuroprotection BY MATERNALLY-ADMINISTERED MAGNESIUM SULFATE (MgSO 4) IN PRETERM INFANTS IS RELATED TO INITIAL …
  758. Central neurogenic regulation of regional cerebral blood flow (rCBF) and relationship to Neuroprotection
  759. Neuroprotection of selective brain hyprothermia to neonates with the hypoxic-ischemic brain damage
  760. Neuroprotection with tetracyclines in brain ischemia models
  761. Lack of Neuroprotection by glutamate antagonist lubeluzole after transient global cerebral ischemia in fetal sheep
  762. Head Cooling and Neuroprotection
  763. Preservation Of Ganglion Cells In Adult Retinal Tissue Cultures-An In Vitro-Model For Neuroprotection
  764. prophylactic Neuroprotection • Design of clinical trials for prophylactic Neuroprotection • Conclusion
  765. Neuroprotection During CPB: From Mechanisms to Interventions
  766. Quantitative DWI analysis of Neuroprotection against soman-induced neuropathology
  767. The Endocannabinoid Anandamide: Metabolism & Neuroprotection
  768. 2 Understanding cerebral energy metabolism: a key to successful Neuroprotection
  769. An inhibitor of injury-induced COX-2 transcriptional activation elicits Neuroprotection in a brain damage model
  770. Substrate and mechanism of central neurogenic Neuroprotection .
  771. Neuroprotection in Parkinson’s Disease
  772. Neuroprotection as a possible therapy in glaucoma
  773. Neuroprotection in cerebral ischemia
  774. Poster Sessions CP11: Neurotoxicity and Neuroprotection
  775. Lubeluzole pretreatment does not provide Neuroprotection against transient global cerebral ischemia in fetal sheep near term
  776. Head Injuries: A Target for Neuroprotection
  777. Neuroprotection and Stroke: Neuroprotectants as initial therapy
  778. New evidence for Neuroprotection by estrogen
  779. Nitric oxide-induced neurotoxicity versus Neuroprotection ; relationship with selective motor neuronal death
  780. Neuroprotection of Excitotoxic brain Lesions in the Newborn Mouse by Glycine Antagonist and Inhibitor of No°. 159
  781. Sex hormones, Neuroprotection and cognition
  782. Neuregulins, Neuroprotection and Parkinson’s Disease
  783. Cerebral ischemia and Neuroprotection from the viewpoint of the neurosurgeon
  784. Hypothermia for Neuroprotection
  785. Probing into signaling transduction mechanisms of ischemic preconditioning based on generality of cardioprotection and Neuroprotection
  786. PPARγ: a new avenue to Neuroprotection
  787. Global cerebral ischemia and Neuroprotection .
  788. Early detection of paracentral defects: Implications for Neuroprotection in primary open-angle glaucoma
  789. Mechanisms of reversible injury and Neuroprotection
  790. Reactive oxygen species mediate Neuroprotection induced by mitochondrial ATP-sensitive potassium channel opener in rat hippocampal slices during hypoxia
  791. Neuroprotection and neurotransplantation strategies in models of Parkinson’s disease
  792. Electrocortical concomitants of Neuroprotection and ischemic damage following cerebral circulatory arrest.
  793. Is Neuroprotection the Next Wave In Glaucoma Management?
  794. NEURODEGENRATION AND Neuroprotection IN SEVERE RETINAL DYSFUNCTION
  795. Possible Mechanisms of Neuroprotection in Response to Diverse Insults
  796. Deep brain Stimulation and Neuroprotection
  797. Neuroprotection in optic neuropathy: assessment of effect
  798. Medical management of head injury and Neuroprotection
  799. Cerebral Ischemia: Pathophysiology and Neuroprotection
  800. An experimental study on the Neuroprotection of magnesium sulfate.
  801. Serum from patients with diabetic neuropathy impairs laminin Neuroprotection by altering laminin receptor integrin expression
  802. Correlation between 5‐HT Content and Uptake Site Density following (S)‐MDMA and Dexfenfluramine‐induced Depletion, and with Neuroprotection by the Glycine …
  803. Neuroprotection : the next step in glaucoma therapy
  804. Neuroprotection in schizophrenia-What does it mean?-What means do we have?
  805. Neuroprotection : Rescuing the brain from endogenous assassins
  806. Physical and Pharmacological Neuroprotection in Cardiac Surgery
  807. Dual-action drug gives good Neuroprotection
  808. Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson’s Disease
  809. Milestones in Neurotoxicity and Neuroprotection : A Tribute to Professor Toshiharu Nagatsu
  810. Neuroprotection : ion flux and receptor mechanisms
  811. Effects of oxidative stress and Neuroprotection in apoptosis in neuronal cell models
  812. Minocycline Provides Neuroprotection
  813. Limiting Apoptosis as a Strategy for CNS Neuroprotection
  814. Neuroprotection : The Next Breakthrough in Glaucoma?
  815. Neuroprotection for acute ischemic stroke: Who is most to blame for current failure?
  816. Angiotensin II receptors: New targets for Neuroprotection
  817. Neuroprotection in an animal model of retinal ischemia
  818. Carotid artery stenting with Neuroprotection : a single center experience
  819. Pay attention to the study and clinical application of Neuroprotection for retinal diseases
  820. Combined Neuroprotection /Thrombolysis in Acute Stroke
  821. Partial Neuroprotection to oxidative stress by selective antioxidants in culture
  822. Insulin, Hypoglycemia, and Ischemic Neuroprotection
  823. Neuroprotection From Op-Induced Seizures and Neuropathology.
  824. Neuroprotection effect of taurine in young rats and the mechanism involved
  825. Blood perfusion-independent Neuroprotection induced by antiplatelet agents and its gender-difference
  826. Expression and Neuroprotection of Vascular Endothelial Growth Factor in an in vitro Ischemia
  827. Neuroprotection by Drug-Induced Neurotrophic Factors
  828. The study of Neuroprotection of bcl-2 gene by transfecting it into PC12 cell line
  829. Novel mediators of ischemic preconditioning induced Neuroprotection
  830. c‐DNA Microarray to determine molecular events in neurodegeneration and Neuroprotection
  831. Combining Neuroprotection with thrombolysis: how to translate laboratory success to our clinical trials
  832. Neuroprotection and Stroke: Stroke and the role of the emergency physician
  833. Transcriptional mechanisms of Neuroprotection by iron chelators
  834. Neuroprotection IN CNS DISEASES. 1997. Edited by PR Bar and M. Flint Beal. Published by Marcel Dekker Publishers. 585 pages. $ C241. 00
  835. Neuroprotection With NPS1506, A Novel NMDA Receptor Antagonist: 605
  836. Novel players in Neuroprotection and tissue reorganisation after hippocampal lesion
  837. Neuroprotection for Nerve Agent-Induced brain Damage
  838. Putative mechanisms of cortical spreading depression-induced Neuroprotection .
  839. Neurochemical Changes Following Stroke: Role in Neuroprotection and Cardiac Susceptibility
  840. Blood perfusion-independent Neuroprotection induced by antiplatelet agents and its gender-difference
  841. Neuroprotection and Functional Alterations in Mice Over-Expressing Heat Shock Protein 70i
  842. An investigation into the mechanism responsible for clomethiazole-induced Neuroprotection in a rat model of severe global ischemia.
  843. Neuroprotection : A Society of Cardiovascular Anesthesiologists Monograph
  844. Molecules for Neuroprotection and Regeneration in Animal Models of Parkinson’s Disease
  845. Neuroprotection from brain Injury by Novel Estrogens
  846. Neuroprotection of retinal ganglion cells in experimental models of glaucoma. A review
  847. Results of two controlled studies on estrogen: avenue to Neuroprotection in schizophrenia
  848. Neuroprotection by Progesterone Through Simulation of Mitochondrial Gene Expression
  849. Postmortem interval and anesthetic Neuroprotection in regenerating cortical neuron cultures used as a model for TNF Neuroprotection from beta-amyloid toxicity.
  850. Assessment of ischemic damage and Neuroprotection in an experimental model of forebrain ischemia
  851. Diltiazem-Induced Neuroprotection in an In Vitro Model of Photoreceptor Degeneration
  852. Neuroprotection from delayed post-ischemic administration of a metalloporphyrin catalytic antioxidant in the rat
  853. Neuroprotection Profile of the High Affinity NMDA Receptor Antagonist Conantokin-G
  854. Neuroprotection by heat shock protein 27 in sensory and motor neurons
  855. The Neuroprotection effects of basic fibroblast growth factor on focal cerebral ischemia in rats and the expression of bax
  856. Neuroprotection of Propofol during an In Vitro Cerebral Ischemia: Glutamate Transporters Are a Major Target
  857. Interactions Between Hypothermia and the Latency to Ischemic Depolarization: Implications for Neuroprotection
  858. Prenatal Choline Supplementation Modifies brain Development: Improved cognition and Neuroprotection
  859. East of England Neonatal Neuroprotection Guideline Diagnosis & Management of Neonatal Seizures in the Term Infant
  860. Delayed post ischemic hypothermia: A six month survival study using behavioral and histological assessments of Neuroprotection
  861. Neuroprotection of Hypothermia in Full Term Neonates After Asphyxia: a Safety Study
  862. The Neuroprotection effects of basic fibroblast growth factor on focal cerebral ischemia in rats and the expression of bax
  863. Neuroprotection with the N-methyl-D-aspartate antagonist dizocilpine (MK-801) in a model of focal ischaemia
  864. Estrogen provides Neuroprotection in focal cerebral ischemia modulation and bcl-2 protein expression
  865. Role of intracellular calcium in neuronal death following cerebral ischemica: Neuroprotection by dantrolene and BCL-2.
  866. Neuroprotection by Selective Nitric Oxide Synthase Inhibition at 24 Hours After Perinatal Hypoxia-Ischemia
  867. Electrophysiologic Evidence of Functional Neuroprotection of Photoreceptors by X-Linked Inhibitor of Apoptosis (XIAP) in a Chemotoxic Model of Retinal …
  868. Hippocampal Expression of a Human GRINL1A Complex Transcription Unit (CTU) Splice Variant Suggests a Role in Neuroprotection
  869. Apoptotic degeneration induction in retinal cells by acute ocular hypertension and Neuroprotection by troxolol
  870. The Neuroprotection effect of acute infective brain edema induced by pertussis bacilli in rat
  871. MODULATION OF CEREBRAL BLOOD FLOW IS NOT THE MECHANISM OF Neuroprotection IN TRANSGENIC MICE OVER EXPRESSING HUMAN …
  872. Tumor necrosis factor appear the Neuroprotection through the enhancement of transient outward potassium currents in cultured rat cortical neurons
  873. … family is the largest and fastest-growing family of ion channels. Evidence is accumulating that modulation of potassium channels is a new approach to Neuroprotection
  874. Neuroprotection for Parkinson’s disease using viral vector-mediated delivery of GDNF
  875. Nimodipine Neuroprotection does not decrease thromboxane release following global cerebral ischemia
  876. ESTROGEN PROVIDES PERFUSION-INDEPENDENT Neuroprotection IN RAT TRANSIENT FOREbrain ISCHEMIA
  877. Mechanisms of dopamine D2-induced Neuroprotection against glutamate neurotoxicity in rat mesencephalon
  878. Neuroprotection of 1400W, a Selective Inhibitor of Inducible Nitric Oxide Synthetase in Rat after Traumatic brain Injury
  879. Chromosome Mapping of the Human Homologue of a New Glutamate Receptor Gene Suggests Roles in Neuroprotection and Autism
  880. Investigation of sigma and dextromethorphan-like Neuroprotection using glutamate-induced LDH release, cellular morphology and dynamic calcium signaling.
  881. 11 Beyond NMDA antagonists: looking to the future of Neuroprotection
  882. Neuroprotection of Progesterone on the Hippocampal Neurons of Gerbil Following Transient Forebrain Ischemia
  883. Delayed neurodegeneration induced by extracellular lactacidity and Neuroprotection by basic fibroblast growth factor in rat hippocampal neurons
  884. Neuroprotection effects of exogenous adrenomedullin against hypoxic-ischemia reperfusion brain damage in neonatal rats
  885. Outcome From Temporary brain Artery Clipping Using Etomidate or Desflurane for Neuroprotection
  886. Mechanisms of cerebral injury and strategies for Neuroprotection following deep hypothermic circulatory arrest in the neonatal piglet
  887. Poster Sessions CP11: Neurotoxicity and Neuroprotection . Secretory phospholipase A2 signalling partly overlaps glutamate‐mediated events
  888. Roles of hypoxia regulated genes/protein in Neuroprotection against hypoxia injury in differentiated SH-SY5Y cells preconditioned with CoCl_2
  889. Nitric oxide synthase is required for nerve growth factor-mediated Neuroprotection in cerebellar granule cell cultures [J]
  890. Neuroprotection in the hibernating brain : tissue trauma and glutamate studied by microdialysis
  891. DEXAMETHASONE Neuroprotection IS ASSOCIATED WITH PRESERVED EXPRESSION OF BCL-2 AND SUPPRESSION OF GLIAL FIBRILLARY ACID …
  892. Development of novel treatment against glaucoma; Intraocular pressure-lowering by cytoskeletal drugs and Neuroprotection by neurotrophic factors.
  893. … of mild hypothermia-assisted stereotactic hematoma puncture and catheter drainage on postoperative intracranial pressure and Neuroprotection in elderly patients …
  894. Alzheimer’s Disease–Neuroprotection
  895. Blockade of the N-methyl-D-aspartate-type glutamate receptor in the animal: Target for Neuroprotection in head trauma and brain ischemia
  896. Low-dose dipyridamole infusion acutely increases exercise capacity in angina pectoris-serendipitous demonstration of Neuroprotection induced by endogenous …
  897. Serotonin (5-HT)1A Receptor Agonists and Neuroprotection
  898. Acidosis and Neuroprotection in two types of acidosis model rats under isoflurane anesthesia: evaluation of blood flow, pH and amino acid levels in the cortex
  899. GABA and Neuroprotection : Do GABAergic circuitries play a critical role in the regulation of seizure-induced neuronal damage and synaptic reorganization in the rat …
  900. Enhancement of entorhinal-dentate evoked potentials following repeated electroconvulsive shock seizures in the rat, Neuroprotection studies
  901. Akerud P, Canals JM, Snyder EY, et al. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of …
  902. α‐Amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid‐mediated Neuroprotection requires TRKB receptor activation
  903. … Resource Utilization in the Three Months after Acute Stroke: A Report on 1604 Patients from the Glycine Antagonist in Neuroprotection (GAIN) Americas Trial
  904. Erratum: Sheardown MJ, Knutsen LJS (1996): Unexpected Neuroprotection observed with the adenosine A2A receptor agonist CGS 21680. Drug Dev Res 39:108 …
  905. Posthypoxic hypothermia for 24 hrs in unsedated newborn pigs gives no Neuroprotection
  906. 5 Selective modulation of voltage-gated sodium channels: a rational approach for Neuroprotection
  907. Identification of a novel synergistic interaction between 17 B-estradiol and glutathione in Neuroprotection .
  908. Neurotoxicity and clonal mouse hippocampal cell line (HT-22): Neuroprotection by tamoxifen, bisphenol-A and pregnenalone.
  909. … ICAM-1 MONOCLONAL ANTIBODY DECREASES LEUKOCYTE RECRUITMENT AND INFILTRATION AND OFFERS Neuroprotection AFTER SPINAL CORD …
  910. 398. Non-Viral Gene Delivery to the Primate CNS: A Model for Pre-Operative Neuroprotection
  911. 21 Neuroprotection IN HEAD INJURY
  912. … of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for Neuroprotection
  913. 907 Potent O1-Receptor Ligand, PPBP [4-Phenyl-1-(4-Phenylbutyl) piperidine] Affords Neuroprotection From Focal Ischemia and Prolonged Reperfusion
  914. Neuroprotection by flavonoids
  915. Ischemic tolerance and endogenous Neuroprotection
  916. Neuroprotection and neurodegenerative disease
  917. Neurosphere-derived multipotent precursors promote Neuroprotection by an immunomodulatory mechanism
  918. Neuroprotection for ischemic stroke: two decades of success and failure
  919. Neuroprotection in cerebral ischaemia: facts and fancies–the need for new approaches
  920. Estrogen and ischemic Neuroprotection : an integrated view
  921. Neuroprotection in glaucoma.
  922. Astrocyte apoptosis: implications for Neuroprotection
  923. Mechanisms of radiation injury to the central nervous system: implications for Neuroprotection
  924. Neuroprotection in experimental stroke with targeted neurotrophins
  925. Multifunctional activities of green tea catechins in Neuroprotection
  926. Heat shock proteins and Neuroprotection
  927. VEGF: once regarded as a specific angiogenic factor, now implicated in Neuroprotection
  928. Neuroprotection and acute spinal cord injury: a reappraisal
  929. Neuroprotection by tetracyclines
  930. Molecular and cellular mechanisms of Neuroprotection by vascular endothelial growth factor
  931. β-Lactam antibiotics offer Neuroprotection by increasing glutamate transporter expression
  932. Optic nerve and Neuroprotection strategies
  933. Neurodegeneration and Neuroprotection in Parkinson disease
  934. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions
  935. Bioenergetic approaches for Neuroprotection in Parkinson’s disease
  936. Lithium Neuroprotection : molecular mechanisms and clinical implications
  937. Critical appraisal of Neuroprotection trials in head injury: what have we learned?
  938. A focus on the synapse for Neuroprotection in Alzheimer disease and other dementias
  939. From clinical evidence to molecular mechanisms underlying Neuroprotection afforded by estrogens
  940. Microglia and Neuroprotection : implications for Alzheimer’s disease
  941. Neuroprotection by KATP channels
  942. Fibroblast growth factors and Neuroprotection
  943. Hypothermia for Neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis
  944. (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and Neuroprotection
  945. Cannabinoid receptors and their role in Neuroprotection
  946. Effect of magnesium sulfate given for Neuroprotection before preterm birth: a randomized controlled trial
  947. Quinol-based cyclic antioxidant mechanism in estrogen Neuroprotection
  948. VEGF-induced Neuroprotection , neurogenesis, and angiogenesis after focal cerebral ischemia
  949. Mechanisms of hyperbaric oxygen and Neuroprotection in stroke
  950. Neuroprotection by osteopontin in stroke
  951. The TREK K2P channels and their role in general anaesthesia and Neuroprotection
  952. Neuroprotection in Parkinson’s disease: clinical trials
  953. Neuroprotection from the collateral perspective.
  954. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels
  955. Neuroprotection by crocetin in a hemi-parkinsonian rat model
  956. Lost in translation: taking Neuroprotection from animal models to clinical trials
  957. Mitochondria in cell death: novel targets for Neuroprotection and cardioprotection
  958. Neuroprotection by adenosine in the brain : From A1 receptor activation to A2A receptor blockade
  959. Lipid signaling in neural plasticity, brain repair, and Neuroprotection
  960. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice
  961. Neuroprotection associated with running: is it a result of increased endogenous neurotrophic factors?
  962. Catechin polyphenols: neurodegeneration and Neuroprotection in neurodegenerative diseases
  963. Pharmacological inhibition of AMP-activated protein kinase provides Neuroprotection in stroke
  964. Erythropoietin: a candidate compound for Neuroprotection in schizophrenia
  965. Neuroprotection by bioactive components in medicinal and food plant extracts
  966. Lipid signaling: sleep, synaptic plasticity, and Neuroprotection
  967. Activation of complement in the central nervous system: roles in neurodegeneration and Neuroprotection
  968. Molecular mechanisms of light-induced photoreceptor apoptosis and Neuroprotection for retinal degeneration
  969. Control of nerve agent-induced seizures is critical for Neuroprotection and survival
  970. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, Neuroprotection : the 2002 Thomas Willis Lecture
  971. Mechanisms of ischemic Neuroprotection by acetyl-L-carnitine
  972. A role for hypoxia-inducible factor-1α in desferoxamine Neuroprotection
  973. The mechanism of Neuroprotection by topiramate in an animal model of epilepsy
  974. Xenon and hypothermia combine to provide Neuroprotection from neonatal asphyxia
  975. Inhibition of GSK3β is a common event in Neuroprotection by different survival factors
  976. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for Neuroprotection in stroke
  977. Antiepileptic drugs and Neuroprotection : current status and future roles
  978. Neurogenic Neuroprotection
  979. Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radical‐scavenging activity
  980. Immunomodulation in multiple sclerosis: from immunosuppression to Neuroprotection
  981. Dual effects of nicotine on oxidative stress and Neuroprotection in PC12 cells
  982. Akt contributes to Neuroprotection by hypothermia against cerebral ischemia in rats
  983. Neuroprotection by estrogen in animal models of global and focal ischemia
  984. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage
  985. Prion protein accumulation and Neuroprotection in hypoxic brain damage
  986. Anaesthesia induced Neuroprotection
  987. Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation
  988. Nanotechnology approaches for the regeneration and Neuroprotection of the central nervous system
  989. The potential of minocycline for Neuroprotection in human neurologic disease
  990. Mechanism of estrogen-mediated Neuroprotection : regulation of mitochondrial calcium and Bcl-2 expression
  991. Organotypic hippocampal slice cultures for studies of brain damage, Neuroprotection and neurorepair
  992. Participation of adenosine receptors in Neuroprotection .
  993. Erythropoietin: novel approaches to Neuroprotection in human brain disease
  994. Neuroprotection in ophthalmology: a review
  995. Mechanisms of hyperbaric oxygen-induced Neuroprotection in a rat model of subarachnoid hemorrhage
  996. Antiepileptic drugs in Neuroprotection
  997. Regulation of body temperature and Neuroprotection by endogenous interleukin-6 in cerebral ischemia
  998. Cell cycle inhibition provides Neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury
  999. The role of α‐synuclein in both Neuroprotection and neurodegeneration
  1000. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport
  1001. Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members
  1002. brain edema induced by in vitro ischemia: causal factors and Neuroprotection
  1003. Effect of two different Neuroprotection systems on microembolization during carotid artery stenting
  1004. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats
  1005. Estrogen activates classical and alternative mechanisms to orchestrate Neuroprotection
  1006. Neuroprotection by a selective estrogen receptor β agonist in a mouse model of global ischemia
  1007. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways
  1008. Neuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity
  1009. Protective autoimmunity and Neuroprotection in inflammatory and noninflammatory neurodegenerative diseases
  1010. Interactions between the cells of the immune and nervous system: neurotrophins as Neuroprotection mediators in CNS injury
  1011. Carotid artery stenting with Neuroprotection : assessing the learning curve and treatment outcome
  1012. Purines and Neuroprotection
  1013. Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia
  1014. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis
  1015. α2-Adrenoceptor agonists: shedding light on Neuroprotection ?
  1016. Optimal delivery of minocycline to the brain : implication for human studies of acute Neuroprotection
  1017. Physiological roles of hydrogen sulfide: synaptic modulation, Neuroprotection , and smooth muscle relaxation
  1018. Prophylactic creatine administration mediates Neuroprotection in cerebral ischemia in mice
  1019. Neurogenesis and Neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis
  1020. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in Neuroprotection
  1021. Forebrain -specific neuronal inhibition of nuclear factor-κB activity leads to loss of Neuroprotection
  1022. Signal transduction pathways implicated in neural recognition molecule L1 triggered Neuroprotection and neuritogenesis
  1023. Incipient neurovulnerability and Neuroprotection in early psychosis
  1024. Rasagiline: neurodegeneration, Neuroprotection , and mitochondrial permeability transition
  1025. Neuroprotection in Huntington’s disease: a 2-year study on minocycline
  1026. Role of mitochondria in neuronal cell death induced by oxidative stress; Neuroprotection by Coenzyme Q10
  1027. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons
  1028. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke
  1029. Targeting mitochondrial ATP-sensitive potassium channels—a novel approach to Neuroprotection
  1030. Choroid plexus megalin is involved in Neuroprotection by serum insulin-like growth factor I
  1031. A preclinical view of cholinesterase inhibitors in Neuroprotection : do they provide more than symptomatic benefits in Alzheimer’s disease?
  1032. Transforming Growth Factor-β1-Mediated Neuroprotection against Excitotoxic Injury in Vivo
  1033. Indicators of Neuroprotection with galantamine
  1034. Erythropoietin exerts Neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings
  1035. Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for Neuroprotection
  1036. CB1 cannabinoid receptors are involved in Neuroprotection via NF-κB inhibition
  1037. Calpain in the pathophysiology of spinal cord injury: Neuroprotection with calpain inhibitors
  1038. Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive Neuroprotection induced by chronic fenofibrate treatment
  1039. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease
  1040. Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin
  1041. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic Neuroprotection
  1042. Methodological quality of animal studies on Neuroprotection in focal cerebral ischaemia
  1043. Astrocyte mitochondrial mechanisms of ischemic brain injury and Neuroprotection
  1044. Paraquat induces oxidative stress and neuronal cell death; Neuroprotection by water-soluble Coenzyme Q10
  1045. Estrogen activates protein kinase C in neurons: role in Neuroprotection
  1046. Pharmacologic Neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma
  1047. Blockade of gap junctions in vivo provides Neuroprotection after perinatal global ischemia
  1048. Clinical perspectives: Neuroprotection lessons from hypoxia-tolerant organisms
  1049. Isoflurane preconditioning induces Neuroprotection against ischemia via activation of P38 mitogen-activated protein kinases
  1050. Signal transduction pathways involved in melatonin‐induced Neuroprotection after focal cerebral ischemia in mice
  1051. Neuroprotection by hyperbaric oxygenation after experimental focal cerebral ischemia monitored by MRI
  1052. Creatine therapy provides Neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice
  1053. Antiepileptogenesis, Neuroprotection , and disease modification in the treatment of epilepsy: focus on levetiracetam
  1054. Effect of Antioxidant Flavanone, Naringenin, from Citrus junos on Neuroprotection
  1055. Is white matter involved in patients entered into typical trials of Neuroprotection ?
  1056. Some current ideas on the pathogenesis and the role of Neuroprotection in glaucomatous optic neuropathy
  1057. A novel mechanism of FK506‐mediated Neuroprotection : downregulation of cytokine expression in glial cells
  1058. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for Neuroprotection /neurodegeneration …
  1059. Magnesium Neuroprotection is limited in humans with acute brain injury
  1060. Isoflurane preconditioning induces Neuroprotection that is inducible nitric oxide synthase–dependent in neonatal rats
  1061. Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for Neuroprotection in Alzheimer’s disease.
  1062. Activin: an important regulator of wound repair, fibrosis, and Neuroprotection
  1063. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia
  1064. Endogenous Neuroprotection in the retina
  1065. Involvement of tyrosine kinases and STAT3 in Humanin-mediated Neuroprotection
  1066. Neuroprotection by Brazilian green propolis against in vitro and in vivo ischemic neuronal damage
  1067. Delayed secondary phase of peri-infarct depolarizations after focal cerebral ischemia: relation to infarct growth and Neuroprotection
  1068. Neuroprotection and neurorescue against Aβ toxicity and PKC‐dependent release of non‐amyloidogenic soluble precursor protein by green tea polyphenol (‐) …
  1069. Effects of estrogen on brain development and Neuroprotection —implications for negative symptoms in schizophrenia
  1070. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for Neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative …
  1071. Neuroprotection in hypothermia linked to redistribution of oxygen in brain
  1072. Melatonin‐induced Neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late‐phase activation of NF‐κB and AP‐1
  1073. CD4-positive T cell-mediated Neuroprotection requires dual compartment antigen presentation
  1074. Neuroprotection in brain and spinal cord trauma
  1075. TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: Neuroprotection by NFκB inhibition
  1076. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia
  1077. brain nitric oxide and its dual role in neurodegeneration/Neuroprotection : understanding molecular mechanisms to devise drug approaches
  1078. Nicotinic acetylcholine receptor-mediated Neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons
  1079. Thioredoxin as a neurotrophic cofactor and an important regulator of Neuroprotection
  1080. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: Potential strategies for Neuroprotection 1
  1081. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: Neuroprotection of dopaminergic neurons
  1082. Topiramate extends the therapeutic window for hypothermia-mediated Neuroprotection after stroke in neonatal rats
  1083. Neurodegeneration and Neuroprotection in glaucoma: development of a therapeutic Neuroprotective vaccine: the Friedenwald lecture
  1084. Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious Neuroprotection in the postischemic brain
  1085. Rise and fall of minocycline in Neuroprotection : need to promote publication of negative results
  1086. Free radical trapping as a therapeutic approach to Neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers
  1087. Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway
  1088. Pharmacology update/Neuroprotection for ischemic stroke
  1089. Differential effects of ethanol antagonism and Neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity
  1090. Neuroprotection against transient cerebral ischemia by exercise pre-conditioning in rats
  1091. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson’s disease
  1092. … hippocampal slice cultures: a model system to study basic cellular and molecular mechanisms of neuronal cell death, Neuroprotection , and synaptic plasticity
  1093. BDNF-induced white matter Neuroprotection and stage-dependent neuronal survival following a neonatal excitotoxic challenge
  1094. Neuroprotection of photoreceptors by minocycline in light-induced retinal degeneration
  1095. Stroke units, tissue plasminogen activator, aspirin and Neuroprotection : which stroke intervention could provide the greatest community benefit?
  1096. α-Tocotrienol provides the most potent Neuroprotection among vitamin E analogs on cultured striatal neurons
  1097. Melatonin provides Neuroprotection in the late-gestation fetal sheep brain in response to umbilical cord occlusion
  1098. Estrogen-like compounds for ischemic Neuroprotection
  1099. Different levels of Neuroprotection by two insulin-like growth factor-I splice variants
  1100. Preconditioning with isoflurane produces dose-dependent Neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral …
  1101. Metallothionein-mediated Neuroprotection in genetically engineered mouse models of Parkinson’s disease
  1102. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B
  1103. Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFκB
  1104. Simultaneous Neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
  1105. Intracerebral transplantation of porcine choroid plexus provides structural and functional Neuroprotection in a rodent model of stroke
  1106. Neuroprotection in glaucoma: a model for Neuroprotection in optic neuropathies
  1107. Glutathione monoethyl ester provides Neuroprotection in a rat model of stroke
  1108. Enhancement of glutamate uptake mediates the Neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes
  1109. Activity-dependent Neuroprotection and cAMP response element-binding protein (CREB): kinase coupling, stimulus intensity, and temporal regulation of CREB …
  1110. Significant Neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with …
  1111. IGF‐I Neuroprotection in the immature brain after hypoxia‐ischemia, involvement of Akt and GSK3β?
  1112. Glycogen synthase kinase 3β links Neuroprotection by 17β-estradiol to key Alzheimer processes
  1113. Neuroprotection by NGF in the PC12 In Vitro OGD Model: Involvement of Mitogen‐Activated Protein Kinases and Gene Expression
  1114. The Neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation
  1115. Estrogen receptor-mediated Neuroprotection from oxidative stress requires activation of the mitogen-activated protein kinase pathway
  1116. Tumor necrosis factor (TNF)-mediated Neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation …
  1117. Propofol Neuroprotection in cerebral ischemia and its effects on low-molecular-weight antioxidants and skilled motor tasks
  1118. Progesterone Neuroprotection in spinal cord trauma involves up-regulation of brain -derived neurotrophic factor in motoneurons
  1119. A potent antioxidant, lycopene, affords Neuroprotection against microglia activation and focal cerebral ischemia in rats
  1120. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression
  1121. Coactivation of GABAA and GABAB Receptor Results in Neuroprotection During In Vitro Ischemia
  1122. Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia
  1123. Mechanisms of progesterone‐induced Neuroprotection
  1124. Reconstituted high-density lipoprotein exhibits Neuroprotection in two rat models of stroke
  1125. Uric acid administration for Neuroprotection in patients with acute brain ischemia
  1126. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases
  1127. Neuronal growth‐promoting and inhibitory cues in Neuroprotection and neuroregeneration
  1128. β-Synuclein Regulates Akt Activity in Neuronal Cells: A POSSIBLE MECHANISM FOR Neuroprotection IN PARKINSON′ S DISEASE
  1129. Immunosuppressants: Neuroprotection and promoting neurological recovery following peripheral nerve and spinal cord lesions
  1130. Sensory Neuroprotection , mitochondrial preservation, and therapeutic potential of N-acetyl-cysteine after nerve injury
  1131. Pharmacological Neuroprotection
  1132. Cannabinoids produce Neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores
  1133. Role of PPAR-γ ligands in Neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells
  1134. Valproic acid-mediated Hsp70 induction and anti-apoptotic Neuroprotection in SH-SY5Y cells
  1135. Local saline infusion into ischemic territory induces regional brain cooling and Neuroprotection in rats with transient middle cerebral artery occlusion
  1136. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to Neuroprotection in Parkinson’s disease and other …
  1137. … low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides Neuroprotection and induces behavioral …
  1138. Neuroprotection and regeneration in glaucoma.
  1139. Insulin Neuroprotection against oxidative stress in cortical neurons—involvement of uric acid and glutathione antioxidant defenses
  1140. Neuroprotection and neuronal dysfunction upon repetitive inhibition of oxidative phosphorylation
  1141. Neuroprotection by transforming growth factor-β1 involves activation of nuclear factor-κB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein …
  1142. A responsive outcome for Parkinson’s disease Neuroprotection futility studies
  1143. Neuroprotection from complement‐mediated inflammatory damage
  1144. Unequal Neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic …
  1145. Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation
  1146. Microglial NADPH oxidase is a novel target for femtomolar Neuroprotection against oxidative stress
  1147. Neuroprotection after Transient Global Cerebral Ischemia in Wlds Mutant Mice
  1148. Blood-brain barrier drug targeting enables Neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins
  1149. Wide therapeutic time window for nimesulide Neuroprotection in a model of transient focal cerebral ischemia in the rat
  1150. T-cell-based vaccination for morphological and functional Neuroprotection in a rat model of chronically elevated intraocular pressure
  1151. Prospects for Neuroprotection in multiple sclerosis.
  1152. Novel role for gabapentin in Neuroprotection of central nervous system in streptozotocine-induced diabetic rats
  1153. Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration
  1154. The mitochondrial permeability transition as a target for Neuroprotection
  1155. Tenascin-R plays a role in Neuroprotection via its distinct domains that coordinate to modulate the microglia function
  1156. Erythropoietin and Neuroprotection : a therapeutic perspective
  1157. Preclinical evidence for Neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease
  1158. Neuroprotection by human neural progenitor cells after experimental contusion in rats
  1159. Behavioral and histological Neuroprotection by tamoxifen after reversible focal cerebral ischemia
  1160. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of Neuroprotection by an ERα agonist
  1161. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration
  1162. Local brain hypothermia for Neuroprotection in stroke treatment and aneurysm repair
  1163. Neuroprotection by α-lipoic acid in streptozotocin-induced diabetes
  1164. Neuroprotection of catalpol in transient global ischemia in gerbils
  1165. The c‐Raf inhibitor GW5074 provides Neuroprotection in vitro and in an animal model of neurodegeneration through a MEK‐ERK and Akt‐independent mechanism
  1166. brain -derived neurotrophic factor gene: a portal to transform mesenchymal stem cells into advantageous engineering cells for neuroregeneration and Neuroprotection
  1167. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for Neuroprotection
  1168. Clinical trials of Neuroprotection for Parkinson’s disease
  1169. Neuroprotection with angiotensin receptor antagonists
  1170. L-DOPA treatment from the viewpoint of Neuroprotection
  1171. Neuroprotection in transient focal cerebral ischemia by combination drug therapy and mild hypothermia: comparison with customary therapeutic regimen
  1172. Cannabinoids and Neuroprotection in CNS inflammatory disease
  1173. The kinder side of killer proteases: caspase activation contributes to Neuroprotection and CNS remodeling
  1174. Retinal Neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium-derived factor
  1175. Gene activation and protein expression following ischaemic stroke: strategies towards Neuroprotection
  1176. Voluntary running provides Neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle
  1177. Transplantation of vascular endothelial growth factor-transfected neural stem cells into the rat brain provides Neuroprotection after transient focal cerebral ischemia
  1178. Central nervous system–targeted complement inhibition mediates Neuroprotection after closed head injury in transgenic mice
  1179. Neuroprotection and regeneration strategies for spinal cord repair
  1180. Hypothesis for a common basis for Neuroprotection in glaucoma and Alzheimer’s disease: anti-apoptosis by alpha-2-adrenergic receptor activation
  1181. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson’s disease?
  1182. The intracerebral application of the PPARγ‐ligand pioglitazone confers Neuroprotection against focal ischaemia in the rat brain
  1183. Neuroprotection trek—the next generation: neuromodulation I. Techniques—deep brain stimulation, vagus nerve stimulation, and transcranial magnetic stimulation
  1184. Structural and functional Neuroprotection in a rat model of Huntington’s disease by viral gene transfer of GDNF
  1185. Functional aspects of estrogen Neuroprotection
  1186. Neuroprotection with carotenoids in glaucoma
  1187. Optical coherence tomography: measuring in-vivo axonal survival and Neuroprotection in multiple sclerosis and optic neuritis
  1188. … colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated Neuroprotection against Alzheimer’s disease …
  1189. Vascular aspects of Neuroprotection
  1190. Isoflurane Neuroprotection in Hypoxic Hippocampal Slice Cultures Involves Increases in Intracellular Ca2+and Mitogen-activated Protein Kinases
  1191. Insulin exerts Neuroprotection by counteracting the decrease in cell‐surface GABAA receptors following oxygen–glucose deprivation in cultured cortical neurons
  1192. Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase
  1193. Adenosine, neurodegeneration and Neuroprotection
  1194. Neuroprotection and neurodegenerative diseases: from biology to clinical practice
  1195. Provoking Neuroprotection by peroxynitrite
  1196. Zinc-induced apoptosis in substantia nigra of rat brain : Neuroprotection by vitamin D3
  1197. Neuroprotection of naloxone against ischemic injury in rats: role of mu receptor antagonism
  1198. Rubia cordifolia, Fagonia cretica linn and Tinospora cordifolia exert Neuroprotection by modulating the antioxidant system in rat hippocampal slices subjected …
  1199. Neuroprotection by nicotine against hypoxia-induced apoptosis in cortical cultures involves activation of multiple nicotinic acetylcholine receptor subtypes
  1200. Neuroprotection following fluid percussion brain trauma: a pilot study using quercetin
  1201. Role of insulin-like growth factors in neuronal plasticity and Neuroprotection
  1202. Timing of neutrophil depletion influences long-term Neuroprotection in neonatal rat hypoxic-ischemic brain injury
  1203. NF-E2-related factor-2 mediates Neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary …
  1204. Neuroprotection in acute ischemic stroke
  1205. Empirical evidence of Neuroprotection by dual cholinesterase inhibition in Alzheimer’s disease
  1206. Clomethiazole: mechanisms underlying lasting Neuroprotection after hypoxia‐ischemia
  1207. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced Neuroprotection in transgenic R6/2 mouse model of Huntington’s …
  1208. In vitro Gender Differences in Neuronal Survival on Hypoxia and in 17β-Estradiol-Mediated Neuroprotection
  1209. Estrogen provides Neuroprotection against activated microglia‐induced dopaminergic neuronal injury through both estrogen receptor‐α and estrogen receptor‐β in …
  1210. What can adenosine neuromodulation do for Neuroprotection ?
  1211. Novel Diketopiperazine Enhances Motor and cognitive Recovery after Traumatic brain Injury in Rats and Shows Neuroprotection In Vitro and In Vivo
  1212. Neuroprotection as a treatment for glaucoma: pharmacological and immunological approaches
  1213. Depth of delayed cooling alters Neuroprotection pattern after hypoxia‐ischemia
  1214. Long-term Neuroprotection with 2-iminobiotin, an inhibitor of neuronal and inducible nitric oxide synthase, after cerebral hypoxia-ischemia in neonatal rats
  1215. Neuroprotection and enhancement of learning and memory by BF-7
  1216. Neuroprotection of edaravone on hypoxic-ischemic brain injury in neonatal rats
  1217. Inhibition of mitochondrial respiration by nitric oxide: its role in glucose metabolism and Neuroprotection
  1218. Neuroprotection trek—the next generation: neuromodulation II. Applications—epilepsy, nerve regeneration, neurotrophins
  1219. NF-κB factor c-Rel mediates Neuroprotection elicited by mGlu5 receptor agonists against amyloid β-peptide toxicity
  1220. Dual role of DENN/MADD (Rab3GEP) in neurotransmission and Neuroprotection
  1221. The role of the estrogen in Neuroprotection : implications for neurodegenerative diseases.
  1222. Circulatory arrest as a model for studies of global ischemic injury and Neuroprotection
  1223. Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm
  1224. Perioperative Neuroprotection : are we asking the right questions?
  1225. Estrogen and Neuroprotection : higher constitutive expression of glutaredoxin in female mice offers protection against MPTP‐mediated neurodegeneration
  1226. Challenges of Neuroprotection and neurorestoration in ischemic stroke treatment
  1227. Imaging end points for monitoring Neuroprotection in Parkinson’s disease
  1228. Neuroprotection by tempol in a model of iron-induced oxidative stress in acute ischemic stroke
  1229. Protease-activated receptors in neuronal development, neurodegeneration, and Neuroprotection : thrombin as signaling molecule in the brain
  1230. Neuroprotection and enhanced recovery with edaravone after acute spinal cord injury in rats
  1231. Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term Neuroprotection with brimonidine
  1232. A3 receptors in cortical neurons: Pharmacological aspects and Neuroprotection during hypoxia
  1233. Neurotrophin-based strategies for Neuroprotection
  1234. Estrogen Neuroprotection against the neurotoxic effects of ethanol withdrawal: potential mechanisms
  1235. Cannabinoids in neurodegeneration and Neuroprotection
  1236. Possible sources of Neuroprotection following subretinal silicon chip implantation in RCS rats
  1237. Asymptomatic ischemic cerebrovascular disorders and Neuroprotection with vinpocetine.
  1238. Mitochondria are involved in the neurogenic Neuroprotection conferred by stimulation of cerebellar fastigial nucleus
  1239. γ-Aminobutyric acid-A receptors contribute to isoflurane Neuroprotection in organotypic hippocampal cultures
  1240. Heat acclimation increases hypoxia-inducible factor 1α and erythropoietin receptor expression: implication for Neuroprotection after closed head injury in mice
  1241. Glucagon-like peptide-1 receptor is involved in learning and Neuroprotection
  1242. Dose-dependent Neuroprotection by 17β-estradiol after cardiac arrest and cardiopulmonary resuscitation
  1243. TREK‐1, a K+ channel involved in Neuroprotection and general anesthesia
  1244. Cellular strategies of estrogen-mediated Neuroprotection during brain development
  1245. Advances in stroke Neuroprotection : hyperoxia and beyond
  1246. Neuroprotection by encapsulated choroid plexus in a rodent model of Huntington’s disease
  1247. Models of epilepsy in the developing and adult brain : implications for Neuroprotection
  1248. Glial‐mediated Neuroprotection : Evidence for the protective role of the NO‐cGMP pathway via neuron–glial communication in the peripheral nervous system
  1249. Neuroprotection and peptide toxins
  1250. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase‐2 inhibitor APHS can be reversed by a prostanoid
  1251. Plasma membrane oestrogen receptor mediates Neuroprotection against β‐amyloid toxicity through activation of Raf‐1/MEK/ERK cascade in septal‐derived …
  1252. Multiple calcium channels and kinases mediate α7 nicotinic receptor Neuroprotection in PC12 cells
  1253. Neuroprotection against Aβ and glutamate toxicity by melatonin: Are GABA receptors involved?
  1254. Induction of thioredoxin and mitochondrial survival proteins mediates preconditioning‐induced cardioprotection and Neuroprotection
  1255. l‐Carnitine and Neuroprotection in the Animal Model of Mitochondrial Dysfunction
  1256. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides Neuroprotection in a rat model of Parkinson’s disease
  1257. NO stimulation of ATP-sensitive potassium channels: involvement of Ras/mitogen-activated protein kinase pathway and contribution to Neuroprotection
  1258. Synaptophysin enhances the Neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells
  1259. A “cure” for Parkinson’s disease: can Neuroprotection be proven with current trial designs?
  1260. Role of protein phosphatases in estrogen-mediated Neuroprotection
  1261. Galantamine and memantine produce different degrees of Neuroprotection in rat hippocampal slices subjected to oxygen–glucose deprivation
  1262. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo …
  1263. Neuroprotection in ischemic stroke—combination drug therapy and mild hypothermia in a rat model of permanent focal cerebral ischemia
  1264. Combining insulin-like growth factor derivatives plus caffeinol produces robust Neuroprotection after stroke in rats
  1265. Neuroprotection of immortalized hippocampal neurones by brain ‐derived neurotrophic factor and Raf‐1 protein kinase: role of extracellular signal‐regulated protein …
  1266. Combined cyclosporine-A and methylprednisolone treatment exerts partial and transient Neuroprotection against ischemic stroke
  1267. Corticotropin-releasing factor (CRF) and related peptides confer Neuroprotection via type 1 CRF receptors
  1268. Aging blunts ischemic-preconditioning-induced Neuroprotection following transient global ischemia in rats
  1269. Immune-mediated neurodegeneration and Neuroprotection in MS.
  1270. Expression of apoptosis inhibitor protein Mcl1 linked to Neuroprotection in CNS neurons
  1271. Neuroprotection in PD—a role for dopamine agonists?
  1272. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and Neuroprotection by distinct signaling pathways
  1273. Dexamethasone downregulates chemokine receptor CXCR4 and exerts Neuroprotection against hypoxia/ischemia-induced brain injury in neonatal rats
  1274. Caspase 3 activation is essential for Neuroprotection in preconditioning
  1275. Prolonged opportunity for ischemic Neuroprotection with selective κ-opioid receptor agonist in rats
  1276. Neuroprotection by fructose-1, 6-bisphosphate involves ROS alterations via p38 MAPK/ERK
  1277. Neuroprotection in Parkinson disease
  1278. Partial characterization of retina-derived cone Neuroprotection in two culture models of photoreceptor degeneration
  1279. Neuroprotection by Na+ channel blockade
  1280. Ionotropic glutamate receptors: still a target for Neuroprotection in brain ischemia? Insights from in vitro studies
  1281. Role of nonfeminizing estrogen analogues in Neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity
  1282. Neuroprotection by D-securinine against neurotoxicity induced by beta-amyloid (25–35)
  1283. Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts Neuroprotection in autoimmune encephalomyelitis
  1284. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for Neuroprotection in the central nervous system
  1285. … element binding protein signal pathway and BCL-2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen-induced Neuroprotection
  1286. Kappa-opioid receptor selectivity for ischemic Neuroprotection with BRL 52537 in rats
  1287. Signaling cascades involved in Neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38
  1288. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury
  1289. Mitochondrial ATP-sensitive potassium channel: a novel site for Neuroprotection
  1290. Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels
  1291. Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker
  1292. Role of alpha-2 agonists in Neuroprotection
  1293. Consensus review. Pharmacological Neuroprotection in cerebral ischemia: is it still a therapeutic option?
  1294. Mechanisms of neuronal death and Neuroprotection
  1295. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson’s disease?
  1296. FGF-2 promotes neurogenesis and Neuroprotection and prolongs survival in a transgenic mouse model of Huntington’s disease
  1297. Lack of Neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia
  1298. Reduction of calcium release from the endoplasmic reticulum could only provide partial Neuroprotection against beta‐amyloid peptide toxicity
  1299. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to Neuroprotection
  1300. Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in Neuroprotection against N-methyl-D-aspartate receptor-mediated …
  1301. Nicotine‐induced Neuroprotection against N‐methyl‐d‐aspartic acid or β‐amyloid peptide occur through independent mechanisms distinguished by pro …
  1302. Mechanisms involved in prostaglandin E2-mediated Neuroprotection against TNF-α: possible involvement of multiple signal transduction and β-catenin/T-cell factor
  1303. Neuroprotection against NMDA excitotoxicity by group I metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents
  1304. Molecular mechanisms of cytokine-induced Neuroprotection : NFκB and neuroplasticity
  1305. Peroxynitrite protects neurons against nitric oxide-mediated apoptosis: a key role for glucose-6-phosphate dehydrogenase activity in Neuroprotection
  1306. Single-dose ebselen does not afford sustained Neuroprotection to rats subjected to severe focal cerebral ischemia
  1307. Phosphatidylinositol 3‐kinase and Akt effectors mediate insulin‐like growth factor‐I Neuroprotection in dorsal root ganglia neurons
  1308. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia
  1309. Retinal detachment neuropathology and potential strategies for Neuroprotection
  1310. SOD1 overexpression and female sex exhibit region-specific Neuroprotection after global cerebral ischemia due to cardiac arrest
  1311. First clinical experiences with an endovascular clamping system for Neuroprotection during carotid stenting
  1312. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector
  1313. Involvement of insulin/phosphoinositide 3-kinase/Akt signal pathway in 17β-estradiol-mediated Neuroprotection
  1314. Neuroprotection in cardiac surgery.
  1315. Neurotoxicity of lidocaine: implications for spinal anesthesia and Neuroprotection
  1316. Neuroprotection in brain ischemia–doubts and hopes
  1317. Neuroprotection from soman-induced seizures in the rodent: evaluation with diffusion-and T2-weighted magnetic resonance imaging
  1318. Mitochondrial medicine: Neuroprotection and life extension by the new amphiphilic nitrone LPBNAH1 acting as a highly potent antioxidant agent
  1319. … derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: Neuroimmunophilin ligand‐mediated Neuroprotection in a model of …
  1320. Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models.
  1321. Regulation of c‐Jun N‐terminal kinase, p38 kinase and AP‐1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium Neuroprotection
  1322. Levodopa therapy from the Neuroprotection viewpoint
  1323. Pharmacological strategies to block rod photoreceptor apoptosis caused by calcium overload: a mechanistic target-site approach to Neuroprotection
  1324. Severe hypotension is not essential for isoflurane Neuroprotection against forebrain ischemia in mice
  1325. The Neuroprotection of resveratrol in the experimental cerebral ischemia
  1326. Neuroprotection in progressive brain disorders
  1327. Inhibition of release of taurine and excitatory amino acids in ischemia and Neuroprotection
  1328. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma
  1329. Neuroprotection by aminoguanidine after lateral fluid-percussive brain injury in rats: a combined magnetic resonance imaging, histopathologic and functional study
  1330. Designing Neuroprotection trials in Parkinson’s disease
  1331. Neuroprotection in Parkinson’s disease: an elusive goal
  1332. Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following Neuroprotection by FK506 in the ischemic rat brain
  1333. Mediation of BMP7 Neuroprotection by MAPK and PKC IN rat primary cortical cultures
  1334. Microglial NADPH oxidase mediates leucine enkephalin dopaminergic Neuroprotection
  1335. Prenatal hypoxia-induced adaptation and Neuroprotection that is inducible nitric oxide synthase-dependent
  1336. Polycyclic phenols, estrogens and Neuroprotection : a proposed mitochondrial mechanism
  1337. Electroacupuncture provides a new approach to Neuroprotection in rats with induced glaucoma
  1338. Female-specific Neuroprotection against transient brain ischemia observed in mice devoid of prion protein is abolished by ectopic expression of prion protein-like …
  1339. Gonadotropins and Alzheimer’s disease: the link between estrogen replacement therapy and Neuroprotection
  1340. An in vitro model of inflammatory neurodegeneration and its Neuroprotection
  1341. Neuroprotection and epilepsy
  1342. Time for a cool head—Neuroprotection becomes a reality
  1343. Targeting Neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy
  1344. Long-term Neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system
  1345. Signaling pathways involved with serotonin1A agonist-mediated Neuroprotection against ethanol-induced apoptosis of fetal rhombencephalic neurons
  1346. Retinal ganglion cell death and Neuroprotection : involvement of the CaMKIIα gene
  1347. Opportunities for Neuroprotection in ALS using cell death mechanism rationales
  1348. Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist
  1349. brain after transient forebrain ischemia accompanied by an increased expression of galectin-1, and the implication of ΔFosB and galectin-1 in Neuroprotection
  1350. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides Neuroprotection , and reduces inflammation in a rat model of traumatic brain injury
  1351. A novel mechanism for pergolide-induced Neuroprotection : inhibition of NF-κB nuclear translocation
  1352. Atrial natriuretic peptide expression is increased in rat cerebral cortex following spreading depression: possible contribution to sd-induced Neuroprotection
  1353. Neuroprotection against hypoxia-ischemia by insulin-like growth factor-I (IGF-I).
  1354. Modulation of calcium/calmodulin kinase‐II provides partial Neuroprotection against beta‐amyloid peptide toxicity
  1355. Glutathione peroxidase-1 contributes to the Neuroprotection seen in the superoxide dismutase-1 transgenic mouse in response to ischemia/reperfusion injury
  1356. A comparison of carotid artery stenting with Neuroprotection versus carotid endarterectomy under local anesthesia
  1357. Challenge of conducting trials of Neuroprotection in the asphyxiated term infant
  1358. VPAC2 receptors mediate vasoactive intestinal peptide-induced Neuroprotection against neonatal excitotoxic brain lesions in mice
  1359. Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring Neuroprotection in experimental focal cerebral ischemia in the rat …
  1360. Monoamine oxidase B inhibition and Neuroprotection : studies on selective adenosine A2A receptor antagonists
  1361. Neuroprotection for Parkinson’s disease: a call for clinically riven experimental design
  1362. Involvement of γ protein kinase C in estrogen‐induced Neuroprotection against focal brain ischemia through G protein‐coupled estrogen receptor
  1363. 681. Non-Viral DNA and mRNA Gene Delivery to the CNS Pre-Operatively for Neuroprotection and Following Neurotrauma
  1364. Mechanism of electrical stimulation-induced Neuroprotection : effects of verapamil on protection of primary auditory afferents
  1365. Failure of ischemic Neuroprotection by potentiators of gamma-aminobutyric acid
  1366. Neuroprotection induced by the adenosine A 2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways
  1367. The dual role of prostaglandin E2 in excitotoxicity and preconditioning-induced Neuroprotection
  1368. Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4. 1) motoneurons exposed to glutamate: calpain inhibition provides functional Neuroprotection
  1369. Long-term Neuroprotection induced by regional brain cooling with saline infusion into ischemic territory in rats: a behavioral analysis
  1370. Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring Neuroprotection
  1371. Oxidative injury to the locus coeruleus of rat brain : Neuroprotection by melatonin
  1372. What is the learning curve for carotid artery stenting with Neuroprotection ? Analysis of 200 consecutive cases at an academic institution
  1373. Cerebral ischemia-hypoxia and biophysical mechanisms of neurodegeneration and Neuroprotection effects
  1374. Lack of Neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma
  1375. Synthesis and evaluation of peptidic metal chelators for Neuroprotection in neurodegenerative diseases
  1376. 17β‐Estradiol activates ICI 182,780‐sensitive estrogen receptors and cyclic GMP‐dependent thioredoxin expression for Neuroprotection
  1377. An alternative Ca2+‐dependent mechanism of Neuroprotection by the metalloporphyrin class of superoxide dismutase mimetics
  1378. Anesthetic mediated Neuroprotection : established fact or passing fancy?
  1379. Combination of early perinatal factors to identify near-term and term neonates for Neuroprotection
  1380. Biological and molecular mechanisms of hypothermic Neuroprotection
  1381. In vitro Neuroprotection by novel antioxidants in guinea-pig urinary bladder subjected to anoxia-glucopenia/reperfusion damage
  1382. nNOS is involved in estrogen mediated Neuroprotection in neuroblastoma cells
  1383. Neuroprotection and nerve grafts in the treatment of neurogenic erectile dysfunction
  1384. Diltiazem-induced Neuroprotection in glutamate excitotoxicity and ischemic insult of retinal neurons
  1385. Humanin antagonists: mutants that interfere with dimerization inhibit Neuroprotection by Humanin
  1386. Antisense oligonucleotide against GTPase Rab5b inhibits metabotropic agonist DHPG-induced Neuroprotection
  1387. The use of hypothermia as a method of Neuroprotection during neurosurgical procedures and after traumatic brain injury: a survey of clinical practice in Great Britain …
  1388. The Ras Inhibitor S-Trans, Trans-Farnesylthiosalicylic Acid Exerts Long-Lasting Neuroprotection in a Mouse Closed Head Injury Model
  1389. Dopamine transporter as a marker of Neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol
  1390. STN stimulation and Neuroprotection in Parkinson’s disease—when beautiful theories meet ugly facts
  1391. Mechanisms of Neuroprotection by polyphenols
  1392. Neuroprotection in the PNS: erythropoietin and immunophilin ligands
  1393. Postischemic Neuroprotection in the ischemia-tolerant state gerbil hippocampus is associated with increased ligand binding to inhibitory GABA A receptors
  1394. Reactive oxygen species mediate the Neuroprotection conferred by a mitochondrial ATP-sensitive potassium channel opener during ischemia in the rat hippocampal …
  1395. Single intravenous injection of naked plasmid DNA encoding erythropoietin provides Neuroprotection in hypoxia–ischemia rats
  1396. Ischemic Neuroprotection with selective κ-opioid receptor agonist is gender specific
  1397. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to Neuroprotection
  1398. Neuroprotection with delayed initiation of prolonged hypothermia after in vitro transient global brain ischemia
  1399. Neuroprotection against hypoxia-ischemia in neonatal rat brain by novel superoxide dismutase mimetics
  1400. Caffeinol confers cortical but not subcortical Neuroprotection after transient focal cerebral ischemia in rats
  1401. Estrogen receptor alpha mediates neuronal differentiation and Neuroprotection in PC12 cells: critical role of the A/B domain of the receptor
  1402. In vitro model of neurotoxicity of Aβ 1–42 and Neuroprotection by a pentapeptide: irreversible events during the first hour
  1403. Neurochemical correlates of differential Neuroprotection by long-term dietary creatine supplementation
  1404. Adenosine A2A Receptor Antagonism and Neuroprotection : Mechanisms, Lights, and Shadows
  1405. Morphinan Neuroprotection : new insight into the therapy of neurodegeneration
  1406. Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration
  1407. Detailed in vitro pharmacological analysis of FK506-induced Neuroprotection
  1408. Hypothermia for 24 hours after asphyxic cardiac arrest in piglets provides striatal Neuroprotection that is sustained 10 days after rewarming
  1409. Neuroprotection and protein damage prevention by estradiol replacement in rat hippocampal slices exposed to oxygen-glucose deprivation
  1410. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: Neuroprotection with brimonidine
  1411. Neuroprotection in cardiac surgery
  1412. Inhibition of neuronal nitric oxide synthase-mediated activation of poly (ADP-ribose) polymerase in traumatic brain injury: Neuroprotection by 3-aminobenzamide
  1413. Transactivation in astrocytes as a novel mechanism of Neuroprotection
  1414. Poly (ADP‐Ribose) polymerase‐1 in acute neuronal death and inflammation: a strategy for Neuroprotection
  1415. Effects of neonatal and prepubertal hormonal manipulations upon estrogen Neuroprotection of the nigrostriatal dopaminergic system within female and male mice
  1416. Mechanisms of Neuroprotection against glaucoma
  1417. Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells
  1418. Health care resource use after acute stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas trial
  1419. The therapeutic window of hypothermic Neuroprotection in experimental ischemic neuropathy: protection in ischemic phase and potential deterioration in later …
  1420. Potent ς1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Provides Ischemic Neuroprotection Without Altering Dopamine Accumulation In Vivo in Rats
  1421. Neuroprotection
  1422. … deprivation-induced c-Jun amino-terminal kinase 1 and stress-activated kinases p38α and p38β activation and confers Neuroprotection in the pheochromocytoma …
  1423. Nicotinic receptor modulation for Neuroprotection and enhancement of functional recovery following brain injury or disease
  1424. The lipid‐activated two‐pore domain K+ channel TREK‐1 is resistant to hypoxia: implication for ischaemic Neuroprotection
  1425. Uncoupling protein 2: a novel player in Neuroprotection
  1426. Cannabinoid‐mediated Neuroprotection following interferon‐gamma treatment in a three‐dimensional mouse brain aggregate cell culture
  1427. Angiotensin II blocks nicotine-mediated Neuroprotection against β-amyloid (1-42) via activation of the tyrosine phosphatase SHP-1
  1428. Neuroprotection and regeneration after traumatic lesion of the optic nerve
  1429. Neuroprotection by nitrous oxide and xenon and its relation to minimum alveolar concentration
  1430. Clinical trials in Neuroprotection
  1431. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson’s disease and Neuroprotection ; are there links?
  1432. Neuroprotection assessment by topographic electroencephalographic analysis: effects of a sodium channel blocker to reduce polymorphic delta activity following …
  1433. In vitro Neuroprotection against oxidative stress by pre-treatment with a combination of dihydrolipoic acid and phenyl-butyl nitrones
  1434. Transplantation of fetal kidney cells: Neuroprotection and neuroregeneration
  1435. Neuroprotection by the caspase-1 inhibitor Ac-YVAD-(acyloxy) mk in experimental neuroAIDS is independent from IL-1 β generation
  1436. No magic bullets: the ephemeral nature of anesthetic-mediated Neuroprotection
  1437. How to keep injured CNS neurons viable—strategies for Neuroprotection and gene transfer to retinal ganglion cells
  1438. Strategies for Neuroprotection in the newborn
  1439. The immunophilin‐ligands FK506 and V‐10,367 mediate Neuroprotection by the heat shock response
  1440. The prospects for Neuroprotection in MS.
  1441. Neuroprotection of adult rat dorsal root ganglion neurons by combined hypothermia and alkalinization against prolonged ischemia
  1442. Post-ischemic diazepam does not reduce hippocampal CA1 injury and does not improve hypothermic Neuroprotection after forebrain ischemia in gerbils
  1443. Neuroprotection : Where Are We Going?
  1444. Neuroprotection of Parkin against apoptosis is independent of inclusion body formation
  1445. Does Neuroprotection prevent epileptogenesis?
  1446. Neuroprotection in traumatic brain injury
  1447. The inhibition of glycogen synthase kinase 3β by a metabotropic glutamate receptor 5 mediated pathway confers Neuroprotection to Aβ peptides
  1448. Neuroprotection mediated by subtoxic dose of NMDA in SH-SY5Y neuroblastoma cultures: activity-dependent regulation of PSA-NCAM expression
  1449. Molecular targets for Neuroprotection
  1450. Rapid Report: Acute hypoxia occludes hTREK‐1 modulation: re‐evaluation of the potential role of tandem P domain K+ channels in central Neuroprotection
  1451. Neuroprotection in Glaucoma
  1452. Dietary supplementation with 3-deaza adenosine, N-acetyl cysteine, and S-adenosyl methionine provide Neuroprotection against multiple consequences of vitamin …
  1453. Lens epithelium-derived growth factor: Neuroprotection on rat retinal damage induced by N-methyl-D-aspartate
  1454. Possible involvement of astrocytes in Neuroprotection by the cognitive enhancer T-588
  1455. VEGF–mediated Neuroprotection in ischemic retina
  1456. Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis
  1457. Calcineurin and cyclophilin D are differential targets of Neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage
  1458. Angiotensin receptor gene expression in candesartan mediated Neuroprotection
  1459. Neuroprotection possibilities in epileptic children
  1460. Angiotensin type 2 receptor Neuroprotection against chemical hypoxia is dependent on the delayed rectifier K+ channel, Na+/Ca2+ exchanger and Na+/K+ ATPase in …
  1461. Clinical trials in Neuroprotection . 23-25 January 2003, Key Biscayne, FL, USA.
  1462. Inhibition of nitric oxide production and protein tyrosine nitration contribute to Neuroprotection by a novel calmodulin antagonist, DY-9760e, in the rat microsphere …
  1463. Endogenously expressed estrogen receptors mediate Neuroprotection in hippocampal cells (HT22)
  1464. Astrocytic cytochromes p450: an enzyme subfamily critical for brain metabolism and Neuroprotection
  1465. Small molecule activators of the heat shock response and Neuroprotection from stroke
  1466. Clinical pharmacology and Neuroprotection in Parkinson’s disease
  1467. Retinal ganglion cell Neuroprotection in culture
  1468. Remyelination as Neuroprotection
  1469. Strategies of Neuroprotection for intracranial aneurysms
  1470. Suppression of protein kinase Cε mediates 17β‐estradiol‐induced Neuroprotection in an immortalized hippocampal cell line
  1471. In the rostral ventrolateral medulla, the 70-kDa heat shock protein (HSP70), but not HSP90, confers Neuroprotection against fatal endotoxemia via augmentation of …
  1472. P2 receptor antagonist PPADS confers Neuroprotection against glutamate/NMDA toxicity
  1473. C5b‐9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and Neuroprotection
  1474. Neuroprotection of vestibular sensory cells from gentamicin ototoxicity obtained using nitric oxide synthase inhibitors, reactive oxygen species scavengers, brain
  1475. Introduction: A2A receptors in Neuroprotection of dopaminergic neurons
  1476. Con: Retrograde cerebral perfusion is not an optimal method of Neuroprotection in thoracic aortic surgery
  1477. Perioperative cerebral ischemia and the possibility of Neuroprotection by inhalational anesthetics
  1478. Neuronal injury and Neuroprotection
  1479. Role of peroxynitrite in methamphetamine-induced dopaminergic neurodegeneration and Neuroprotection by antioxidants and selective NOS inhibitors
  1480. Assessment and explorations on the mechanism of Neuroprotection of patients in ischemic stroke by traditional Chinese medicine
  1481. Perinatal brain damage–from Neuroprotection to neuroregeneration using cord blood stem cells
  1482. Gene therapy and Neuroprotection for cerebral infarction
  1483. Neuroprotection by the stable nitroxide 3-carbamoyl-proxyl during reperfusion in a rat model of transient focal ischemia
  1484. Neuroprotection in epilepsy: the Holy Grail of antiepileptogenic therapy.
  1485. Secondary Neuroprotection
  1486. New directions in Neuroprotection : Basic mechanisms, molecular targets and treatment strategies
  1487. Neuroprotection Becomes Reality
  1488. Delayed transient ischemic attacks kill some CA1 neurons previously salvaged with postischemic hypothermia: Neuroprotection undone
  1489. … effects of hypothermia ranging from 34 degrees C to 31 degrees C on brain ischemia in gerbils and determination of the mechanism of Neuroprotection .
  1490. Neuroprotection and dopamine agonists
  1491. Neuroprotection
  1492. Poly (ADP-ribosyl) ation enzyme-1 as a target for Neuroprotection in acute central nervous system injury
  1493. Monoamine oxidase inhibitors, their structural analogues, and Neuroprotection
  1494. Neuroprotection : A realistic goal for aged brain ?
  1495. Current status of Neuroprotection in cerebrovascular disease
  1496. Erythropoiesis and Neuroprotection : two sides of the same coin?
  1497. … expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent Neuroprotection
  1498. Ocular Neuroprotection
  1499. Neuroprotection against glaucoma remains a concept
  1500. Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke Neuroprotection
  1501. Neuro-overprotection? A functional evaluation of clomethiazole-induced Neuroprotection following hypoxic-ischemic injury
  1502. Cell-permeant calcium buffer induced Neuroprotection after cortical devascularization
  1503. Gap junction-mediated intercellular communication in astrocytes and Neuroprotection
  1504. Low molecular weight compounds with affinity to melanocortin receptors exert Neuroprotection in spinal cord injury—an experimental study in the rat
  1505. Neuroprotection or Neurotoxicity
  1506. Limiting iron availability confers Neuroprotection from chronic mild carbon monoxide exposure in the developing auditory system of the rat
  1507. CAI is a potent inhibitor of neovascularization and imparts Neuroprotection in a mouse model of ischemic retinopathy
  1508. Neuroprotection by estrogen in animal models of ischemia and Parkinson’s disease
  1509. Time Window of Fibroblast Growth Factor-18—Mediated Neuroprotection after Occlusion of the Middle Cerebral Artery in Rats
  1510. Involvement of phosphatidylinositol 3-kinase and insulin-like growth factor-I in YXLST-mediated Neuroprotection
  1511. The risks of extending the controversial use of tocolytic magnesium sulfate for the purpose of Neuroprotection in preterm labor
  1512. The role of BF-7 on Neuroprotection and enhancement of cognitive function
  1513. The synthetic estrogen 4-estren-3α, 17β-diol (estren) induces estrogen-like Neuroprotection
  1514. COMT inhibition in the treatment of Parkinson’s disease: Neuroprotection and future perspectives
  1515. Pontine cholinergic neurons depend on three Neuroprotection systems to resist nitrosative stress
  1516. Fenfluramine‐induced serotonergic neurotoxicity in mice: lack of Neuroprotection by inhibition/ablation of nNOS
  1517. Neuroprotection in Ischemic/Hypoxic Disorders
  1518. Magnesium sulfate for preterm Neuroprotection
  1519. Postischemic nitrous oxide alone versus intraischemic nitrous oxide in the presence of isoflurane: What it may change for Neuroprotection against cerebral stroke in …
  1520. Neuroprotection trek—the next generation: the measurement is the message
  1521. Vasopressin mediates Neuroprotection in mice by stimulation of V1 vasopressin receptors: Influence of PI-3 kinase and gap junction inhibitors
  1522. Neuroprotection against focal ischemia in the hyperbilirubinemic rat model
  1523. Microwave‐assisted synthesis and chiral HPLC separation of 18F‐labeled MaxiPost™. An agent for post‐stroke Neuroprotection
  1524. Advances in neuroregulation and Neuroprotection
  1525. Effect of magnesium sulfate given for Neuroprotection before preterm birth
  1526. Multi-organ protection and the kidney. From nephroprotection, cardioprotection, Neuroprotection to multi-organ protection
  1527. Magnesium sulfate and Neuroprotection
  1528. Monounsaturated fatty acids and Neuroprotection . The results of a study of cognitive decline in old age. Is there a case for this treatment in multiple sclerosis?
  1529. Transfert cérébral et Neuroprotection
  1530. N-methyl-D-aspartate attenuates CXCR2-mediated Neuroprotection through enhancing the receptor phosphorylation and blocking the receptor recycling
  1531. Role of erythropoietin in brain homeostasis, neurodevelopment and Neuroprotection
  1532. Characteristic features of optic nerve ganglion cells and approaches for Neuroprotection . From intracellular to capillary processes and therapeutic considerations
  1533. Neuroprotection in Hungtington’s disease
  1534. Neuroprotection in the peripheral nervous system
  1535. Neuroprotection of nerve growth factor in experiment retinal detachment
  1536. Neuroprotection against Apoptosis
  1537. Ca2+-ATPase isoforms are expressed in Neuroprotection in rat, but not human, neurons
  1538. Oxidative Toxicity in BV‐2 Microglia Cells: Sesamolin Neuroprotection of H2O2 Injury Involving Activation of p38 Mitogen‐Activated Protein Kinase
  1539. Nanoceria particles confer Neuroprotection in retinal cells in vitro
  1540. The Gtx homeodomain transcription factor exerts Neuroprotection using its homeodomain
  1541. Neuroprotection of photoreceptor cells in rod-cone dystrophies: from cell therapy to cell signalling
  1542. Progestins and antiprogestins: mechanisms of action, Neuroprotection and myelination
  1543. Inhibition of brain phospholipase A2 by antimalarial drugs: Implications for Neuroprotection in neurological disorders
  1544. Green tea catechins Neuroprotection mediated by nAChR
  1545. Erythropoietic agents in the management of cancer patients. Part 2: studies on their role in Neuroprotection and neurotherapy.
  1546. Neuroprotection by cAMP
  1547. Neurotoxicity and Neuroprotection , two aspects of microglial activation in human immunodeficiency virus (HIV) infection
  1548. Perinatal Neuroprotection by muscle relaxants against hypoxic-ischemic lesions: Is it a possible hypothesis?
  1549. A viable Neuroprotection strategy following soman-induced status epilepticus
  1550. Advances in studies on Neuroprotection of natural medicines
  1551. Neuronal nicotinic receptors and Neuroprotection : newer ligands may help us understand their role in neurodegeneration
  1552. Neuroprotection with Aminoguanidine treatment after brain injury in rats
  1553. Possible role of cerebellar fastigial nucleus in preconditioned Neuroprotection
  1554. International Journal of Neuroprotection and Neuroregeneration: IJNN
  1555. … 14C labeled (S)‐3‐(5‐chloro‐2‐methoxyphenyl)‐1, 3‐dihydro‐3‐fluoro‐6‐(trifluoromethyl)‐2H‐indol‐2‐one, maxipost™. An agent for post‐stroke Neuroprotection
  1556. Advances in Neuroprotection research for neurodegenerative diseases
  1557. Magnesium Sulfate for Preterm Neuroprotection —Reply
  1558. Neuroprotection by resveratrol against cytotoxicity of oxidized low density lipoprotein in PC12 cells
  1559. Seizure-Induced Neuroprotection
  1560. Neuroprotection by ketamine
  1561. Experimental Neuroprotection : translation to human stroke trials
  1562. brain atrophy as a measure of neurodegeneration and Neuroprotection
  1563. Primary Neuroprotection
  1564. Polycyclic aminoguanidines: novel entities for Neuroprotection
  1565. Neuroprotection and neurodegenerative parkinsonian syndromes
  1566. Evolution of the Neuroprotection concept
  1567. An improved quantitative method for evaluation of ischemic injury and Neuroprotection in mouse brain slices
  1568. Effect of magnesium sulfate given for Neuroprotection before preterm birth: a randomized, controlled trial
  1569. Proceedings of the Perioperative Neuroprotection Symposium
  1570. Neuroprotection of lithium and the antagonism of lithium to toxic effects of lead on primary culturing cerebrocortical neurons in vitro
  1571. Cholecystokinin and Neuroprotection
  1572. Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
  1573. White matter Neuroprotection in preterm infants
  1574. Neuroprotection induced by Estrogen Against Focal Cerebral Ischemic-reperfusion Injury in Ovariectomized Rats
  1575. Neutrophil elastase: a target of Neuroprotection
  1576. Molecular mechanisms of neurodegeneration and Neuroprotection -experimental approaches and the diseased brain .
  1577. Soyisoflavones provide Neuroprotection in focal cerebral ischemia of ovariectmized female rats
  1578. Xenon Exhibits Its Neuroprotection Through an Anti-Apoptotic Mechanism
  1579. Clinical Trials Promote treatment and Neuroprotection in Parkinson Disease
  1580. Neuroprotection in Hungtington’s Disease: RESPONSE FROM THE AUTHORS
  1581. Estratriene Neuroprotection through Antioxidant, Non-Estrogen Receptor Mediated Mechanisms
  1582. Mechanisms of Neuroprotection in hippocampal organotypic culture
  1583. Incipient neurovulnerability and Neuroprotection in early psychosis: A proton spectroscopy study of the anterior hippocampus at 3Tesla
  1584. Carbon dioxide provides Neuroprotection in fluid percussion injured rats
  1585. Neuroprotection for Ischemic Injury in the immature brain
  1586. Neuroprotection in Stroke
  1587. Session IV: Role of Carnitines and Other agents in Neuroprotection
  1588. Perioperative Neuroprotection Symposium
  1589. Role of Akt1 in estrogen-mediated Neuroprotection
  1590. Neuroprotection of Hypothermia Combined with Salvia Miltiorrhiza Bunge on brain Damage in the Immature Rat
  1591. Neuroprotection of Veratrum nigrum var. ussurience alkaloids on focal cerebral ischemia-reperfusion injury in rats
  1592. Apoptosis and glaucoma: new insight from basic research to the development of novel strategies for Neuroprotection
  1593. … of N-type Ca2+ currents. An increase in the isoflurane blocking potency of N-type Ca2+ currents may contribute to the known Neuroprotection action of isoflurane …
  1594. Blocking the axonal injury cascade: Neuroprotection in multiple sclerosis and its models
  1595. Effects of aging on hypothermic Neuroprotection in acute stroke
  1596. Neuroprotection by the α2-adrenoceptor agonist, dexmedetomidine, in experimental stroke models
  1597. Mechanism of isoflurane preconditioning’s Neuroprotection against global cerebral ischemia in rat [J]
  1598. Endogenous mechanisms of Neuroprotection and neuroregeneration
  1599. Nicotinic acetylcholine receptor-mediated mechanisms of Neuroprotection in AD
  1600. Lithium and Neuroprotection
  1601. Effect of two different Neuroprotection systems on microembolization during carotid artery stenting
  1602. … CHRONIC OCULAR HYPERTENSION RESULTS IN DEGENERATION OF RETINO–TECTAL AFFERENTS: Neuroprotection WITH TOPICAL BRIMONIDINE.
  1603. Neuroprotection in Parkinson’s Disease
  1604. Neuroprotection Therapeutics: Part 2-Companies & Drugs in Development
  1605. Neuroprotection and the anesthesiologist
  1606. The functional change in the 5-HT1A receptor induced by stress and the role of the 5-HT1A receptor in Neuroprotection
  1607. ELECTRIC MAGNETIC NEUROSTIMULA-TIONS ARE REALLY Neuroprotection
  1608. Intravenous Magnesium for Neuroprotection in Acute Stroke: Neuropharmacology Supports Clinical Hope: Response
  1609. Persistent Neuroprotection Against Focal Cerebral Ischemia Induced By Cortical Spreading Depression In Mice
  1610. Preventive Neuroprotection : from experimental data to therapeutic
  1611. The role of neuregulins in Neuroprotection following acute stroke
  1612. Cerebral transfer and Neuroprotection
  1613. Long-lasting Neuroprotection induced in mouse retina by repeated hypoxic preconditioning
  1614. Glycosaminoglycans and Neuroprotection : effect on cholinergic neurodegeneration
  1615. Anesthesia for neurosurgery Neuroprotection 2005
  1616. 17 The Essentiality of Iron Chelation in Neuroprotection : A Potential Role of Green Tea Catechins
  1617. Development of sleep therapeutic instrument based on the mechanism of Neuroprotection
  1618. Updating the Dual Role of brain Nitric Oxide in Neurodegeneration/Neuroprotection : Understanding Molecular Mechanisms to Devise Drug Approaches
  1619. Regulation of immune-dependent Neuroprotection for arresting neuronal degeneration in optic neuropathies
  1620. Preconditioning Neuroprotection afforded by xenon requires new protein synthesis in an vitro nodel of neuronal injury
  1621. Society for Neuroscience–34th Annual Meeting. Neuroprotection and Anxiety. 23-27 October 2004, San Diego, CA, USA
  1622. Neuroprotection in Parkinson’s Disease
  1623. Quality of preclinical evidence for Neuroprotection in stroke
  1624. Ketamine and Neuroprotection : hemodynamic and metabolic effects in severe traumatic brain injury
  1625. Molecular Mechanisms of Dopaime Receptor Mediated Neuroprotection
  1626. Neuroprotection by Brimonidine Treatment in a Rat Model of Anterior Ischemic Optic Neuropathy
  1627. Neuroprotection in Progressive brain Disorders
  1628. The Neuroprotection of polysaccharidesulfate in the experimental cerebral ischemia
  1629. Neuroprotection Therapeutics: Part 1-New Scientific Strategies & Broader Clinical Applications
  1630. Lamotrigine Neuroprotection in the rabbit retina after pars plana vitrectomy with silicone oil tamponade
  1631. Modulators of endogenous Neuroprotection : Estrogen, corticotropin-releasing hormone and endocannabinoids
  1632. Approaches to Neuroprotection and Recovery Enhancement After Acute Stroke
  1633. Endovanilloid and endocannabinoid mechanism in Neuroprotection
  1634. Neuroprotection in Huntington; s Disease
  1635. Apoptosis and Neuroprotection an exciting and rapidly expanding field of research in ophthalmology
  1636. From a cage to a model, from the heart to the brain : novel concepts in Neuroprotection
  1637. Adenosine-induced Neuroprotection
  1638. Mechanisms underlying in vivo Neuroprotection by the endocannabinoid anandamide and the cannabinoid/vanilloid receptor agonist, arvanil
  1639. … ) on Retinal Ganglion Cells (RGCs) Survival After Optic Nerve Crush, and the Role of brain Derived Neurotrophic Factor (BDNF) in Immune Mediated Neuroprotection
  1640. Anti-apoptotic mechanism of androgen Neuroprotection
  1641. Neuroprotection by drug-induced growth factors
  1642. The müller glia: role in Neuroprotection
  1643. Adaptation of different Neuroprotection devices during carotid stenting procedures
  1644. Mechanisms of Neuroprotection by acetyl-L-carnitine
  1645. Neuroprotection and ageing in sensory neurons.
  1646. Immuno-pharmacological properties of panaxadiol and panaxatriol and their potential effects in Neuroprotection in vitro
  1647. Assessment of functional Neuroprotection in a rat model of neonatal stroke
  1648. Preface [Hot Topic: Current Status of Neuroprotection in Traumatic brain Injury (Executive Editors: Maria Mataro and Juan Sahuquillo)]
  1649. Neuroprotection against ischemic stroke by early or delayed treatment with MC4 receptor-stimulating melanocortins
  1650. Erythropoietin: A Beneficial Approach to Neuroprotection in Stroke
  1651. Acid–base management during hypothermic Neuroprotection
  1652. A-type potassium currents and Neuroprotection after ischemia
  1653. Correlation between Mitochondrial Membrane Potential and Topiramate′ s Neuroprotection
  1654. Low stroke rates during carotid artery stenting with Neuroprotection
  1655. Neuroprotection Effect of Ascorbic Acid in Model of Ischemic Retinal Injury
  1656. Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, Italy.
  1657. Postischemic Hypothermia Provides Long-Term Neuroprotection in Rodents
  1658. Modern Therapeutic Approaches to Acute Focal brain Ischemia. Basic Strategies for Neuroprotection
  1659. Neuroprotection During Acute Oxidative Stress: Role of the PKG
  1660. Neuroprotection in Acute Ischemic Stroke: Lessons for Early Treatment in Multiple Sclerosis
  1661. Cell Death and Neuroprotection of Retinal Ganglion (RGC–5) Cells
  1662. In vivo Neuroprotection of melatonin against focal cerebral
  1663. Parkinson’s Disease: Possible Mechanisms of Neurodegeneration and Strategies for Neuroprotection
  1664. Perspectives on Neuroprotection . Could acid-sensing ion channels be a target of new treatments?
  1665. Albumin therapy for Neuroprotection in ischemic stroke: Alias I trial
  1666. WHAT CAUSES RETINAL GANGLION CELLS TO DIE? NEUROTOXICITY AND Neuroprotection
  1667. Neuroprotection in acute cerebral ischemia by acetylsalicylic acid
  1668. Metallothionein is Implicated in Zn” Neuroprotection of
  1669. Combined Neuroprotection by Xenon and Dexmedetomidine in vitro
  1670. Mechanism of isoflurane preconditioning’s Neuroprotection against global cerebral ischemia in rat
  1671. Neurodegeneration and Neuroprotection in transient cerebral ischemic stroke
  1672. Tenascin-R plays a role in Neuroprotection via its distinct
  1673. Neurodegeneration and Neuroprotection : epilepsy and Parkinsonism
  1674. Molecular Basis of Neuroprotection in a Mouse Model of Focal Cerebral Ischaemia
  1675. Developmental effects of gonadal steriod hormones upon Neuroprotection of the nigrostriatal dopaminergic system
  1676. Estrogen Regulate Neuroprotection and PDI Gene Expression in Ischemic Rat brain
  1677. Estrogen Regulate Neuroprotection and PDI Gene Expression in Ischemic Rat brain
  1678. Therapeutic T-cell-based vaccination versus pharmacological intervention for Neuroprotection : restoring lost homeostasis
  1679. Mechanisms of HBO-induced Neuroprotection in a Neonatal Hypoxia-ischemia Model
  1680. Neuroprotection BY TEMPOL IN A MODEL OF IRON INDUCED
  1681. Neuroprotection of zinc against apoptotic cell death in model of anoxia in vitro
  1682. The role of activin in Neuroprotection and long-term potentiation
  1683. Neuroprotection of ginsenoside Rg3 and signal evidences in neuroblastom a cell line (SK-N-MC)
  1684. Evaluation of Early and Prolonged Effects of Acute Neurotoxicity and Neuroprotection Using Novel Functional Imaging Techniques
  1685. Gene expression and spinal cord injury: Using microarrays to find genes associated with Neuroprotection and regeneration.
  1686. In vitro modelling of neurodegeneration and Neuroprotection specific for Alzheimer’s disease in cell cultures
  1687. Sigma Agonists Afford Neuroprotection via a Post-Synaptic Mechanism
  1688. Neuroprotection by 3-CP During Reperfusion in a Rat Model of Transient Focal Ischemia
  1689. Ischemic preconditioning promotes Neuroprotection via cyclooxygenase-2 induction in vitro
  1690. Organ Cultures of Adult Porcine Retina: A Model for Studing Neuroprotection in the Retina
  1691. The role of glia cells in purine receptor-induced Neuroprotection
  1692. CAI Appears to Provide Neuroprotection in Mouse Model of Ischemia Induced Retinal Neovascularization
  1693. Is tumor necrosis factor-α-converting enzyme (TACE) a therapeutic target for Neuroprotection ?
  1694. Neuroprotection of sini decoction after focal cerebral ischemia in rat and mechanism
  1695. Mechanisms of dantrolene‐induced Neuroprotection against excitotoxic injury
  1696. Neuroprotection of Fructose-1, 6-bisphosphate Modifying ROS through p38 MAPK/ERK
  1697. Survivin expression after traumatic brain injury: Potential roles in Neuroprotection
  1698. Progress in study on Neuroprotection of erythropoietin against hypoxic-ischemic brain damage
  1699. Neuroprotection following acute spinal cord injury through inhibition of the Fas apoptotic pathway.
  1700. Adenosine-induced Neuroprotection : involvement of glia cells and cytokines
  1701. Ischemic preconditioning and erythropoietin Neuroprotection share common downstream pathways
  1702. The multiple effects of mood stabilizers and antidepressants on Neuroprotection : translating basic findings into clinical practice
  1703. Mechanisms of Neuroprotection by estrogen and selective estrogen receptor modulators
  1704. Neuroprotection induced by delta-9-THC in a model of transient global cerebral ischemia
  1705. Uptake of Tavocept™ in dorsal root ganglia (DRG) cells: Evidence for pharmacological effects of Neuroprotection
  1706. Neuroprotection Following Acute Spinal Cord Injury Through Inhibition of the Fas Apoptotic
  1707. Transgenic VEGF induces post-ischemic Neuroprotection , but facilitates hemodynamic steal phenomena
  1708. Cannabinoids and Neuroprotection in mouse models of demyelination.
  1709. Glia-regulated, apolipoprotein E specific mechanisms of Neuroprotection and neurodegeneration
  1710. Pathological study on the Neuroprotection effect of mikvetch and memantine against hypoxic-ischemic reperfusion damage in neonatal rats
  1711. Sexual dimorphism and Neuroprotection by sex steroids in an animal model of Parkinson
  1712. A quantitative measurement of formazan for evaluating ischemic injury and Neuroprotection in mouse brain slices
  1713. Sigma-Receptor Mediated Neuroprotection Occurs by a Post-Synaptic Mechanism in Neuronal Cell Culture
  1714. Prolonged Therapeutic Window for Ischemic Neuroprotection with Selective Kappa-Opioid Receptor Agonist, BRL 52537 in Rat
  1715. Neuroprotection of estrogen against injury induced by?-amyloid protein (25-35) in rat cortical neurons
  1716. Isoflurane Neuroprotection is dependent on post-ischemic hypothermia in rats subjected to severe global forebrain ischemia, Alex
  1717. Neuroprotection of retinal ganglion cells in BDNF over–expression mice with induced elevated intraocular pressure
  1718. Peroxisome proliferator-activated receptor-γ activation as a mechanism of preventive Neuroprotection induced by pioglitazone treatment
  1719. Neuroprotection in Ischemic Stroke Mediated by Intracerebral Transplantation of Human Umbilical Cord Cells
  1720. Role of microtubule-associated kinases and phosphatases in Neuroprotection against amyloid-beta toxicity.
  1721. Distribution, Expression, and Inflammatory Response after Non-Viral Gene Delivery to the Primate CNS: A Model for Operative Neuroprotection
  1722. Neuroprotection of MK-801 and magnesium sulfate in 7-day rats with hypoxic ischemic encephalathy (HIE)
  1723. Sigma receptors mediate potent Neuroprotection in vivo and inhibit neuronal depolarisation and swelling in rat brain slices
  1724. Neuroprotection action of Aspirin on cerebral ischemia-reperfusion rats with different treatment time-window and its effect on ATP levels
  1725. Estrogen mediates Neuroprotection via estrogen receptor α, not β, in a neuronal in vitro model
  1726. Caffeine, adenosine A2A receptors, and Neuroprotection in PD Schwarzschiid MA Massacusetts General Hospital, Boston, USA
  1727. Analogous Neuroprotection induced by resveratrol and ischemic preconditioning in CA1 region of hippocampus after ischemia
  1728. Strategies for Neuroprotection Using Passive (Neurotrophin-Deprivation) and Active (Virotoxin Exposure) Models of Neuronal Cell Death
  1729. SPONTANEOUS HYPOTHERMIA PROVIDES ENDOGENOUS Neuroprotection FROM CARDIAC ARREST AND CARDIOPULMONARY RESUSCITATION (CPR …
  1730. Neuroprotection From Calcineurin–Mediated Retinal Ganglion Cell Apoptosis by FK506 in Experimental Glaucoma
  1731. Neuroprotection by LAU–0901 in light–induced retinal damage: rod and cone photoreceptor sparing
  1732. ACh Receptor Activation Links Two Separate Signaling Proteins to Neuroprotection Against Glutamate–Induced Excitotoxicity in Isolated Pig Retinal Ganglion Cells
  1733. Neuroprotection by Native Wild Vegetable Extract against Oxidative Damage in the Mouse brain Induced by Kainic Acid
  1734. Stroke units, tissue plasminogen activator, aspirin and Neuroprotection : which stroke intervention could provide the greatest community benefit?
  1735. Ketamine Neuroprotection in the Rabbit Retina after Pars Plana Vitrectomy with Silicone Oil Tamponade
  1736. Understanding apoptosis: the key to Neuroprotection in glaucoma; As researchers unlock the secrets of programmed cell death, they shed new light on optic …
  1737. Secreted Proteins from Retinal Mueller Glia Enhance Photoreceptor Survival: An Approach to Detection of New Candidates for Neuroprotection
  1738. … Protein Co-Localizes with an NMDA Receptor Subunit in Transfected Cells and Is Detectable in brain Extracts: Prerequisites for a Possible Role in Neuroprotection
  1739. Isoflurane Neuroprotection in Hypoxic Hippocampal Slice Cultures Involves Increases in Intracellular Ca2+ and MAP Kinases
  1740. Pretreament with repeated electroacupuncture induced Neuroprotection against spinal cord ischemia-reperfusion injury in rabbits
  1741. Metabotropic glutamate receptors in spinal cord injury: Roles in Neuroprotection , chronic central pain, and locomotor recovery.
  1742. Aggravation of ischemic brain injury by prion protein deficiency, but lack of Neuroprotection by elevated prion protein levels: Role of tyrosine kinases
  1743. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against In Vivo excitoxicity in the rat: Role of vanilloid receptors and lipoxygenases
  1744. Transient Ischemia of the Retina Results in Altered Retrograde Axonal Transport by Retinal Ganglion Cells: Neuroprotection With Brimonidine
  1745. Correlative Electrophysiological and Anatomical Studies on the Effects of Retinal Ischemia on the ERG and Orthograde Axonal Transport: Neuroprotection with …
  1746. Mechanism of Apoptosis in Rat Retinal Ganglion Cell Line RGC–5 Involves Calpain–Mediated Proteolysis: Calpain Inhibition Provides Functional Neuroprotection
  1747. … AND ANATOM-ICAL STUDIES ON THE EFFECTS OF RETINAL ISCHEMIA ON THE ERG AND ORTHOGRADE AXONAL TRANSPORT: Neuroprotection WITH …
  1748. NF-B factor c-Rel mediates Neuroprotection elicited by mGlu5 receptor agonists against amyloid-peptide toxicity
  1749. Neuroprotection against ischemic CA1 neurodegeneration by pituitary adenylate cyclase activating polypeptide via cAMP-response-element-binding protein-mediated …
  1750. Neuroprotection in hippocampal slices from the hibernating species Arctic ground squirrel, Spermophilus parryii
  1751. Hypothermia Prolongs the Viability of Ischemic brain Tissue Due to Neuroprotection Linked to Redistribution of Oxygen in brain : Positron Emission Tomography Study …
  1752. … in the brain after transient forebrain ischemia accompanied by an increased expression of galectin-1, and the implication of ΔFosB and galectin-1 in Neuroprotection
  1753. 4 Cellular brain Ischemia and Stroke: Neuroprotection , Metabolism, and New Strategies for brain
  1754. … Three Months Later in Altered Erg, Degeneration of Inner Retinal Layers, and Deafferentation of the Contralateral Superior Colliculus: Long–Term Neuroprotection
  1755. Copolymer-1 vaccination regimens for Neuroprotection in laser-induced retinal injuries
  1756. Uncoupling Proteins: Regulation by IGF-1 and Neuroprotection during Hyperglycemia in Vitro
  1757. 155 Combined Inhibition of Neuronal and Inducible Nos Provides Neuroprotection After Hypoxia-Ischaemia in P3 and P7 Rat Pups
  1758. … Meeting of the American Society for Experimental Neurotherapeutics, Washington, DC, March 13-15, 2003—Editor’s Note: Neuroprotection : Translation of Mechanism …
  1759. The role of cyclooxygenase-2 in neurotoxicity and preconditioning-induced Neuroprotection .
  1760. 234 Magnesium Sulphate Given for Neuroprotection Before Preterm Birth
  1761. Optimization of Copolymer–1 Vaccination regimen for Neuroprotection in Laser–Induced Retinal Injuries
  1762. LINGO–1 Exerts Neuroprotection in a Rat Glaucoma Model
  1763. 17 valerate regulates Protein Disulfide Isomerase, c-fos and Nrf2 gene expressions to provide ischemic Neuroprotection in ovariectomized rat
  1764. … BETWEEN THE NEURONAL TRANSCRIPTION FACTOR NOct-3 AND THE HIV-1 TAR AND RRE RNAS: ARationale FOR Neuroprotection ?
  1765. Metallothionein is implicated in zinc (2+) Neuroprotection of cultured rat dopaminergic neurons.
  1766. Age-associated biochemical changes, Alzheimer’s disease and Neuroprotection
  1767. Oxidative Toxicity in BV-2 Microglia Cells: Sesamolin Neuroprotection of H2O2 Injury Involving Activation of p38 Mitogen-Activated Protein Kinase
  1768. PB-007 Memantine Provides Neuroprotection in Animal Models at Therapeutically Relevant Doses
  1769. Neuroprotection : challenges and opportunities
  1770. Pathologically activated therapeutics for Neuroprotection
  1771. Hypothermic Neuroprotection
  1772. Future of Neuroprotection for acute stroke: in the aftermath of the SAINT trials
  1773. Glaucoma Neuroprotection : What is it? Why is it needed?
  1774. Mechanisms of Neuroprotection by estrogen
  1775. Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity
  1776. Neuroprotection and stroke: time for a compromise
  1777. Microglia provide Neuroprotection after ischemia
  1778. Pharmacological Neuroprotection for glaucoma
  1779. Minocycline for short‐term Neuroprotection
  1780. Neurotrophins and their receptors: roles in plasticity, neurodegeneration and Neuroprotection
  1781. Cell survival matters: docosahexaenoic acid signaling, Neuroprotection and photoreceptors
  1782. Kynurenine pathway in major depression: evidence of impaired Neuroprotection
  1783. Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature
  1784. PPAR: a new pharmacological target for Neuroprotection in stroke and neurodegenerative diseases
  1785. Paradigm shift in Neuroprotection by NMDA receptor blockade: memantine and beyond
  1786. Neuroprotection targets after traumatic brain injury
  1787. Neuroprotection by ovarian hormones in animal models of neurological disease
  1788. Neuroprotection and neuroplasticity–a holistic approach and future perspectives
  1789. Magnesium sulfate for Neuroprotection after traumatic brain injury: a randomised controlled trial
  1790. Novel mechanisms for estrogen-induced Neuroprotection
  1791. Estrogen action in Neuroprotection and brain inflammation
  1792. brain aromatase: roles in reproduction and Neuroprotection
  1793. The role of T helper cells in Neuroprotection and regeneration
  1794. Autophagy, bafilomycin and cell death: the “aB-cs” of plecomacrolide-induced Neuroprotection
  1795. Neuroprotection by resveratrol against traumatic brain injury in rats
  1796. Role of astrocytes in reproduction and Neuroprotection
  1797. Molecular and cellular immune mediators of Neuroprotection
  1798. Prolonged activation of ASIC1a and the time window for Neuroprotection in cerebral ischaemia
  1799. Progesterone: therapeutic opportunities for Neuroprotection and myelin repair
  1800. Neuroprotection by pharmacologic blockade of the GAPDH death cascade
  1801. Auto-catalytic ceria nanoparticles offer Neuroprotection to adult rat spinal cord neurons
  1802. Lymphocytes: potential mediators of postischemic injury and Neuroprotection
  1803. brain Neuroprotection by scavenging blood glutamate
  1804. Preconditioning doses of NMDA promote Neuroprotection by enhancing neuronal excitability
  1805. Neuroprotection by histone deacetylase-related protein
  1806. Aspects of growth hormone and insulin-like growth factor-I related to Neuroprotection , regeneration, and functional plasticity in the adult brain
  1807. Activation of the Keap1/Nrf2 pathway for Neuroprotection by electrophillic phase II inducers
  1808. PPARs: a new target for Neuroprotection
  1809. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia
  1810. Role of astrocytes in estrogen-mediated Neuroprotection
  1811. On the hypes and falls in Neuroprotection : targeting the NMDA receptor
  1812. Cell biology and clinical promise of G‐CSF: immunomodulation and Neuroprotection
  1813. A systematic review of cooling for Neuroprotection in neonates with hypoxic ischemic encephalopathy–are we there yet?
  1814. Role of δ‐opioid receptor function in neurogenesis and Neuroprotection
  1815. Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia
  1816. Dopamine in neurotoxicity and Neuroprotection : what do D2 receptors have to do with it?
  1817. Neuroprotection by erythropoietin administration after experimental traumatic brain injury
  1818. Nicotine Neuroprotection against nigrostriatal damage: importance of the animal model
  1819. A select combination of neurotrophins enhances Neuroprotection and functional recovery following spinal cord injury
  1820. Neurorepair versus Neuroprotection in stroke
  1821. Progesterone-induced Neuroprotection
  1822. Inhibition of mitochondrial function in astrocytes: implications for Neuroprotection
  1823. Dual effects of antioxidants in neurodegeneration: direct Neuroprotection against oxidative stress and indirect protection via suppression of gliamediated inflammation
  1824. Inflammation, demyelination, neurodegeneration and Neuroprotection in the pathogenesis of multiple sclerosis
  1825. Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats
  1826. The ischemic penumbra: a new opportunity for Neuroprotection
  1827. Cystine/glutamate exchange modulates glutathione supply for Neuroprotection from oxidative stress and cell proliferation
  1828. Neuroprotection in emerging psychotic disorders
  1829. Peptide Neuroprotection through specific interaction with brain tubulin
  1830. Transplantation of human neural stem cells exerts Neuroprotection in a rat model of Parkinson’s disease
  1831. Chinese herbs and herbal extracts for Neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease
  1832. Erythropoietin enhances long-term Neuroprotection and neurogenesis in neonatal stroke
  1833. Xenon provides short-term Neuroprotection in neonatal rats when administered after hypoxia-ischemia
  1834. Improved reperfusion and Neuroprotection by creatine in a mouse model of stroke
  1835. Cannabinoids and Neuroprotection in basal ganglia disorders
  1836. SIRT1 activation confers Neuroprotection in experimental optic neuritis
  1837. Human neural stem cells over-expressing VEGF provide Neuroprotection , angiogenesis and functional recovery in mouse stroke model
  1838. Neuro (active) steroids actions at the neuromodulatory sigma1 (σ1) receptor: biochemical and physiological evidences, consequences in Neuroprotection
  1839. Pleiotropic functions of PACAP in the CNS: Neuroprotection and neurodevelopment
  1840. Eicosapentaenoic acid confers Neuroprotection in the amyloid-β challenged aged hippocampus
  1841. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats
  1842. Dissecting the signaling pathway of nicotine‐mediated Neuroprotection in a mouse Alzheimer disease model
  1843. Adenosine A2A receptors and brain injury: broad spectrum of Neuroprotection , multifaceted actions and “fine tuning” modulation
  1844. Modulation of interleukin-1β mediated inflammatory response in human astrocytes by flavonoids: implications in Neuroprotection
  1845. Suppression of mitochondrial oxidative stress provides long-term Neuroprotection in experimental optic neuritis
  1846. Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with Neuroprotection
  1847. Protease-activated receptors in the brain : receptor expression, activation, and functions in neurodegeneration and Neuroprotection
  1848. Parkin mediates Neuroprotection through activation of IκB kinase/nuclear factor-κB signaling
  1849. Mitochondrial mechanism of Neuroprotection by CART
  1850. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated Neuroprotection
  1851. Structure–nongenomic Neuroprotection relationship of estrogens and estrogen-derived compounds
  1852. Neuroprotection by endogenous and exogenous PACAP following stroke
  1853. Hypothermia for Neuroprotection after cardiac arrest: mechanisms, clinical trials and patient care
  1854. Calcium: a role for Neuroprotection and sustained adaptation
  1855. Life after cerovive: a personal perspective on ischemic Neuroprotection in the post–NXY-059 era
  1856. Valproic acid-mediated Neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation
  1857. Neuroprotection and free radical scavenging effects of Osmanthus fragrans
  1858. Estrogen, neuroinflammation and Neuroprotection in Parkinson’s disease: glia dictates resistance versus vulnerability to neurodegeneration
  1859. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/Neuroprotection
  1860. Novel Neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson’s disease
  1861. A novel role for Sema3A in Neuroprotection from injury mediated by activated microglia
  1862. Pathologically-activated therapeutics for Neuroprotection : mechanism of NMDA receptor block by memantine and S-nitrosylation
  1863. Gender-Specific Neuroprotection by 2-Iminobiotin after Hypoxia—Ischemia in the Neonatal Rat via a Nitric Oxide Independent Pathway
  1864. The seek of Neuroprotection : introducing cannabinoids
  1865. The dynamics of statins: from event prevention to Neuroprotection
  1866. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in Neuroprotection
  1867. Estrogen receptor α and β differentially regulate intracellular Ca2+ dynamics leading to ERK phosphorylation and estrogen Neuroprotection in hippocampal neurons
  1868. T lymphocyte trafficking: a novel target for Neuroprotection in traumatic brain injury
  1869. Neuroprotection at the nanolevel—Part I: Introduction to nanoneurosurgery
  1870. The role of erythropoietin in Neuroprotection : therapeutic perspectives.
  1871. Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing Neuroprotection
  1872. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone
  1873. Fractalkine: moving from chemotaxis to Neuroprotection
  1874. New insights into the roles of metalloproteinases in neurodegeneration and Neuroprotection
  1875. Cross-talk between IGF-I and estradiol in the brain : focus on Neuroprotection
  1876. Role of cocaine-and amphetamine-regulated transcript in estradiol-mediated Neuroprotection
  1877. Antenatal magnesium sulphate Neuroprotection in the preterm infant
  1878. Serotonin and Neuroprotection in functional bowel disorders
  1879. Mechanisms of cell death and Neuroprotection by poloxamer 188 after mechanical trauma
  1880. Neuroprotection in the peripheral nervous system: rationale for more effective therapies
  1881. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and Neuroprotection by PSD-95 inhibitors
  1882. Upregulation of thioredoxin system via Nrf2-antioxidant responsive element pathway in adaptive-retinal Neuroprotection in vivo and in vitro
  1883. … in epigenetic modulators superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron Neuroprotection studies
  1884. Peroxisome proliferator‐activated receptor‐γ agonists induce Neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as …
  1885. Induction of multiple heat shock proteins and Neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis
  1886. Extensive Neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys
  1887. Distinct mechanisms underlie distinct polyphenol-induced Neuroprotection
  1888. Neuroprotection against ischaemic brain injury by a GluR6-9c peptide containing the TAT protein transduction sequence
  1889. Blueberry supplemented diet reverses age-related decline in hippocampal HSP70 Neuroprotection
  1890. Tumor necrosis factor α but not interleukin 1β mediates Neuroprotection in response to acute nitric oxide excitotoxicity
  1891. Neuroprotection against neurodegenerative diseases
  1892. Neuroprotection against surgically induced brain injury
  1893. Transient Neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or …
  1894. Deterioration in acute ischemic stroke as the target for Neuroprotection
  1895. Therapeutic time window of post-ischemic mild hypothermia and the gene expression associated with the Neuroprotection in rat focal cerebral ischemia
  1896. Physiological Neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson’s disease
  1897. Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis
  1898. Neurodegeneration and Neuroprotection in multiple sclerosis and other neurodegenerative diseases
  1899. Cardiac glycosides provide Neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform
  1900. Neurotoxicity of reactive aldehydes: the concept of “aldehyde load” as demonstrated by Neuroprotection with hydroxylamines
  1901. Neuroprotection : a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide
  1902. Activation of cerebral peroxisome proliferator‐activated receptors gamma promotes Neuroprotection by attenuation of neuronal cyclooxygenase‐2 overexpression …
  1903. G-CSF and Neuroprotection : a therapeutic perspective in cerebral ischaemia
  1904. Estrogen prevents Neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson’s disease
  1905. Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in Neuroprotection against glutamate-induced …
  1906. Can imaging techniques measure Neuroprotection and remyelination in multiple sclerosis?
  1907. The function of microglia, either Neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro
  1908. Intrinsic and extrinsic erythropoietin enhances Neuroprotection against ischemia and reperfusion injury in vitro
  1909. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington’s disease
  1910. Neuroprotection in multiple sclerosis
  1911. Preclinical evidence of Neuroprotection by cholinesterase inhibitors
  1912. Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia
  1913. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in α7 nicotinic receptor knockout mice
  1914. Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in Neuroprotection
  1915. Neuroprotection of nicotiflorin in permanent focal cerebral ischemia and in neuronal cultures
  1916. Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke
  1917. Axonal loss and Neuroprotection in optic neuropathies
  1918. Mechanisms of Neuroprotection during ischemic preconditioning: lessons from anoxic tolerance
  1919. Pregnane X receptor (PXR) activation: a mechanism for Neuroprotection in a mouse model of Niemann–Pick C disease
  1920. Post‐trauma Lipitor treatment prevents endothelial dysfunction, facilitates Neuroprotection , and promotes locomotor recovery following spinal cord injury
  1921. Neuroprotection in cerebral infarction: the opportunity of new studies
  1922. Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and Neuroprotection
  1923. Cell signaling pathways in the mechanisms of Neuroprotection afforded by bergamot essential oil against NMDA‐induced cell death in vitro
  1924. Sigma receptor agonists provide Neuroprotection in vitro by preserving bcl-2
  1925. Vanilloid VR1 receptor is involved in rimonabant‐induced Neuroprotection
  1926. Role of the Fas-signaling pathway in photoreceptor Neuroprotection
  1927. Mild hypothermia diminishes oxidative DNA damage and pro-death signaling events after cerebral ischemia: a mechanism for Neuroprotection
  1928. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres
  1929. Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion
  1930. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat
  1931. Neuroprotection in epilepsy
  1932. Neuroprotection in Parkinson models varies with toxin administration protocol
  1933. Methamphetamine‐induced alterations in monoamine transport: implications for neurotoxicity, Neuroprotection and treatment
  1934. Issues in Neuroprotection clinical trials in Parkinson’s disease
  1935. Gene transfer of insulin-like growth factor–I providing Neuroprotection after spinal cord injury in rats
  1936. Opioid preconditioning induces opioid receptor-dependent delayed Neuroprotection against ischemia in rats
  1937. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor κB (NF-κB), inflammatory gene expression, and …
  1938. Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity
  1939. Aldehyde load in ischemia–reperfusion brain injury: Neuroprotection by neutralization of reactive aldehydes with phenelzine
  1940. Neuroprotection from secondary injury by polyethylene glycol requires its internalization
  1941. Calpeptin provides functional Neuroprotection to rat retinal ganglion cells following Ca2+ influx
  1942. Nonredundant role of Akt2 for Neuroprotection of rod photoreceptor cells from light-induced cell death
  1943. Wide therapeutic time window for fasudil Neuroprotection against ischemia-induced delayed neuronal death in gerbils
  1944. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or Neuroprotection
  1945. Mechanism of progesterone Neuroprotection of rat cerebellar Purkinje cells following oxygen–glucose deprivation
  1946. Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins
  1947. A novel immune-based therapy for stroke induces Neuroprotection and supports neurogenesis
  1948. Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, Neuroprotection , food application and chemoprevention …
  1949. Gender-dependent pathways of hypoxia-ischemia-induced cell death and Neuroprotection in the immature P3 rat
  1950. Role of Nrf2-dependent ARE-driven antioxidant pathway in Neuroprotection
  1951. Immune control by endocannabinoids—new mechanisms of Neuroprotection ?
  1952. Erythropoietin: a new paradigm for Neuroprotection
  1953. Reduction in oxidative stress and cell death explains hypothyroidism induced Neuroprotection subsequent to ischemia/reperfusion insult
  1954. Neuroprotection during chemotherapy: a systematic review
  1955. Prevention of inflammation is a mechanism of preconditioning-induced Neuroprotection against focal cerebral ischemia
  1956. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion
  1957. Lentivirus-mediated expression of glutathione peroxidase: Neuroprotection in murine models of Parkinson’s disease
  1958. Tryptophan, adenosine, neurodegeneration and Neuroprotection
  1959. Neuroprotection against ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal kinase (JNK) via nuclear and non-nuclear pathways
  1960. Zinc attenuates malathion-induced depressant-like behavior and confers Neuroprotection in the rat brain
  1961. Preventing clinical deterioration in the course of schizophrenia: the potential for Neuroprotection .
  1962. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent Neuroprotection
  1963. Enhancement of Neuroprotection of mulberry leaves (Morus alba L.) prepared by the anaerobic treatment against ischemic damage
  1964. The role of nitric oxide in the Neuroprotection of limb ischemic preconditioning in rats
  1965. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice
  1966. Clinical trials for Neuroprotection in Parkinson’s disease: overcoming angst and futility?
  1967. Broad spectrum Neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation
  1968. Dose-dependent Neuroprotection of delta opioid peptide [D-Ala2, D-Leu5] enkephalin in neuronal death and retarded behavior induced by forebrain ischemia in rats
  1969. An in vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP+ toxicity and GDNF Neuroprotection
  1970. Neuroprotection and neurosupplementation in ischaemic brain
  1971. Polyphenol amentoflavone affords Neuroprotection against neonatal hypoxic‐ischemic brain damage via multiple mechanisms
  1972. Neuroprotection by cAMP
  1973. Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic Neuroprotection conferred by the slow …
  1974. Melanocortins defend their territory: multifaceted Neuroprotection in cerebral ischemia
  1975. Age-related changes in Neuroprotection
  1976. Cannabinoids and Neuroprotection in motor-related disorders
  1977. Neuroprotection by GDNF-secreting stem cells in a Huntington’s disease model: optical neuroimage tracking of brain -grafted cells
  1978. Overexpression of APP provides Neuroprotection in the absence of functional benefit following middle cerebral artery occlusion in rats
  1979. Ischaemic brain damage after stroke: new insights into efficient therapeutic strategies: International Symposium on Neurodegeneration and Neuroprotection
  1980. Dexmedetomidine and Neuroprotection
  1981. Immune-mediated Neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4+ T cells
  1982. Experimental models of Neuroprotection relevant to multiple sclerosis
  1983. XIAP-mediated Neuroprotection in retinal ischemia
  1984. NO‐induced Neuroprotection in ischemic preconditioning stimulates mitochondrial Mn‐SOD activity and expression via RAS/ERK1/2 pathway
  1985. Edaravone Neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats
  1986. The role of extracellular signal-regulated kinases in the Neuroprotection of limb ischemic preconditioning
  1987. The Neuroprotection conferred by activating the mitochondrial ATP-sensitive K+ channel is mediated by inhibiting the mitochondrial permeability transition pore
  1988. Slit modulates cerebrovascular inflammation and mediates Neuroprotection against global cerebral ischemia
  1989. Neuroprotection : a therapeutic strategy to prevent deterioration associated with schizophrenia.
  1990. Galantamine postischemia provides Neuroprotection and memory recovery against transient global cerebral ischemia in gerbils
  1991. Neuroprotection during cardiac surgery
  1992. Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants
  1993. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of …
  1994. Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth
  1995. Transplants of encapsulated rat choroid plexus cells exert Neuroprotection in a rodent model of Huntington’s disease
  1996. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in Neuroprotection afforded by 17β‐estradiol
  1997. Evolving paradigms for Neuroprotection : molecular identification of ischemic penumbra
  1998. Why hasn’t Neuroprotection worked in Parkinson’s disease?
  1999. Neuroprotection by estradiol: a role of aromatase against spine synapse loss after blockade of GABAA receptors
  2000. Novel thyroxine derivatives, thyronamine and 3-iodothyronamine, induce transient hypothermia and marked Neuroprotection against stroke injury
  2001. Omega-3 fatty acids, pro-inflammatory signaling and Neuroprotection
  2002. Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window
  2003. The application of proteomics and genomics to the study of age-related neurodegeneration and Neuroprotection
  2004. Stroke: the dashed hopes of Neuroprotection .
  2005. Neuroprotection of G-CSF in cerebral ischemia.
  2006. Neuroprotection of Tat-GluR6-9c against neuronal death induced by kainate in rat hippocampus via nuclear and non-nuclear pathways
  2007. Neuroprotection by sodium ferulate against glutamate‐induced apoptosis is mediated by ERK and PI3 kinase pathways1
  2008. Neuroprotection conferred by astrocytes is insufficient to protect animals from succumbing to Japanese encephalitis
  2009. Role of estrogen receptors in Neuroprotection by estradiol against MPTP toxicity
  2010. Geranylgeranylacetone, a noninvasive heat shock protein inducer, induces protein kinase C and leads to Neuroprotection against cerebral infarction in rats
  2011. Impact of Neuroprotection on incidence of Alzheimer’s disease
  2012. New insights into purinergic receptor signaling in neuronal differentiation, Neuroprotection , and brain disorders
  2013. Neuroprotection of selenite against ischemic brain injury through negatively regulating early activation of ASK1/JNK cascade via activation of PI3K/AKT pathway1
  2014. Behavioral and histologic Neuroprotection of aqueous garlic extract after reversible focal cerebral ischemia
  2015. Peripheral inflammation and Neuroprotection : systemic pretreatment with complete Freund’s adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of …
  2016. Neurogenesis and Neuroprotection in the CNS—fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders
  2017. Neuroprotection in the juvenile rat model of light-induced retinopathy: evidence suggesting a role for FGF-2 and CNTF
  2018. Purinergic receptor-stimulated IP3-mediated Ca2+ release enhances Neuroprotection by increasing astrocyte mitochondrial metabolism during aging
  2019. Neuroprotection for Parkinson’s disease
  2020. Group I metabotropic receptor Neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and β-catenin during oxidative stress
  2021. Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased Neuroprotection after chronic cerebral hypoperfusion in …
  2022. Neuronal death and Neuroprotection : a review
  2023. Currently evaluated calpain and caspase inhibitors for Neuroprotection in experimental brain ischemia
  2024. Deprenyl: from chemical synthesis to Neuroprotection
  2025. Synergistic Neuroprotection by bis (7)-tacrine via concurrent blockade of N-methyl-D-aspartate receptors and neuronal nitric-oxide synthase
  2026. Selective cerebral hypothermia for post-hypoxic Neuroprotection in neonates using a solid ice cap
  2027. NMDA Neuroprotection against a phosphatidylinositol‐3 kinase inhibitor, LY294002 by NR2B‐mediated suppression of glycogen synthase kinase‐3β‐induced …
  2028. Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional Neuroprotection and neurorestoration in MPTP‐treated monkeys
  2029. Evidence for Neuroprotection and remyelination using imaging techniques
  2030. In vitro and in vivo Neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson’s disease
  2031. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design
  2032. Neuroprotection by extract of Petasites japonicus leaves, a traditional vegetable, against oxidative stress in brain of mice challenged with kainic acid
  2033. Evidence of GLP-1-mediated Neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy
  2034. Thrombolysis and Neuroprotection in cerebral ischemia
  2035. Enhancement of Neuroprotection and heat shock protein induction by combined prostaglandin A1 and lithium in rodent models of focal ischemia
  2036. Testosterone induces Neuroprotection from oxidative stress. Effects on catalase activity and 3-nitro-L-tyrosine incorporation into alpha-tubulin in a mouse …
  2037. Endogenous α2-adrenergic receptor-mediated Neuroprotection after severe hypoxia in preterm fetal sheep
  2038. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERα in primary cultures of mouse mesencephalon
  2039. The role of CaMKII in BDNF-mediated Neuroprotection of retinal ganglion cells (RGC-5)
  2040. ERK 1/2 signaling pathway is involved in nicotine‐mediated Neuroprotection in spinal cord neurons
  2041. Non-pharmacological Neuroprotection : role of emergency stroke management
  2042. Neuroprotection in Parkinson’s disease: an elusive goal
  2043. Multimodal assessment of Neuroprotection applied to the use of MK-801 in the endothelin-1 model of transient focal brain ischemia
  2044. What constitutes clinical evidence for Neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?
  2045. Neuroprotection by propargylamines in Parkinson’s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers
  2046. Akt phosphorylation is required for heat acclimation‐induced Neuroprotection
  2047. Neuroprotection via inhibition of nitric oxide synthase by bis (7)-tacrine
  2048. Molecular mechanisms of Neuroprotection in the eye
  2049. Neuroprotection for ischemic stroke using hypothermia
  2050. … -traumatic application of brain -derived neurotrophic factor and glia-derived neurotrophic factor on the rat spinal cord enhances Neuroprotection and improves motor …
  2051. Neuroprotection and stroke rehabilitation: modulation and enhancement of recovery
  2052. Prophylactic Neuroprotection
  2053. Complement activation in autoimmune demyelination: dual role in neuroinflammation and Neuroprotection
  2054. Neuroprotection by taurine and taurine analogues
  2055. A critical appraisal of the NXY-059 Neuroprotection studies for acute stroke: a need for more rigorous testing of Neuroprotective agents in animal models of stroke
  2056. Dopaminergic Neuroprotection by neurturin-expressing c17. 2 neural stem cells in a rat model of Parkinson’s disease
  2057. Exogenous erythropoietin provides Neuroprotection of grafted dopamine neurons in a rodent model of Parkinson’s disease
  2058. Neuroprotection by nicotine in hippocampal slices subjected to oxygen-glucose deprivation
  2059. Neuroprotection : A new strategy in the treatment of schizophrenia
  2060. Sex, Neuroprotection , and neonatal ischemia’/’Johnston and Hagberg reply’
  2061. Estimation of the hypothermic component in Neuroprotection provided by cannabinoids following cerebral ischemia
  2062. Neuroprotection and enhanced recovery with hypericum perforatum extract after experimental spinal cord injury in mice
  2063. Gene expression in cerebral ischemia: a new approach for Neuroprotection
  2064. Evidence to implicate early modulation of interleukin‐1β expression in the Neuroprotection afforded by 17β‐Estradiol in male rats undergone transient middle cerebral …
  2065. Neuroprotection of adenoviral-vector-mediated GDNF expression against kainic-acid-induced excitotoxicity in the rat hippocampus
  2066. Conventional protein kinase C isoforms mediate Neuroprotection induced by phorbol ester and estrogen
  2067. VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new Neuroprotection target
  2068. Neuroprotection of insulin against oxidative stress‐induced apoptosis in cultured retinal neurons: involvement of phosphoinositide 3‐kinase/Akt signal pathway
  2069. Neuroprotection of retinal ganglion cell function and their central nervous system targets
  2070. Neuroprotection by small molecule activators of the nerve growth factor receptor
  2071. Estrogen receptor beta agonist diarylpropiolnitrile (DPN) does not mediate Neuroprotection in a rat model of permanent focal ischemia
  2072. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated Neuroprotection through increased levels of glutathione …
  2073. Substance P provides Neuroprotection in cerebellar granule cells through Akt and MAPK/Erk activation: evidence for the involvement of the delayed rectifier potassium …
  2074. Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces Neuroprotection in cerebral ischemia
  2075. Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat
  2076. … oxidative stress mediated by 2, 2-azobis (2-amidino-propane) dihydrochloride (AAPH) or Fe2+/H2O2: Insight into mechanisms of Neuroprotection and relevance to …
  2077. Rab‐mediated endocytosis: linking neurodegeneration, Neuroprotection , and synaptic plasticity?
  2078. Neuroprotection in vascular dementia
  2079. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain : Neuroprotection versus neurotoxicity
  2080. Acetylcholine Neuroprotection against glutamate-induced excitotoxicity in adult pig retinal ganglion cells is partially mediated through α4 nAChRs
  2081. Sustained Neuroprotection and facilitation of behavioral recovery by the Ginkgo biloba extract, EGb 761, after transient forebrain ischemia in rats
  2082. Recent advances in Neuroprotection for treating traumatic brain injury
  2083. Perfusing the cold brain : optimal Neuroprotection for aortic surgery
  2084. Direct evidence for calpain involvement in apoptotic death of neurons in spinal cord injury in rats and Neuroprotection with calpain inhibitor
  2085. Pharmacologic Neuroprotection : the search continues
  2086. Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 Cause Potent Neuroprotection after Experimental Stroke through Noncompletely Overlapping Mechanisms
  2087. Selective γ-aminobutyric acid type A receptor antagonism reverses isoflurane ischemic Neuroprotection
  2088. Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin
  2089. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated Neuroprotection against hippocampal neuronal death after transient global …
  2090. Neuroprotection of rat hippocampal slices exposed to oxygen–glucose deprivation by enrichment with docosahexaenoic acid and by inhibition of hydrolysis of …
  2091. The mechanism of 1, 2, 3, 4‐tetrahydroisoquinolines Neuroprotection : the importance of free radicals scavenging properties and inhibition of glutamate‐induced …
  2092. Neuroprotection : models, mechanisms and therapies
  2093. nPKCε and NMDA receptors participate in Neuroprotection induced by morphine pretreatment
  2094. Glioblastoma in a boy with fragile X: an unusual case of Neuroprotection
  2095. Role of signal transducer and activator of transcription-3 in estradiol-mediated Neuroprotection
  2096. Clinical trials aimed at detecting Neuroprotection in Parkinson’s disease
  2097. Isoflurane Neuroprotection in Rat Hippocampal Slices Decreases with Aging: Changes in Intracellular Ca2+ Regulation and N-methyl-d-aspartate Receptor–mediated …
  2098. Neuroprotection : lessons from a spectrum of neurological disorders
  2099. Bcl-2 upregulation and Neuroprotection in guinea pig brain following chronic simvastatin treatment
  2100. Intracarotid injection of granulocyte–macrophage colony-stimulating factor induces Neuroprotection in a rat transient middle cerebral artery occlusion model
  2101. The limits of viability and the uncertainty of Neuroprotection : challenges in optimizing outcomes in extreme prematurity
  2102. Amine oxidases and their inhibitors: what can they tell us about Neuroprotection and the development of drugs for neuropsychiatric disorders?
  2103. Neuroprotection afforded by diazepam against oxygen/glucose deprivation-induced injury in rat cortical brain slices
  2104. Coenzyme Q 10 provides Neuroprotection in iron-induced apoptosis in dopaminergic neurons
  2105. Gender, sex steroids, and Neuroprotection following traumatic brain injury
  2106. … Heat Stress–Induced cognitive Dysfunction and brain Pathology: An Experimental Study in the Rat, Using Growth Hormone Therapy for Possible Neuroprotection
  2107. … tea polyphenol (–)‐epigallocatechin‐3‐gallate promotes the rapid protein kinase C‐and proteasome‐mediated degradation of Bad: implications for Neuroprotection
  2108. … of new 4H-pyrano [2, 3-b] quinoline derivatives that block acetylcholinesterase and cell calcium signals, and cause Neuroprotection against calcium overload and free …
  2109. Estrogen-mediated Neuroprotection in the cortex may require NMDA receptor activation
  2110. Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector
  2111. Dual effect of adenovirus‐mediated transfer of BMP7 in mixed neuron‐glial cultures: Neuroprotection and cellular differentiation
  2112. Phosphatidylinositol 3-Akt-kinase-dependent phosphorylation of p21Waf1/Cip1 as a novel mechanism of Neuroprotection by glucocorticoids
  2113. Erythropoietin depletes iron stores: antioxidant Neuroprotection for ischemic stroke?
  2114. Hippocampal vulnerability following traumatic brain injury: A potential role for neurotrophin‐4/5 in pyramidal cell Neuroprotection
  2115. Transient expression of Nxf, a bHLH–PAS transactivator induced by neuronal preconditioning, confers Neuroprotection in cultured cells
  2116. Neuroprotection in schizophrenia
  2117. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis
  2118. Farnesyl transferase inhibitors induce Neuroprotection by inhibiting Ha‐Ras signalling pathway
  2119. Global hypothermia for Neuroprotection after cardiac arrest
  2120. Cannabinoids in microglia: a new trick for immune surveillance and Neuroprotection
  2121. Bench to bedside strategies for optimizing Neuroprotection following perinatal hypoxia–ischaemia in high and low resource settings
  2122. Neuroprotection –STAIR-way to the future?
  2123. Macrophage-mediated Neuroprotection and neurogenesis in the olfactory epithelium
  2124. Traumatic brain injury induced Neuroprotection of retinal ganglion cells to optic nerve crush
  2125. Nerve growth factor Neuroprotection of ethanol-induced neuronal death in rat cerebral cortex is age dependent
  2126. T cell independent mechanism for copolymer‐1‐induced Neuroprotection
  2127. Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to Neuroprotection during cardiac surgery
  2128. Delta opioid receptors stimulation with [D-Ala2, D-Leu5] enkephalin does not provide Neuroprotection in the hippocampus in rats subjected to forebrain ischemia
  2129. Trypanosome trans-sialidase mediates Neuroprotection against oxidative stress, serum/glucose deprivation, and hypoxia-induced neurite retraction in Trk-expressing …
  2130. Induced hypothermia for Neuroprotection : understanding the underlying mechanisms
  2131. Glycogen synthase kinase-3 in neurodegeneration and Neuroprotection : lessons from lithium
  2132. Neuroprotection in primary brain tumors: sense or nonsense?
  2133. … the base-excision repair pathway after focal ischemic brain injury: a protein phosphorylation-dependent mechanism reversed by hypothermic Neuroprotection
  2134. I can’t get no satisfaction: still no Neuroprotection for Parkinson disease
  2135. Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for Neuroprotection ?
  2136. Role of CDK5 in Neuroprotection from serum deprivation by μ-opioid receptor agonist
  2137. Neurotrophin-mediated Neuroprotection of hippocampal neurons following traumatic brain injury is not associated with acute recovery of hippocampal function
  2138. Neuroprotection of α-phenyl-n-tert-butyl-nitrone on the neonatal white matter is associated with anti-inflammation
  2139. Exercise-induced Neuroprotection in SMA model mice: a means for determining new therapeutic strategies
  2140. Neuroprotection by a central nervous system–type prostacyclin receptor ligand demonstrated in monkeys subjected to middle cerebral artery occlusion and …
  2141. Translational vehicles for Neuroprotection
  2142. Adenosine in the central nervous system: effects on neurotransmission and Neuroprotection
  2143. … during adolescence changes brain -derived neurotrophic factor and TrkB levels in the rat visual system but does not offer Neuroprotection to retinal ganglion cells …
  2144. Neuroprotection for acute ischaemic stroke: hope reignited.
  2145. Time course of changes in pyridoxal 5′-phosphate (vitamin B6 active form) and its Neuroprotection in experimental ischemic damage
  2146. Oestrogen receptor subtype‐specific repression of calpain expression and calpain enzymatic activity in neuronal cells – implications for Neuroprotection against Ca2+ …
  2147. A call for clinically driven experimental design in assessing Neuroprotection in experimental Parkinsonism
  2148. Effect of cyclosporin a on immediate early gene in rat global ischemia and its Neuroprotection
  2149. New approaches to clinical trials in Neuroprotection : introduction
  2150. Can clinical outcomes be used to detect Neuroprotection in multiple sclerosis?
  2151. Lost in translation: again, another failed Neuroprotection trial
  2152. How to improve Neuroprotection in Parkinson’s disease?
  2153. Model of acute injury to study Neuroprotection
  2154. Mechanisms of VIP‐induced Neuroprotection against neonatal excitotoxicity
  2155. Plasticity of the central nervous system (CNS) following perinatal asphyxia: does nicotinamide provide Neuroprotection ?
  2156. Blockade of PARP activity attenuates poly (ADP‐ribosyl) ation but offers only partial Neuroprotection against NMDA‐induced cell death in the rat retina
  2157. Neuronal cell culture from human embryonic stem cells as in vitro model for Neuroprotection
  2158. Oxidative Stress and Neuroprotection
  2159. Evidence for a role of Hsp70 in the Neuroprotection induced by heat shock pre‐treatment against 3, 4‐methylenedioxymethamphetamine toxicity in rat brain
  2160. Progestins and Neuroprotection : are all progestins created equal?
  2161. Cannabinoid CB 1 receptor stimulation affords Neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro
  2162. Pharmacological Neuroprotection during cardiac surgery
  2163. Marker for a preclinical diagnosis of Parkinson’s disease as a basis for Neuroprotection
  2164. Therapeutic time window of Neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats
  2165. Neuroprotection at the nanolevel—Part II: Nanodevices for neuromodulation—Deep brain stimulation and spinal cord injury
  2166. Effects of long-term adrenalectomy on apoptosis and Neuroprotection in the rat hippocampus
  2167. Neuroprotection with or without erythropoiesis; sometimes less is more
  2168. Neuroprotection in Parkinson’s disease: clinical trials
  2169. Overexpression of lentivirus-mediated glial cell line-derived neurotrophic factor in bone marrow stromal cells and its Neuroprotection for the PC12 cells damaged by …
  2170. Acute implantation of an avulsed lumbosacral ventral root into the rat conus medullaris promotes Neuroprotection and graft reinnervation by autonomic and motor …
  2171. Perturbed synaptosomal calcium homeostasis and behavioral deficits following carbofuran exposure: Neuroprotection by N-acetylcysteine
  2172. Glutamate-related excitotoxicity Neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer’s disease and vascular …
  2173. Activations of nPKCε and ERK1/2 were involved in oxygen-glucose deprivation-induced Neuroprotection via NMDA receptors in hippocampal slices of mice
  2174. Lead and Neuroprotection by iron in ADHD
  2175. Molecular mechanism of ischemic brain injuries and perspectives of drug therapies for Neuroprotection
  2176. Polysialylation of NCAM is upregulated by hyperthermia and participates in heat shock preconditioning-induced Neuroprotection
  2177. Simultaneous bilateral carotid stenting under the circumstance of Neuroprotection device: a retrospective analysis
  2178. … pressure augmentation during retrograde cerebral perfusion under moderate hypothermia provides adequate Neuroprotection : An experimental study
  2179. Quantitative EEG assessment of brain injury and hypothermic Neuroprotection after cardiac arrest
  2180. Potentiation of in vivo Neuroprotection by BclX L and GDNF co-expression depends on post-lesion time in deafferentiated CNS neurons
  2181. Effects of Pravastatin on Neuroprotection and neurogenesis after cerebral ischemia in rats.
  2182. Assessing Neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo
  2183. 1, 1′-Xylyl bis-1, 4, 8, 11-tetraaza cyclotetradecane: a new potential copper chelator agent for Neuroprotection in Alzheimer’s disease. Its comparative effects with …
  2184. Transcervical carotid stenting with flow reversal for Neuroprotection : technique, results, advantages, and limitations
  2185. Neuroprotection in glaucoma
  2186. Vitamin E in the Neuroprotection of cisplatin induced peripheral neurotoxicity and ototoxicity
  2187. Clinical diagnosis of lacunar stroke in the first 6 hours after symptom onset: analysis of data from the glycine antagonist in Neuroprotection (GAIN) Americas trial
  2188. Back to basics—ephrins, axonal guidance, Neuroprotection and glaucoma
  2189. Neuroprotection : present and future
  2190. Neuroprotection associated with alternative splicing of NMDA receptors in rat cortical neurons
  2191. Increases in expression of 14‐3‐3 eta and 14‐3‐3 zeta transcripts during Neuroprotection induced by Δ9‐tetrahydrocannabinol in AF5 cells
  2192. Carotid artery stenting with distal protection using the carotid wallstent and filterwire Neuroprotection : single-center experience of 380 cases with midterm outcomes
  2193. … immunodeficiency virus–induced neurodegeneration using isolated populations of human neurons, astrocytes, and microglia and Neuroprotection mediated by insulin …
  2194. Nefopam is more potent than carbamazepine for Neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical …
  2195. Neuroprotection by 7-nitroindazole against iron-induced hippocampal neurotoxicity
  2196. Inhibition of MLK3‐MKK4/7‐JNK1/2 pathway by Akt1 in exogenous estrogen‐induced Neuroprotection against transient global cerebral ischemia by a non‐genomic …
  2197. Neuroprotection in perinatal hypoxic-ischemic encephalopathy. Effective treatment and future perspectives
  2198. Bacterial DNA confers Neuroprotection after optic nerve injury by suppressing CD4+ CD25+ regulatory T-cell activity
  2199. Optimising clinical trial design for proof of Neuroprotection in acute ischaemic stroke: the SAINT clinical trial programme
  2200. Neuroprotection of photoreceptors in the RCS rat after implantation of a subretinal implant in the superior or inferior retina
  2201. Development of non-erythropoietic erythropoietin variants for Neuroprotection
  2202. 4th Global College of Neuroprotection and Neuroregeneration meeting
  2203. Retrograde cerebral perfusion with intermittent pressure augmentation provides adequate Neuroprotection : diffusion-and perfusion-weighted magnetic …
  2204. Neuroanesthesia and Neuroprotection : where are we now?
  2205. Identification of Fasting‐induced Genes in the Rat Hypothalamus: Relationship with Neuroprotection
  2206. Neuroprotection induced by mucosal tolerance is epitope-dependent: conflicting effects in different strains
  2207. The combination of isoflurane and caspase 8 inhibition results in sustained Neuroprotection in rats subject to focal cerebral ischemia
  2208. Neuroprotection in malignant mca infarction
  2209. Injections of vehicle, but not cyclosporin A or tacrolimus (FK506) afford Neuroprotection following injury in the developing rat brain
  2210. Competing approaches to excitotoxic Neuroprotection by inert and catalytic antioxidant porphyrins
  2211. Lithium-mediated Neuroprotection during cranial irradiation: a phase I trial
  2212. Adenylyl cyclase isoforms as novel therapeutic targets: an exciting example of excitotoxicity Neuroprotection
  2213. The direct and indirect effects of serofendic acid on Neuroprotection
  2214. Preconditioning with estradiol abolishes its Neuroprotection in cerebellar neurons
  2215. Up-regulation of Bcl-2 in APP transgenic mice is associated with Neuroprotection
  2216. Perinatal Neuroprotection
  2217. Neuroprotection and enhancement of neurite outgrowth with small molecular weight compounds from screens of chemical libraries
  2218. PAN-811 provides Neuroprotection against glutamate toxicity by suppressing activation of JNK and p38 MAPK
  2219. Heat shock proteins and Neuroprotection
  2220. Neuroprotection : where to now?
  2221. Neuroprotection : new pharmacological targets
  2222. Unconventional Neuroprotection against Ca2+‐dependent insults by metalloporphyrin catalytic antioxidants
  2223. Insulin-like growth factor-I and Neuroprotection
  2224. Neuroprotection by diazoxide in animal models for cerebrovascular disorders
  2225. Neuroprotection and neurogenesis: modulation of cornus ammonis 1 neuronal survival after transient forebrain ischemia by prior fimbria-fornix deafferentation
  2226. Neuroprotection of adult human neurons against ischemia by hypothermia and alkalinization
  2227. A clinical trial studying Neuroprotection in low-pressure glaucoma
  2228. Short-and long-term outcome after carotid artery stenting with Neuroprotection : single-center experience within a prospective registry
  2229. EndothelinA receptor antagonist BSF-208075 causes immune modulation and Neuroprotection after stroke in gerbils
  2230. Inhibition of caspase-9 activation and apoptosis is involved in ischemic preconditioning-induced Neuroprotection in rat brain
  2231. Prospects for Neuroprotection in Parkinson’s disease
  2232. Involvement of purα gene in Neuroprotection effects of estrogen in rat ischemic brain model
  2233. How to judge animal models of Parkinson’s disease in terms of Neuroprotection
  2234. Hypertension, vascular cognitive disorders and Neuroprotection
  2235. Breathing, Feeding, and Neuroprotection
  2236. Heparan sulfate mediates Neuroprotection from degeneration in experimental glutaric aciduria
  2237. Motoneurons and CD4+ effector T cell subsets: Neuroprotection and repair
  2238. 15 Lipidomic Approaches to Neuroprotection Signaling in the Retinal Pigment Epithelium
  2239. Rasagiline preclinical studies: Implications for Neuroprotection
  2240. The role of vasoactive intestinal peptide in Neuroprotection : Professor Illana Gozes is interviewed by Emma Quigley.
  2241. Estrogen, neuroinflammation and Neuroprotection in Parkinson’s disease: key role of neuron-glia crosstalk
  2242. Mitochondrial Nutrition as a Strategy for Neuroprotection in Parkinson’s Disease—Research Focus in the Department of Alternative Medicine and Experimental …
  2243. Assessment of the optic disc to measure Neuroprotection
  2244. Neuroprotection by dexmedetomidine
  2245. Study on Chemical and Optic Neuroprotection Components of Erigeron breviscapus
  2246. C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and Neuroprotection
  2247. Cleft-type cyclophanes confer Neuroprotection against excitatory neurotoxicity in vitro and in vivo through inhibition of NMDA receptors
  2248. Neuroprotection during carotid angioplasty and stenting: Comparison of no protection, occlusion, or filters
  2249. Neuroprotection and repair by using adult-derived neural stem cell grafting for neurological disorders
  2250. Neuroprotection of Baicalin on brain Damage Following Experimental Intracerebral Hemorrhage in Rats
  2251. Effects of selective head mild hypothermia on endogenous Neuroprotection in brain following global cerebral ischemia/reperfusion injury: experiment with dogs
  2252. Neuroprotection and drugs used to treat psychiatric disorders
  2253. Anesthetic Neuroprotection : some things do last
  2254. Are cinnamic acids responsible for in vitro Neuroprotection exerted by Bryothamnion triquetrum (SG Gmelin) Howe aqueous extract?
  2255. Neuroprotection : A valuable goal in glaucoma management?
  2256. THE Neuroprotection OF DIETHYLSTILBESTROL ON MESENCEPHALIC NEURONS IN VITRO [J]
  2257. Glutamate transport modulation: a possible role in retinal Neuroprotection
  2258. NXY-059 for acute ischemic stroke: the promise of Neuroprotection is finally realized?
  2259. Mild hypothermia for Neuroprotection after cardiac arrest
  2260. Neuroprotection AND NEUROPLASTICITY IN CRANIOCEREBRAL TRAUMA.
  2261. Shc proteins and brain functions: Possible implications for Neuroprotection
  2262. Detecting the effects of Neuroprotection in living cells
  2263. Neuroprotection with methylaminochroman and lazaroid of embryonic ventral mesencephalic tegmental dopaminergic neurons in cold storage
  2264. Neuroprotection methods and protocols
  2265. Neurodegeneration, Neuroprotection , glial cells, and myelin in multiple sclerosis
  2266. Understanding optic nerve degeneration: key to Neuroprotection in glaucoma
  2267. Superoxide dismutase participates in p38 MAPK-mediated Neuroprotection of limb ischemic preconditioning in global brain ischemic rats
  2268. What have we learned about Neuroprotection in the lab?
  2269. The study on the Neuroprotection of cerebrospinal fluid containing LDP components [J]
  2270. Neuroprotection : Promise and Pitfalls
  2271. Approaches to Neuroprotection and Recovery
  2272. Pharmacologic Neuroprotection in patients with spinal cord injury and the efficacy of early decompressive surgery
  2273. The role of the estrogen in Neuroprotection : Implications for neurodegenerative diseases
  2274. Preface–Special Issue: Molecular mechanisms of CNS injury and Neuroprotection : new roles of amino acids, heme oxygenase system, stress proteins and …
  2275. In vivo tomographic imaging studies of neurodegeneration and Neuroprotection : a review
  2276. Neuroprotection in traumatic brain injury: practical implications for Papua New Guinea and some research developments
  2277. Erythropoietin and Neuroprotection in the central nervous system: intracellular signaling pathways
  2278. Genetical character of CNS injury and autoimmune Neuroprotection [J]
  2279. TRANSCRIPTIONS AND Neuroprotection
  2280. Role of Exercise and GDNF in an Animal Model of Parkinson’s Disease: Implications for Neuroprotection
  2281. Neuroprotection of chloride channel blockers against NMDA-induced apoptosis of cultured rat hippocampal neurons
  2282. Effects of acupuncture at the LU8· KI7 on Anti-apoptotic cell death and Neuroprotection in Rat hippocampus following focal brain ischemic injury induced by …
  2283. ECT and Neuroprotection : a review and proposed study
  2284. Neuronal plasticity as an evolutionary strategy: Implications for Neuroprotection in response to hypoxic challenge
  2285. MHP-133, a drug with multiple CNS targets: potential for Neuroprotection and enhanced cognition
  2286. Global hypothermia for Neuroprotection after cardiac arrest
  2287. Neuroprotection , the role of iron in photoreceptor toxicity induced by subretinal hemorrhage
  2288. Polycyclic indole derivatives as novel structures for Neuroprotection
  2289. Erythropoietin and Neuroprotection in the Peripheral Nervous System: In Vivo Studies
  2290. Novel Endocannabinoids Confer Neuroprotection in NMDA Rat Model
  2291. Pharmacological Neuroprotection against experimental acute cerebral ischemia of neurons of sensomotor area of frontal cortex and hippocampus in rats
  2292. ACUTE STROKE Neuroprotection MODEL
  2293. Selective β1-adrenoreceptor antagonists provide Neuroprotection after focal ischemia in rats
  2294. Neuroprotection in Glaucoma: Is It Possible?
  2295. Neuroprotection strategies from the research lab (’cause there aren’t any ready for prime time yet)
  2296. Recent progress in Neuroprotection of humanin against Alzheimer’s disease-relevant neurotoxicity
  2297. Nitric oxide and histamine in hibernation and Neuroprotection
  2298. Possible sources of Neuroprotection following subretinal silicon chip implantation in RCS rats
  2299. Pharmacological Neuroprotection for glaucoma
  2300. Neuronal restoration of memory disturbances and Neuroprotection for fall in vegetation after cardiac arrest
  2301. Neuroprotection after stroke
  2302. Neuregulins, Neuroprotection and Parkinson’s Disease
  2303. Behavioural aspects of neurodegeneration and Neuroprotection
  2304. Interaction of prion protein with divalent metals: possible role in Neuroprotection and neurodegeneration in prion disease model
  2305. Thyroid hormone regulation of neural and oligodendrocyte precursors in the mature brain : a possibility for remyelination and Neuroprotection
  2306. Phytocannabinoids and Neuroprotection : mechanisms of action and in vitro models
  2307. NT2N cell transplantation and GDNF treatment in stroke: Linking neurotrophic factor therapy and Neuroprotection
  2308. Timecourse of haloperidol-induced midbrain tyrosine hydroxylase downregulation and interventions for Neuroprotection
  2309. Insulin Confers Neuroprotection Against Hyperglycemic Stress-Induced Apoptosis Through PI3K/Akt/mTOR/Nrf2/GCL/Redox Signaling.
  2310. Neuroprotection IN brain HYPOXIA
  2311. Visual Cycle Controls Neuroprotection Switch in the Eye
  2312. Mechanisms of Neuroprotection by Erythropoietin
  2313. A New Dawn for Neuroprotection : NXY-059 for Acute Ischemic Stroke
  2314. Regulation of Calcium Influx in Retinal Ganglion Cells by Sigma-1 Receptor Ligands and Neuroprotection Relevance
  2315. The proteomic study of Ras-induced Neuroprotection
  2316. Cellular and molecular studies of ciliary neurotrophic factor receptor alpha expression and ciliary neurotrophic factor mediated Neuroprotection in the canine retina
  2317. Role of MAPK in Neuroprotection by cart in ischemic stroke
  2318. Neurogeneration and Neuroprotection by Copolymer 1 and Therapeutic Vaccines
  2319. Reduced Neuroprotection by aged astrocytes
  2320. Receptor abuse-dependent antagonism for Neuroprotection
  2321. The role of vasoactive intestinal peptide in Neuroprotection : interview with Professor Illana Gozes
  2322. Does Neuroprotection with NXY-059 improve patient outcome after acute ischemic stroke?
  2323. Erythropoietin signaling and Neuroprotection
  2324. CATHEPSIN B, ANTIAMYLOIDOGENESIS, AND Neuroprotection
  2325. Ginkgo biloba extract and Alzheimer’s disease: Is the Neuroprotection explained merely by antioxidant action
  2326. GROWTH FACTORS AND Neuroprotection OF THE PERINATAL brain
  2327. Neurotoxicity in oncology: Is Neuroprotection (NP) attainable? A critical review
  2328. Neuroprotection by N-methyl-D-aspartate antagonists
  2329. Initiation mechanism of estrogen Neuroprotection pathway
  2330. Exercise induced Neuroprotection in spontaneuosly running rats
  2331. Neurodegenerazione, neuroprotezione e sclerosi multipla [Neurodegeneration, Neuroprotection and multiple sclerosis]
  2332. Cellular and Molecular Mechanisms that Distinguish the Effects of Progestorone and Medroxyprogesterone Acetate on Neuroprotection
  2333. Mechanisms underlying Neuroprotection by PARP inhibitors
  2334. Introduction-Neuroprotection : A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia
  2335. Erythropoietin Neuroprotection in the Retina
  2336. In vitro models to investigate the role of PI-TPα in Neuroprotection and neurodegeneration
  2337. Role of Serine/Threon protein Phosphateases in Estrogen Mediated Neuroprotection
  2338. Neuroprotection in aortic arch surgery: A risk factor analysis
  2339. Molecular Mechanisms of Neuroprotection in the Anoxia Tolerant
  2340. Molecular mechanisms of Homer protein in ischemic Neuroprotection
  2341. James C. Grotta: Best Stroke Advances in Prevention, Treatment, and Neuroprotection
  2342. Cysteamine metabolism: Relevance to Neuroprotection .
  2343. Perioperative Neuroprotection : is it possible to prevent brain injury in high risk patients?
  2344. 17β-Estradiol Fails To Provide Neuroprotection during Cardiac Surgery
  2345. VIP-and PACAP-Related Neuroprotection
  2346. HOPE FOR BETTER TREATMENTS FOR PARKINSON DISEASE THROUGH ADVANCES IN GENETICS, EPIDEMIOLOGY, AND Neuroprotection
  2347. Genetical character of CNS injury and autoimmune Neuroprotection
  2348. Promising Early Candidates for Neuroprotection Against HIV-Dementia
  2349. Assessing Neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo
  2350. Study of Neuroprotection of 17 beta-estradiol after spinal cord injury in rats
  2351. Neuroprotection of Ischemic Injury in Pig Retina, Part III–Functional Assessment
  2352. Developing New Neuroprotection and Neural Regeneration Strategies Using Mouse Models of Neurological Diseases
  2353. Targeting Cell Cycle in a Coordinated Strategy for Anticancer Treatment and Neuroprotection
  2354. Sex Hormone Modulation of Mitochondrial Function: A Possible Mechanism for Neuroprotection
  2355. Neuroprotection of Ischemic Injury in Pig Retina, Part I: The Injury Model
  2356. Macrophage-mediated Neuroprotection and neurogenesis
  2357. Dynamics of neural stem cell-mediated Neuroprotection in the presence of oxidative stress: studies in vitro and in vivo
  2358. Neuroprotection and sudden infant death. A robust Brussels–Paris collaboration and future perspectives
  2359. Two Signaling Proteins Linked to ACh–Induced Neuroprotection in Isolated Pig Retinal Ganglion Cells
  2360. The activation of ERK1/2 participates in Neuroprotection induced by sevoflurane preconditioning on oxygen-glucose deprivation injury in rat hippocampal slices
  2361. MECHANISMS OF NEURODEGENERATION IN MULTIPLE SCLEROSIS: PREMISE FOR Neuroprotection ?
  2362. Radiated-induced brain injury: advance of molecular mechanisms and Neuroprotection strategies
  2363. S9 CANNABINOID RECEPTORS AND THEIR ROLE IN Neuroprotection
  2364. Duplicate Anesthetic Preconditioning Improves Neuroprotection In Vitro
  2365. The Neuroprotection effect of edaravone on spinal cord injury in rats
  2366. Double Isoflurane Preoconditioning Improves Neuroprotection Againt OGD Injury in Rat brain
  2367. Transferrin in Müller Cells and Neuroprotection in the Retina
  2368. Isoflurane Provides Sustained Neuroprotection in Rats Subjected to Focal Ischemia
  2369. A New Transgenic Mouse Model of Neuroprotection in Ischemic Optic Neuropathy
  2370. Estrogen Neuroprotection in Anterior Ischemic Optic Neuropathy (AION)
  2371. Signaling events in activity dependent Neuroprotection , neurodegeneration, and synaptic plasticity
  2372. A role for uncoupling proteins in Neuroprotection following recurrent hypoglycemia?
  2373. Soluble epoxide hydrolase: Sex differences and role in estrogen-mediated Neuroprotection
  2374. Systematic Pharmacotherapy for Sensory Neuroprotection After Peripheral Nerve Injury
  2375. Erythropoietin Neuroprotection in the Term and Preterm Infant: Safety and Efficacy
  2376. The role of excitatory amino acid transporters in Neuroprotection and neuropathology
  2377. VEGF‐based therapeutic angiogenesis for ischemic stroke is associated with damage of nervous tissue and loss of Neuroprotection
  2378. Does Neuroprotection Still Have a Role in Injured brain Following Aneurysmal Subarachnoid Haemorrhage?
  2379. Preconditioning Triggers Neuroprotection Against Excitotoxicity in Pig Retinal Ganglion Cells
  2380. Neuroprotection by delayed high dose Aspirin treatment in cerebral ischemia
  2381. Molecular Mechanisms of Dietary Restriction on the Neuroprotection and Hippocampal Neurogenesis
  2382. The Neuroprotection of Mild hypothermia in the Acute Phase of Subarachnoid Hemorrhage
  2383. Comparative Neuroprotection of Multi-Dose Lidocaine in a Rabbit Model of Subarachnoid Hemorrhage
  2384. Opioid Preconditioning Induces an Opioid Receptor-Dependent Delayed Neuroprotection
  2385. Estrogen-induced Neuroprotection is Mediated by an Increase in Caspase-12-associated Apoptosis Following MCAO.
  2386. Creatine mediates Neuroprotection towards excitoxicity in an in vitro model of neurodegeneration
  2387. Neuroprotection of AG490 in Oxidative Stress-induced Neuronal Death
  2388. Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection
  2389. Neuroprotection in Non-Arteritic Anterior Ischemic Optic Neuropathy
  2390. Overactivation of NMDA receptors in ammonia neurotoxicity: a target for Neuroprotection ?
  2391. Cell cycle regulation provides Neuroprotection after focal cerebral ischemia brain damage
  2392. P20 NEURODEGENERATION AND Neuroprotection ON MODEL OF PHOTOCHEMICALLY INDUCED ISCHEMIA OF RAT brain CORTEX
  2393. Exercise-induced Neuroprotection against kainic acid-induced seizures in the rat
  2394. 599. Neuron Loss Mediated by HIV-1 gp120 In Vivo: Neuroprotection Using SV40 Gene Transfer of Antioxidant Enzymes
  2395. CELL CYCLE INHIBITOR PROVIDES Neuroprotection IN RATS AFTER FOCAL CEREBRAL ISCHEMIA
  2396. Neuroprotection of Ischemic Injury in Pig Retina, Part II: Ganglion Cell Rescue
  2397. Role of cocaine and amphetamine regulated transcript in estradiol-mediated Neuroprotection .
  2398. Long lasting Neuroprotection by JNK activity blockade in severe cerebral ischemia
  2399. Metabolism of Primary Astrocytes Studied by NMR Metabolic Trafficking and Neuroprotection
  2400. Metabolism of primary astrocytes studied by NMR: metabolic trafficking and Neuroprotection
  2401. CHAPTER III. Neuroprotection FROM OXIDATIVE STRESS IN THE STEM CELL NICHE: CELLULAR NETWORKS AND REGULATION OF ANTIOXIDANT …
  2402. Neuroprotection of spinal cord by application of an extract from Paeonin Lactiflora, animal studies
  2403. Role of LIFR-gp130 Activation in Endogenous Neuroprotection of Retinal Photoreceptors
  2404. Studies into The Mechanisms of Neurodegeneration and Neuroprotection in Rd1 Mouse Retina.
  2405. Neuroprotection by granulocyte colony-stimulating factor (G-CSF) after focal cerebral ischemia
  2406. Anxiety Reactions as a Neuroprotection Strategy: Acetylcholinesterase modulations under stress and neurodegenerative diseases as a case study
  2407. Neuroprotection by 20 (S) Protopanaxadiol in Focal Cerebral Ischemia Mouse Model
  2408. Prophylaxis against nerve agent toxicity: Physiological, behavioral, and Neuroprotection of current and novel treatments
  2409. Neuroprotection by Nicotine in Hippocampal Slices Subjected to Oxygen-Glucose Deprivation: Involvement of the α7…
  2410. Carotid Artery Stenting with Neuroprotection : the first percutaneous revascularization technique shown to be clinically superior to surgery in a randomized trial
  2411. A pilot study of Neuroprotection with umbilical cord blood cell transplantation for preterm very low birth weight infants
  2412. Bacterial DNA Confers Neuroprotection Following Optic Nerve Injury by Suppressing CD4+ CD25+ Regulatory T Cell Activity
  2413. HPLC-based activity profiling of Erigeron breviscapus for optic Neuroprotection
  2414. Neuroprotection in Parkinson’s disease: modafinil and Δ9-tetrahydrocannabinol
  2415. Autoimmune Uveitis Induces Loss of Retinal Ganglion Cells: Immune Modulation Rather Than Suppression for Neuroprotection
  2416. Erythropoietin exerts Neuroprotection during Deep Hypothermic Circulatory Arrest
  2417. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in α7 nicotinic receptor knockout mice
  2418. Neuroprotection of progesterone on retinal ganglion cells in chronic ocular hypertension model rats
  2419. Neuroprotection following repeated hypoxia preconditioning (RHP): pivotal role of brain -derived erythropoietin
  2420. A Perfusion Culture System for Whole Retina From Adult Rat: An in–vitro Model for Neuroprotection on Retinal Ganglion Cells
  2421. Conditional Knock Out of HIF-La and the Consequences for Hypoxia Induced Retinal Neuroprotection in a Model of Light Induced Retinal Degeneration
  2422. PUFA-induced Neuroprotection against cerebral or spinal cord ischemia via the TREK-1 channel
  2423. Assessment of Longterm Neuroprotection by CNTF Gene Transfer in a Mouse Inherited Retinal Degeneration
  2424. Correlation between the repair of oxidative DNA damage and the Neuroprotection in mice after forebrain ischemia
  2425. Pharmacokinetic properties of selective and non-selective AMPA-receptor antagonists and their role in Neuroprotection
  2426. Neuroprotection by 1, 25 (OH) 2-Vitamin D3 Against Kainic Acid-Induced Excitotoxicity in the Rat Hippocampus
  2427. THE Neuroprotection OF OLPRINONE, A PHOSPHODIESTERASE 3 INHIBITOR, ON GLOBAL CEREBRAL ISCHEMIA IN RATS.: 149
  2428. Molecular mechanisms of Neuroprotection by extract from Rosmarinus officinalis (Rosemary) in dopaminergic cell line, SH-SY5Y
  2429. Neuroprotection of Green Tea Derived EGCG: Implications for HIV associated dementia
  2430. Noscapine is synergistic with vincristine and provides Neuroprotection of myelin in cell culture.
  2431. The Insulin Sensitizer Rosiglitazone Decreases Inflammatory Pattern and Improves Vascular Neuroprotection in Insulin-Resistant Type 2 Diabetic Subjects with …
  2432. Neuroinflammation and excitotoxicity in neurobiology of HIV-1 infection and AIDS: targets for Neuroprotection
  2433. Glycogen synthase kinase 3: role in neurodegeneration and Neuroprotection
  2434. Neuroprotection by pharmacological preconditioning, the role of the mitochondrial ATP-sensitive K+ channel
  2435. Leukocyte Anti-adhesion Therapy Provides Neuroprotection after Transient Global Cerebral Ischemia in the Mouse
  2436. GLP-1 secreting encapsulated human mesenchymal stem cells for Neuroprotection
  2437. Riluzole confers Neuroprotection by increasing the amount of HSF1 for a more robust heat shock response
  2438. Erythropoietin Exerts Endogenous Neuroprotection After Ocular Hypertension Induced Glaucoma and Optic Nerve Transection Injuries
  2439. Neuroprotection by sodium ferulate against glutamate-induced apoptosis is mediated by ERK and PI3 kinase pathways1
  2440. Modulation of the endocannabinoid system is implicated in the Neuroprotection afforded by 17Beta-estradiol (E2) against brain damage caused by transient middle …
  2441. … ultrastructural damage in the neurons of hippocampal CA_3 subarea during kainic acid induced status epilepticus and the Neuroprotection of topiramate in rats
  2442. Testosterone-mediated Neuroprotection in NO Induced Cell Death of Motor Neuron Cells Expressing Wild Type or Mutant Cu/Zn Superoxide Dismutase
  2443. The Neuropeptide NAP Provides Neuroprotection of Retinal Ganglion Cells After Optic Nerve Crush and Retinal Ischemia in vivo
  2444. Reversal of Cerebral Vasospasm and Neuroprotection by Injecting Magnesium Sulfate into Cisterna Magna in Rabbit with Subarachnoid Hemorrhage
  2445. … Colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of Colivelin-mediated Neuroprotection against Alzheimer’s disease …
  2446. S07H5 Fuctional analysis of tripartite synapses using membrane potential imaging: memory enhancement and Neuroprotection by neurosteroids (Leading Edge in …
  2447. The Beneficial Role of Extracellular Signal-regulated Kinases 1 and 2 in Exercise-induced Neuroprotection after Stroke
  2448. Concurrent Treatment with Lovastatin and 5‐Aminoimidazole‐4‐Carboxamide‐1‐Beta‐D‐Ribofuranoside provides Neuroprotection and alleviate Neurodegeneration …
  2449. Decrease in Rate of NMDA-induced Ca^ 2^+ Entry May Explain Neuroprotection by Anti-GRINL1A Antibodies
  2450. AM 404 leads to Neuroprotection against ischemia-induced neuronal injury
  2451. Anaesthesia for thoracic and thoraco-abdominal aortic disease—Part 2: Anaesthetic management and Neuroprotection
  2452. Metabotropic glutamate receptor 3 Neuroprotection
  2453. 354 MECHANISMS OF ENDOGENOUS SEX HORMONE MEDIATED Neuroprotection IN THE AGING brain : A SYSTEMATIC REVIEW.
  2454. S20 DIFFERENTIAL ROLES OF 1, 2, 3, 4-TETRAHYDROISOQUINOLINES IN NEURODEGENERATION AND Neuroprotection
  2455. EVIDENCE TO IMPLICATE EARLY MODULATION OF INTERLEUKIN-1 EXPRESSION IN THE Neuroprotection AFFORDED BY 17-ESTRADIOLIN MALE RATS …
  2456. Journal of Neuroal Transmission Suppplement 71: Oxidative Stress and Neuroprotection
  2457. Cytotoxicity of Levodopa on c17. 2 neural stem cell and Neuroprotection of Pergolide
  2458. 8 Erythropoietin Signaling Pathways in Neuroprotection
  2459. 2 Diagnosis and Neuroprotection in Parkinson’s Disease
  2460. Metabotropic glutamate receptor 3 Neuroprotection A. Berent-Spillson and JW Russell Received June 12, 2006; revised manuscript received October 3, 2006; …
  2461. Neurotox-98 Neuroprotection by Progesterones Through Stimulation of Mitochondrial Gene Expression
  2462. Neurone and astrocyte response to Aβ25-35: Role in glutathione in Neuroprotection
  2463. n-3 poly-unsaturated fatty Acid (n-3PUFA) and Neuroprotection : Is docosahexaenoic acid (DHA) involved in glutamate uptake by astrocytes?
  2464. A~ 2-adrenergic system: From neurotransmitans to Neuroprotection
  2465. The role of astroglia in Neuroprotection
  2466. Neuroprotection for ischemic stroke: past, present and future
  2467. Mitochondrial approaches for Neuroprotection
  2468. Statins: mechanisms of Neuroprotection
  2469. Neuroinflammation in Parkinson’s disease: a target for Neuroprotection ?
  2470. Targets for Neuroprotection in Parkinson’s disease
  2471. Metabolic downregulation: a key to successful Neuroprotection ?
  2472. Neuroprotection does not work!
  2473. Current status of Neuroprotection for cerebral ischemia: synoptic overview
  2474. Imaging outcomes for Neuroprotection and repair in multiple sclerosis trials
  2475. Why have we failed to achieve Neuroprotection in Parkinson’s disease?
  2476. The role of kynurenines in disorders of the central nervous system: possibilities for Neuroprotection
  2477. Progress in Neuroprotection in Parkinson’s disease
  2478. The specificity of Neuroprotection by antioxidants
  2479. Magnesium sulphate for women at risk of preterm birth for Neuroprotection of the fetus
  2480. Neuroprotection (and lack of Neuroprotection ) afforded by a series of noble gases in an in vitro model of neuronal injury
  2481. Steroids and Neuroprotection : new advances
  2482. Wnt signaling in Neuroprotection and stem cell differentiation
  2483. Neuroprotection in glaucoma: drug-based approaches
  2484. AMPK in the brain : its roles in energy balance and Neuroprotection
  2485. Antioxidants and Neuroprotection in the adult and developing central nervous system
  2486. Molecular mechanisms of Neuroprotection by two natural antioxidant polyphenols
  2487. Toll-like receptor signaling in endogenous Neuroprotection and stroke
  2488. Mitochondrial mechanisms of estrogen Neuroprotection
  2489. Autophagy and the ubiquitin-proteasome system: collaborators in Neuroprotection
  2490. The multiple faces of quercetin in Neuroprotection
  2491. Assessment of Neuroprotection in the retina with DARC
  2492. Inflammation and its role in Neuroprotection , axonal regeneration and functional recovery after spinal cord injury
  2493. Toll-like receptors: roles in Neuroprotection ?
  2494. Biochemical, molecular and epigenetic mechanisms of valproic acid Neuroprotection
  2495. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease
  2496. Neuroprotection by the NR3A subunit of the NMDA receptor
  2497. Citicoline: update on a promising and widely available agent for Neuroprotection and neurorepair
  2498. Autophagy in Neuroprotection and neurodegeneration: a question of balance
  2499. Estrogen therapy: is time of initiation critical for Neuroprotection ?
  2500. Fluoxetine affords robust Neuroprotection in the postischemic brain via its anti‐inflammatory effect
  2501. Neuroprotection : extrapolating from neurologic diseases to the eye
  2502. History of Neuroprotection and rationale as a therapy for glaucoma
  2503. Alcohol in moderation, cardioprotection, and Neuroprotection : epidemiological considerations and mechanistic studies
  2504. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, Neuroprotection possibly
  2505. Can we achieve Neuroprotection with currently available anti-parkinsonian interventions?
  2506. Recent trends in erythropoietin-mediated Neuroprotection
  2507. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and Neuroprotection
  2508. Neuroprotection in the newborn infant
  2509. Leptin Neuroprotection in the CNS: mechanisms and therapeutic potentials
  2510. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis
  2511. Therapeutic targets and limits of minocycline Neuroprotection in experimental ischemic stroke
  2512. More than a decade of estrogen Neuroprotection
  2513. Forced, not voluntary, exercise effectively induces Neuroprotection in stroke
  2514. Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons
  2515. Estrogen and SERM Neuroprotection in animal models of Parkinson’s disease
  2516. Vitagenes, dietary antioxidants and Neuroprotection in neurodegenerative diseases (498 views visite)
  2517. Delayed post-ischaemic Neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms
  2518. Mechanisms of disease: sodium channels and Neuroprotection in multiple sclerosis—current status
  2519. Adenosine receptors and neurological disease: Neuroprotection and neurodegeneration
  2520. Neuroprotection trials in Parkinson’s disease: systematic review
  2521. Endogenous Neuroprotection : mitochondria as gateways to cerebral preconditioning?
  2522. All-you-can-eat: autophagy in neurodegeneration and Neuroprotection
  2523. The role of Wnt signaling in Neuroprotection
  2524. CD4+ T cells support glial Neuroprotection , slow disease progression, and modify glial morphology in an animal model of inherited ALS
  2525. Experimental and clinical evidence of Neuroprotection by nerve growth factor eye drops: Implications for glaucoma
  2526. Targeting post-mitochondrial effectors of apoptosis for Neuroprotection
  2527. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy
  2528. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement
  2529. Two different molecular mechanisms underlying progesterone Neuroprotection against ischemic brain damage
  2530. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and Neuroprotection
  2531. Recent clinical findings with memantine should not mean that the idea of Neuroprotection in glaucoma is abandoned
  2532. Progesterone Neuroprotection in traumatic CNS injury and motoneuron degeneration
  2533. Neuroinflammation in spinal cord injury: therapeutic targets for Neuroprotection and regeneration
  2534. Effects of antenatal exposure to magnesium sulfate on Neuroprotection and mortality in preterm infants: a meta-analysis
  2535. Cellular stress response: a novel target for chemoprevention and nutritional Neuroprotection in aging, neurodegenerative disorders and longevity
  2536. Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of Neuroprotection
  2537. Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid Neuroprotection
  2538. Taurine increases mitochondrial buffering of calcium: role in Neuroprotection
  2539. Endocannabinoids in the retina: from marijuana to Neuroprotection
  2540. Argon: Neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury
  2541. Mitochondrial mechanisms of cell death and Neuroprotection in pediatric ischemic and traumatic brain injury
  2542. Immunomodulation and Neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other …
  2543. A review of published reports on Neuroprotection in spinal cord injury
  2544. An approach to using recombinant erythropoietin for Neuroprotection in very preterm infants
  2545. Robust docosahexaenoic acid–mediated Neuroprotection in a rat model of transient, focal cerebral ischemia
  2546. Nrf2-mediated Neuroprotection in the MPTP mouse model of Parkinson’s disease: Critical role for the astrocyte
  2547. Adaptive immune Neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice
  2548. Metallothionein‐I+ II in Neuroprotection
  2549. PPAR‐gamma‐mediated Neuroprotection in a chronic mouse model of Parkinson’s disease
  2550. Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired Neuroprotection induced by synaptic activity
  2551. Neuroprotection in diet-induced ketotic rat brain after focal ischemia
  2552. Randomized, double-blinded, placebo controlled study of Neuroprotection with lidocaine in cardiac surgery
  2553. Nicotinic receptor-mediated Neuroprotection in neurodegenerative disease models
  2554. Neuroprotection by radical avoidance: search for suitable agents
  2555. Glucocorticoid receptors modulate mitochondrial function: A novel mechanism for Neuroprotection
  2556. A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for Neuroprotection and tissue repair
  2557. Sex differences in minocycline-induced Neuroprotection after experimental stroke
  2558. Targeting oxidative stress for Neuroprotection
  2559. Molecular and cell-based approaches for Neuroprotection in glaucoma
  2560. Neuronal death after peripheral nerve injury and experimental strategies for Neuroprotection
  2561. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards Neuroprotection
  2562. A core review of temperature regimens and Neuroprotection during cardiopulmonary bypass: does rewarming rate matter?
  2563. Transcribe to survive: transcriptional control of antioxidant defense programs for Neuroprotection in Parkinson’s disease
  2564. Mesenchymal stem cells therapy exerts Neuroprotection in a progressive animal model of Parkinson’s disease
  2565. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for Neuroprotection and neuroregeneration in Parkinson’s disease?
  2566. Nano-drug delivery and Neuroprotection in spinal cord injury
  2567. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced Neuroprotection
  2568. Dantrolene: mechanisms of Neuroprotection and possible clinical applications in the neurointensive care unit
  2569. Regulation of Mn-superoxide dismutase activity and Neuroprotection by STAT3 in mice after cerebral ischemia
  2570. Angiotensin AT2 receptor stimulation causes Neuroprotection in a conscious rat model of stroke
  2571. A Nurr1 pathway for Neuroprotection
  2572. Cooling Combined with Immediate or Delayed Xenon Inhalation Provides Equivalent Long-Term Neuroprotection after Neonatal Hypoxia—Ischemia
  2573. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate
  2574. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated Neuroprotection is independent of its deacetylase activity
  2575. Study of Neuroprotection of donepezil, a therapy for Alzheimer’s disease
  2576. Propofol: Neuroprotection in an in vitro model of traumatic brain injury
  2577. Uric acid administration in patients with acute stroke: a novel approach to Neuroprotection
  2578. Disease progression and the need for Neuroprotection in glaucoma management
  2579. Matrix metalloproteinases inhibition provides Neuroprotection against hypoxia‐ischemia in the developing brain
  2580. Insulin Neuroprotection against oxidative stress is mediated by Akt and GSK-3β signaling pathways and changes in protein expression
  2581. Xenon and hypothermia combine additively, offering long-term functional and histopathologic Neuroprotection after neonatal hypoxia/ischemia
  2582. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in Neuroprotection
  2583. Neuroprotection by pravastatin in acute ischemic stroke in rats
  2584. Erythropoietin modulation of astrocyte water permeability as a component of Neuroprotection
  2585. Cannabinoid-mediated Neuroprotection , not immunosuppression, may be more relevant to multiple sclerosis
  2586. Desipramine prevents stress-induced changes in depressive-like behavior and hippocampal markers of Neuroprotection
  2587. Optimal Neuroprotection by erythropoietin requires elevated expression of its receptor in neurons
  2588. Neuroprotection in cerebral ischemia: emphasis on the SAINT trial
  2589. Is it time to definitely abandon Neuroprotection in acute ischemic stroke?
  2590. Novel anti-Alzheimer’s dimer bis (7)-cognitin: cellular and molecular mechanisms of Neuroprotection through multiple targets
  2591. Neuroprotection by estrogen in the brain : the mitochondrial compartment as presumed therapeutic target
  2592. Research into Neuroprotection must continue… But with a different approach
  2593. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway
  2594. Neuroprotection for diabetic retinopathy
  2595. Physical activity and Neuroprotection in amyotrophic lateral sclerosis
  2596. Secretoneurin promotes Neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke
  2597. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis
  2598. Pathogenesis of ganglion “cell death” in glaucoma and Neuroprotection : focus on ganglion cell axonal mitochondria
  2599. Strong Neuroprotection by inhibition of NF-κB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines
  2600. The impact of neuroimmune dysregulation on Neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment
  2601. Methylene blue provides behavioral and metabolic Neuroprotection against optic neuropathy
  2602. Endocannabinoids mediate Neuroprotection after transient focal cerebral ischemia
  2603. Cellular NAD replenishment confers marked Neuroprotection against ischemic cell death: role of enhanced DNA repair
  2604. Intranasal delivery of erythropoietin plus insulin-like growth factor–I for acute Neuroprotection in stroke
  2605. Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors
  2606. Progesterone and progestins: Neuroprotection and myelin repair
  2607. Ferulic acid provides Neuroprotection against oxidative stress-related apoptosis after cerebral ischemia/reperfusion injury by inhibiting ICAM-1 mRNA expression in …
  2608. TNF receptor I sensitizes neurons to erythropoietin-and VEGF-mediated Neuroprotection after ischemic and excitotoxic injury
  2609. Neuroprotection and repair
  2610. Neuroprotection for Huntington’s disease: ready, set, slow
  2611. Should amplitude-integrated electroencephalography be used to identify infants suitable for hypothermic Neuroprotection ?
  2612. Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the …
  2613. Striatal Neuroprotection with methylene blue
  2614. NAP and D-SAL: Neuroprotection against the β amyloid peptide (1–42)
  2615. Neural stem/progenitor cells initiate the formation of cellular networks that provide Neuroprotection by growth factor‐modulated antioxidant expression
  2616. Neuroprotection by co-treatment and post-treating with calcitriol following the ischemic and excitotoxic insult in vivo and in vitro
  2617. Progesterone reverses 17β‐estradiol‐mediated Neuroprotection and BDNF induction in cultured hippocampal slices
  2618. Phylogeny of proteolipid proteins: divergence, constraints, and the evolution of novel functions in myelination and Neuroprotection
  2619. Bioenergetic‐based Neuroprotection and glaucoma
  2620. P2Y1 receptor signaling enhances Neuroprotection by astrocytes against oxidative stress via IL‐6 release in hippocampal cultures
  2621. New targets of Neuroprotection in ischemic stroke
  2622. Nasal administration of osteopontin peptide mimetics confers Neuroprotection in stroke
  2623. The past and future of Neuroprotection in cerebral ischaemic stroke
  2624. Neuroprotection by nitrous oxide: Facts and evidence.
  2625. Aggravation of infarct formation by brain swelling in a large territorial stroke: a target for Neuroprotection ?
  2626. Neuroprotection in a 6‐hydroxydopamine‐lesioned Parkinson model using lactoferrin‐modified nanoparticles
  2627. Carotid Artery Stenting with Patient-and Lesion-Ta ilo r ed Selection of the Neuroprotection System and Stent Type: Early and 5-Year Results from a Prospective …
  2628. New insight into the molecular pathways of metallothionein‐mediated Neuroprotection and regeneration
  2629. Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13
  2630. Stromal cell-derived factor-1α promotes Neuroprotection , angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats
  2631. Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and Neuroprotection
  2632. Uracil nucleotides: from metabolic intermediates to Neuroprotection and neuroinflammation
  2633. Effects of optic nerve injury, glaucoma, and Neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina
  2634. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1
  2635. … complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21waf1/cip1 in cell cycle-independent Neuroprotection
  2636. Stem cells for Neuroprotection in glaucoma
  2637. Leptin is induced in the ischemic cerebral cortex and exerts Neuroprotection through NF-κB/c-Rel–dependent transcription
  2638. TGF-β in dopamine neuron development, maintenance and Neuroprotection
  2639. In search of clinical Neuroprotection after brain ischemia: the case for mild hypothermia (35 C) and magnesium
  2640. Human neural stem cells genetically modified to overexpress Akt1 provide Neuroprotection and functional improvement in mouse stroke model
  2641. Potential roles of (endo) cannabinoids in the treatment of glaucoma: from intraocular pressure control to Neuroprotection
  2642. The yellow fluorescent protein (YFP-H) mouse reveals Neuroprotection as a novel mechanism underlying chondroitinase ABC-mediated repair after spinal cord injury
  2643. CNTF induces photoreceptor Neuroprotection and Müller glial cell proliferation through two different signaling pathways in the adult zebrafish retina
  2644. Marked calpastatin (CAST) depletion in Alzheimer’s disease accelerates cytoskeleton disruption and neurodegeneration: Neuroprotection by CAST overexpression
  2645. Molecular and clinical pathways to Neuroprotection of dopaminergic drugs in Parkinson disease
  2646. Dimethyl sulfoxide provides Neuroprotection in a traumatic brain injury model
  2647. Neuroprotection by Spirulina platensis protean extract and phycocyanin against iron-induced toxicity in SH-SY5Y neuroblastoma cells
  2648. Progesterone with vitamin D affords better Neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone
  2649. Neuroprotection in mice by NGP1-01 after transient focal brain ischemia
  2650. Lovastatin induces Neuroprotection through tumor necrosis factor receptor 2 signaling pathways
  2651. Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic Neuroprotection in a model of Parkinson’s disease
  2652. Long-term Neuroprotection from a potent redox-modulating metalloporphyrin in the rat
  2653. Current controversies in hypothermic Neuroprotection
  2654. Acute Neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome
  2655. TNF‐α‐mediates Neuroprotection against glutamate‐induced excitotoxicity via NF‐κB‐dependent up‐regulation of KCa2.2 channels
  2656. Progesterone attenuates oestrogen Neuroprotection via downregulation of oestrogen receptor expression in cultured neurones
  2657. Modeling axonal degeneration within the anterior visual system: implications for demonstrating Neuroprotection in multiple sclerosis
  2658. P2X7 receptors in oligodendrocytes: a novel target for Neuroprotection
  2659. Neuroprotection during cardiac surgery
  2660. Acetyl-L-carnitine provides effective in vivo Neuroprotection over 3, 4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain
  2661. The seed extract of Cassia obtusifolia offers Neuroprotection to mouse hippocampal cultures
  2662. DHEA-Neuroprotection and-neurotoxicity after transient cerebral ischemia in rats
  2663. TAT-Hsp70-mediated Neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice
  2664. Analysis of the retinal gene expression profile after hypoxic preconditioning identifies candidate genes for Neuroprotection
  2665. Nrf2 activators provide Neuroprotection against 6‐hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures
  2666. Involvement of TRPC channels in CCL2-mediated Neuroprotection against tat toxicity
  2667. Multifunction of myricetin on Aβ: Neuroprotection via a conformational change of Aβ and reduction of Aβ via the interference of secretases
  2668. Retinal ganglion cell Neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments
  2669. Possible involvement of P2X7 receptor activation in microglial Neuroprotection against focal cerebral ischemia in rats
  2670. Functional mechanism of Neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease
  2671. Neuroprotection of aucubin in primary diabetic encephalopathy
  2672. A closed-circuit neonatal xenon delivery system: a technical and practical Neuroprotection feasibility study in newborn pigs
  2673. Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for Neuroprotection
  2674. Neuroprotection by cord blood stem cells against glutamate-induced apoptosis is mediated by Akt pathway
  2675. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit Neuroprotection properties
  2676. Neuroprotection of ginsenoside Re in cerebral ischemia–reperfusion injury in rats
  2677. Tamoxifen Neuroprotection in cerebral ischemia involves attenuation of kinase activation and superoxide production and potentiation of mitochondrial superoxide …
  2678. Neuroprotection by NGF and BDNF against neurotoxin-exerted apoptotic death in neural stem cells are mediated through Trk receptors, activating PI3-kinase and …
  2679. Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: Neuroprotection and amelioration of symptoms by …
  2680. Post-ischemic helium provides Neuroprotection in rats subjected to middle cerebral artery occlusion-induced ischemia by producing hypothermia
  2681. A critique of SAINT II: wishful thinking, dashed hopes, and the future of Neuroprotection for acute stroke
  2682. The role of the somatotrophic axis in Neuroprotection and neuroregeneration of the addictive brain
  2683. Activation of cerebral peroxisome proliferator-activated receptors gamma exerts Neuroprotection by inhibiting oxidative stress following pilocarpine-induced status …
  2684. Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression
  2685. P2X 7 nucleotide receptor is coupled to GSK-3 inhibition and Neuroprotection in cerebellar granule neurons
  2686. Involvement of ERK1/2 signaling pathway in DJ-1-induced Neuroprotection against oxidative stress
  2687. Lipopolysaccharide preconditioning reduces neuroinflammation against hypoxic ischemia and provides long-term outcome of Neuroprotection in neonatal rat
  2688. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced Neuroprotection and nicotinic receptor up-regulation
  2689. Neuroprotection and neuroregeneration in multiple sclerosis
  2690. Are delayed‐start design trials to show Neuroprotection in Parkinson’s disease fundamentally flawed?
  2691. Docosahexaenoic acid pretreatment confers Neuroprotection in a rat model of perinatal cerebral hypoxia-ischemia
  2692. The APCs of Neuroprotection
  2693. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic Neuroprotection
  2694. Hypoxic-ischemic injury in neonatal brain : involvement of a novel neuronal molecule in neuronal cell death and potential target for Neuroprotection
  2695. Long-term administration of estrogen or tamoxifen to ovariectomized rats affords Neuroprotection to hippocampal neurons by modulating the expression of Bcl-2 and …
  2696. Molecular mechanisms leading to Neuroprotection /ischemic tolerance: effect of preconditioning on the stress reaction of endoplasmic reticulum
  2697. Blood–central nervous system barriers: the gateway to neurodegeneration, Neuroprotection and neuroregeneration
  2698. Neuroprotection by group I mGlu receptors in a rat hippocampal slice model of cerebral ischemia is associated with the PI3K–Akt signaling pathway: A novel …
  2699. Heat shock proteins and the brain : implications for neurodegenerative diseases and Neuroprotection
  2700. Cyclosporine A for Neuroprotection : establishing dosing guidelines for safe and effective use
  2701. Chronic treatment with red wine polyphenol compounds mediates Neuroprotection in a rat model of ischemic cerebral stroke
  2702. Long-term pharmacologic Neuroprotection after birth asphyxia: where do we stand?
  2703. Evidence for Neuroprotection by the fenamate NSAID, mefenamic acid
  2704. Hyperphosphorylation of microtubule-associated tau protein plays dual role in neurodegeneration and Neuroprotection
  2705. Neuroprotection of interleukin-6 against NMDA attack and its signal transduction by JAK and MAPK
  2706. Pharmacological strategies for Neuroprotection in traumatic brain injury.
  2707. Mechanism of guanosine-induced Neuroprotection in rat hippocampal slices submitted to oxygen–glucose deprivation
  2708. Neuroprotection by melatonin on astrocytoma cell death
  2709. Effects of Vinpocetine on mitochondrial function and Neuroprotection in primary cortical neurons
  2710. Uric acid and Neuroprotection
  2711. Diazepam Neuroprotection in excitotoxic and oxidative stress involves a mitochondrial mechanism additional to the GABAAR and hypothermic effects
  2712. Pharmacologic Neuroprotection —Is xenon the light at the end of the tunnel?
  2713. Essential role for zinc-triggered p75NTR activation in preconditioning Neuroprotection
  2714. Rho kinase inhibitor Fasudil induces Neuroprotection and neurogenesis partially through astrocyte-derived G-CSF
  2715. Gabapentin Neuroprotection and seizure suppression in immature mouse brain ischemia
  2716. TRPC channel-mediated Neuroprotection by PDGF involves Pyk2/ERK/CREB pathway
  2717. VEGF as a target for Neuroprotection
  2718. Combination therapy of lovastatin and rolipram provides Neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis
  2719. A novel insight into Neuroprotection against hypoxic/ischemic stress
  2720. HIV protease inhibitors provide Neuroprotection through inhibition of mitochondrial apoptosis in mice
  2721. Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse
  2722. Nicotinamide treatment provides acute Neuroprotection and GFAP regulation following fluid percussion injury
  2723. Differential Neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity
  2724. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation Neuroprotection with statin therapy for acute recovery trial (NeuSTART)
  2725. Small molecule activators of the Trk receptors for Neuroprotection
  2726. Transplantation of human amniotic cells exerts Neuroprotection in MPTP-induced Parkinson disease mice
  2727. Oleoylethanolamide exerts partial and dose-dependent Neuroprotection of substantia nigra dopamine neurons
  2728. Balancing paediatric anaesthesia: preclinical insights into analgesia, hypnosis, Neuroprotection , and neurotoxicity
  2729. PI3 kinase/Akt activation mediates estrogen and IGF‐1 nigral DA neuronal Neuroprotection against a unilateral rat model of Parkinson’s disease
  2730. Retinal Neuroprotection against ischemia-reperfusion damage induced by postconditioning
  2731. Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes
  2732. The neuropeptide NAP provides Neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush
  2733. Desflurane, isoflurane, and sevoflurane provide limited Neuroprotection against neonatal hypoxia-ischemia in a delayed preconditioning paradigm
  2734. Antioxidant Neuroprotection against ethanol-induced apoptosis in HN2-5 cells
  2735. A global view of Parkinson’s disease pathogenesis: Implications for natural history and Neuroprotection
  2736. Oxidative stress in stroke pathophysiology: Validation of hydrogen peroxide metabolism as a pharmacological target to afford Neuroprotection
  2737. Additive Neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade
  2738. Neuroprotection of brain -derived neurotrophic factor against hypoxic injury in vitro requires activation of extracellular signal-regulated kinase and phosphatidylinositol …
  2739. Lactation is a natural model of hippocampus Neuroprotection against excitotoxicity
  2740. The novel Cholinesterase–Monoamine Oxidase inhibitor and Antioxidant, Ladostigil, confers Neuroprotection in neuroblastoma cells and aged rats
  2741. Neuroprotection of γ‐aminobutyric acid receptor agonists via enhancing neuronal nitric oxide synthase (Ser847) phosphorylation through increased neuronal nitric …
  2742. Melatonin provides Neuroprotection by reducing oxidative stress and HSP70 expression during chronic cerebral hypoperfusion in ovariectomized rats
  2743. GABA synapses mediate Neuroprotection after ischemic and εPKC preconditioning in rat hippocampal slice cultures
  2744. Intranasal bFGF-induced progenitor cell proliferation and Neuroprotection after transient focal cerebral ischemia
  2745. Novel regimen through combination of memantine and tea polyphenol for Neuroprotection against brain excitotoxicity
  2746. Prolonged opportunity for Neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity
  2747. Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25–35 model of Alzheimer’s disease
  2748. Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia
  2749. Diphenyl diselenide confers Neuroprotection against hydrogen peroxide toxicity in hippocampal slices
  2750. Neuroprotection and imaging studies in Parkinson’s disease
  2751. The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute …
  2752. Neuroprotection : VEGF, IL-6, and clusterin: the dark side of the moon
  2753. Neuroprotection against Spinal Cord Ischemia–Reperfusion Injury Induced by Different Ischemic Postconditioning Methods: Roles of Phosphatidylinositol 3-Kinase …
  2754. Neuroprotection of microglial conditioned medium on 6‐hydroxydopamine‐induced neuronal death: role of transforming growth factor beta‐2
  2755. Neuroprotection and functional recovery conferred by administration of kappa-and delta1-opioid agonists in a rat model of global ischemia
  2756. Photoreceptor Neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide
  2757. Apolipoprotein E may be a critical factor in hormone therapy Neuroprotection
  2758. Neuronal nicotinic receptors as novel targets for inflammation and Neuroprotection : mechanistic considerations and clinical relevance
  2759. IGF-IR in Neuroprotection and brain tumors
  2760. … receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK‐3beta: connecting neurotransmission with Neuroprotection
  2761. Targeting Neuroprotection as an alternative approach to preventing and treating neuropathic pain
  2762. Synergistic effect of galantamine on nicotine-induced Neuroprotection in hemiparkinsonian rat model
  2763. 17β-estradiol-mediated Neuroprotection and ERK activation require a pertussis toxin-sensitive mechanism involving GRK2 and β-arrestin-1
  2764. Preconditioning Neuroprotection in global cerebral ischemia involves NMDA receptor-mediated ERK-JNK3 crosstalk
  2765. Clinical trials in Neuroprotection
  2766. Limited minocycline Neuroprotection after balloon-compression spinal cord injury in the rat
  2767. PACAP-mediated Neuroprotection of neurochemically identified cell types in MSG-induced retinal degeneration
  2768. L-kynurenine: metabolism and mechanism of Neuroprotection
  2769. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates Neuroprotection against normoxic oxidative death via HIF-and CREB-independent …
  2770. Mechanisms of platelet‐derived growth factor‐mediated Neuroprotection –implications in HIV dementia
  2771. NMDA-induced Neuroprotection in hippocampal neurons is mediated through the protein kinase A and CREB (cAMP-response element-binding protein) pathway
  2772. DJ-1 knock-down in astrocytes impairs astrocyte-mediated Neuroprotection against rotenone
  2773. Delayed post-ischemic administration of CDP-choline increases EAAT2 association to lipid rafts and affords Neuroprotection in experimental stroke
  2774. Interaction between neuropeptide Y (NPY) and brain ‐derived neurotrophic factor in NPY‐mediated Neuroprotection against excitotoxicity: a role for microglia
  2775. Small-molecule mediated Neuroprotection in an in situ model of tauopathy
  2776. Therapeutic hypothermia for Neuroprotection
  2777. Sonic hedgehog mediates BDNF-induced Neuroprotection against mitochondrial inhibitor 3-nitropropionic acid
  2778. Mitochondrial localization of DJ‐1 leads to enhanced Neuroprotection
  2779. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway
  2780. Ischemic preconditioning-induced Neuroprotection is associated with differential expression of IL-1β and IL-1 receptor antagonist in the ischemic cortex
  2781. Propofol exerts greater Neuroprotection with disodium edetate than without it
  2782. 5-HT4 receptor-mediated Neuroprotection and neurogenesis in the enteric nervous system of adult mice
  2783. Potential Neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole
  2784. Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1α truncation
  2785. Progesterone blocks estrogen Neuroprotection from kainate in middle-aged female rats
  2786. Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate
  2787. Neuroprotection by oxygen in acute transient focal cerebral ischemia is dose dependent and shows superiority of hyperbaric oxygenation
  2788. Mitochondrial Ca 2+ overload underlies Aβ oligomers neurotoxicity providing an unexpected mechanism of Neuroprotection by NSAIDs
  2789. A nanomedicine transports a peptide caspase-3 inhibitor across the blood–brain barrier and provides Neuroprotection
  2790. Neuroprotection of GluR5-containing kainate receptor activation against ischemic brain injury through decreasing tyrosine phosphorylation of N-methyl-D …
  2791. Functional characterization of basic helix-loop-helix-PAS type transcription factor NXF in vivo: putative involvement in an “on demand” Neuroprotection system
  2792. Extraluminal cooling of bilateral common carotid arteries as a method to achieve selective brain cooling for Neuroprotection
  2793. Proteomic analysis of differential proteins related to the neuropathic pain and Neuroprotection in the dorsal root ganglion following its chronic compression in rats
  2794. Delta2‐Specific Opioid Receptor Agonist and Hibernating Woodchuck Plasma Fraction Provide Ischemic Neuroprotection
  2795. Role of Dickkopf-1, an antagonist of the Wnt/β-catenin signaling pathway, in estrogen-induced Neuroprotection and attenuation of tau phosphorylation
  2796. Toll‐like receptor 4 is involved in Neuroprotection afforded by ischemic preconditioning
  2797. Allele-specific RNA silencing of mutant ataxin-3 mediates Neuroprotection in a rat model of Machado-Joseph disease
  2798. Neuroprotection by cell permeable TAT-mGluR1 peptide in ischemia: synergy between carrier and cargo sequences
  2799. Atorvastatin enhances hypothermia-induced Neuroprotection after stroke
  2800. Non-conventional MRI techniques for measuring Neuroprotection , repair and plasticity in multiple sclerosis
  2801. Repeated preconditioning with hyperbaric oxygen induces Neuroprotection against forebrain ischemia via suppression of p38 mitogen activated protein kinase
  2802. Selective sigma receptor agonist 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE084) promotes Neuroprotection and neurite elongation through protein …
  2803. Progesterone, BDNF and Neuroprotection in the injured CNS
  2804. Role of melatonin receptors in the effects of melatonin on BDNF and Neuroprotection in mouse cerebellar neurons
  2805. Neuroprotection of muscarinic receptor agonist pilocarpine against glutamate-induced apoptosis in retinal neurons
  2806. CT-guided radiofrequency ablation of spinal osteoid osteomas with concomitant perineural and epidural irrigation for Neuroprotection
  2807. In vivo Neuroprotection by a creatine-derived compound: Phosphocreatine–Mg-complex acetate
  2808. Pharmacological inhibition of mitochondrial membrane permeabilization for Neuroprotection
  2809. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of Neuroprotection
  2810. Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy
  2811. Stereo-selective Neuroprotection against stroke with vitamin A derivatives
  2812. Neuroprotection in Parkinson’s disease: myth or reality?
  2813. Oxidative insults induce DJ-1 upregulation and redistribution: implications for Neuroprotection
  2814. Ischemic insult to cerebellar Purkinje cells causes diminished GABAA receptor function and allopregnanolone Neuroprotection is associated with GABAA receptor …
  2815. Growth hormone‐induced Neuroprotection in the neural retina during chick embryogenesis
  2816. Mechanism of Neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil
  2817. Parameters of optic nerve electrical stimulation affecting Neuroprotection of axotomized retinal ganglion cells in adult rats
  2818. Essential involvement of the NMDA receptor in ethanol preconditioning‐dependent Neuroprotection from amyloid‐βin vitro
  2819. Retinal Neuroprotection by hypoxic preconditioning is independent of hypoxia‐inducible factor‐1α expression in photoreceptors
  2820. Species‐dependent Neuroprotection by activated protein C mutants with reduced anticoagulant activity
  2821. The 2007 Feinberg lecture: a new road map for Neuroprotection
  2822. Unconventional neurotransmitters, neurodegeneration and Neuroprotection
  2823. DNA damage response and Neuroprotection
  2824. Partial Neuroprotection with low-dose infusion of the α2-adrenergic receptor agonist clonidine after severe hypoxia in preterm fetal sheep
  2825. Estrogen receptor-mediated Neuroprotection : The role of the Alzheimer’s disease-related gene seladin-1
  2826. Can overexpression of parkin provide a novel strategy for Neuroprotection in Parkinson’s disease?
  2827. Cannabinoids, multiple sclerosis and Neuroprotection
  2828. Activity of adenosine receptors type 1 is required for CX3CL1-mediated Neuroprotection and neuromodulation in hippocampal neurons
  2829. Estrogen receptor-independent Neuroprotection via protein phosphatase preservation and attenuation of persistent extracellular signal-regulated kinase 1/2 activation
  2830. Neuroplasticity and Neuroprotection in enteric neurons: role of epithelial cells
  2831. How to study Neuroprotection ?
  2832. A pivotal role for interleukin-4 in atorvastatin-associated Neuroprotection in rat brain
  2833. Induced Neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin
  2834. Oxygen-conserving implications of the trigemino-cardiac reflex in the brain : the molecular basis of Neuroprotection ?
  2835. Multiple molecular pathways are involved in the Neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo
  2836. Neuroprotection of soyabean isoflavone co-administration with folic acid against β-amyloid 1-40-induced neurotoxicity in rats
  2837. Neuroprotection by rasagiline in thiamine deficient rats
  2838. Withdrawal of fenofibrate treatment partially abrogates preventive Neuroprotection in stroke via loss of vascular protection
  2839. Neuroprotection against excitotoxic brain injury in mice after ovarian steroid depletion
  2840. Neuroprotection : still achievable in humans
  2841. Microglial inhibition of Neuroprotection by antagonists of the EP1 prostaglandin E2 receptor
  2842. Neuroprotection and enhancement of spatial memory by herbal mixture HT008-1 in rat global brain ischemia model
  2843. New avenue of research: antiepileptic drug and estradiol Neuroprotection in epilepsy
  2844. Morphine: axon regeneration, Neuroprotection , neurotoxicity, tolerance, and neuropathic pain
  2845. Inhibition of PKCgamma membrane translocation mediated morphine preconditioning-induced Neuroprotection against oxygen–glucose deprivation in the …
  2846. The Neuroprotection of prodromal transient ischaemic attack on cerebral infarction
  2847. Mechanisms of DJ‐1 Neuroprotection in a cellular model of Parkinson’s disease
  2848. … oxygen-glucose deprivation: the role of adenosine triphosphate dependent potassium channels and reactive oxygen species in sevoflurane-induced Neuroprotection
  2849. Sodium channel blockers and Neuroprotection in multiple sclerosis using lamotrigine
  2850. Clearing the brain ‘s cobwebs: the role of autophagy in Neuroprotection
  2851. Endothelial nitric oxide synthase overexpression by neuronal cells in neurodegeneration: a link between inflammation and Neuroprotection
  2852. Therapeutic potential of statins in multiple sclerosis: immune modulation, Neuroprotection and neurorepair
  2853. Sirtuin 1 overexpression mice show a reference memory deficit, but not Neuroprotection
  2854. Strategies for Neuroprotection following spinal cord injury.
  2855. Microglial involvement in Neuroprotection following experimental traumatic brain injury in heat-acclimated mice
  2856. Prevention of glutamate accumulation and upregulation of phospho‐akt may account for Neuroprotection afforded by bergamot essential oil against brain injury …
  2857. Neuroprotection and enhancement of remyelination by estradiol and dexamethasone in cocultures of rat DRG neurons and Schwann cells
  2858. Antenatal magnesium sulfate for Neuroprotection before preterm birth?
  2859. PRO: Temperature regimens and Neuroprotection during cardiopulmonary bypass: does rewarming rate matter?
  2860. Linkage between immunomodulation, Neuroprotection and neurogenesis
  2861. Neuroprotection of hypothermia against neuronal death in rat hippocampus through inhibiting the increased assembly of GluR6‐PSD95‐MLK3 signaling module …
  2862. High-dose propofol triggers short-term Neuroprotection and long-term neurodegeneration in primary neuronal cultures from rat embryos
  2863. Inhaled nitric oxide and Neuroprotection in preterm infants
  2864. Interleukin-6 upregulates neuronal adenosine A 1 receptors: implications for neuromodulation and Neuroprotection
  2865. PHYTOMEDICINES FOR Neuroprotection
  2866. Patents related to therapeutic activation of KATP and K2P potassium channels for Neuroprotection : ischemic/hypoxic/anoxic injury and general anesthetics
  2867. Neuroprotection in Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical findings
  2868. Study of red wine Neuroprotection on astrocytes
  2869. Neuroprotection by c-Jun NH2-terminal kinase inhibitor SP600125 against potassium deprivation–induced apoptosis involves the Akt pathway and inhibition of cell …
  2870. Neuroprotection after status epilepticus by targeting protein interactions with postsynaptic density protein 95
  2871. Pharmacology of Neuroprotection in acute ischemic stroke
  2872. The endocannabinoid anandamide: from immunomodulation to Neuroprotection . Implications for multiple sclerosis
  2873. Patterned Neuroprotection in the Inpp4awbl mutant mouse cerebellum correlates with the expression of Eaat4
  2874. Neuroprotection in diabetic encephalopathy
  2875. Repeated exposure to MDMA provides Neuroprotection against subsequent MDMA-induced serotonin depletion in brain
  2876. Effects of simvastatin on Neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington’s disease
  2877. Xenon/hypothermia Neuroprotection regimes in spontaneously breathing neonatal rats after hypoxic-ischemic insult: the respiratory and sedative effects
  2878. Lack of Neuroprotection with pharmacological pretreatment in a paradigm for anticipated spinal cord lesions
  2879. Cyclo-oxygenase-2 mediates hyperbaric oxygen preconditioning-induced Neuroprotection in the mouse model of surgical brain injury
  2880. The continued promise of Neuroprotection for acute stroke treatment
  2881. CON: Temperature regimens and Neuroprotection during cardiopulmonary bypass: does rewarming rate matter?
  2882. Glaucoma: an open-window to neurodegeneration and Neuroprotection
  2883. Redox activated MAP kinase death signaling cascade initiated by ASK1 is not activated in female mice following MPTP: novel mechanism of Neuroprotection
  2884. Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances Neuroprotection from moderate but not severe hypoxia–ischemia
  2885. Hypoxia‐induced deactivation of NGF‐mediated ERK1/2 signaling in hippocampal cells: Neuroprotection by acetyl‐L‐carnitine
  2886. Estrogens and Neuroprotection in retinal diseases
  2887. Acute Neuroprotection to pilocarpine-induced seizures is not sustained after traumatic brain injury in the developing rat
  2888. Neuron‐microglia crosstalk up‐regulates neuronal FGF‐2 expression which mediates Neuroprotection against excitotoxicity via JNK1/2
  2889. Neuroprotection of preconditioning against ischemic brain injury in rat hippocampus through inhibition of the assembly of GluR6—PSD95—mixed lineage kinase 3 …
  2890. … advanced glycation end products‐inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and Neuroprotection by UK‐14,304
  2891. Estrogen receptors increased expression during hippocampal Neuroprotection in lactating rats
  2892. Nicotine attenuates iNOS expression and contributes to Neuroprotection in a compressive model of spinal cord injury
  2893. Additive Neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson’s model
  2894. Role of prions in Neuroprotection and neurodegeneration: a mechanism involving glutamate receptors?
  2895. Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the Neuroprotection after embolic stroke
  2896. New possibilities of Neuroprotection in the treatment of ischemic stroke
  2897. … -ekki-to combined with interferon-gamma moderately enhances daily activity of chronic fatigue syndrome mice by increasing NK cell activity, but not Neuroprotection
  2898. Neuroprotection Against Transient Focal Cerebral Ischemia and Oxygen–Glucose Deprivation by Interference with GluR6-PSD95 Protein Interaction
  2899. Hypothermia-induced increase in galanin concentrations and ischemic Neuroprotection in the rat brain
  2900. Neuroprotection in infant heart surgery
  2901. Effect of endoplasmic reticulum stress in VEGF-induced Neuroprotection
  2902. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced Neuroprotection of the injured nigrostriatal system in the murine …
  2903. Glaucoma as a neuropathy amenable to Neuroprotection and immune manipulation
  2904. Fibroblast growth factor 9 prevents MPP+‐induced death of dopaminergic neurons and is involved in melatonin Neuroprotection in vivo and in vitro
  2905. Estrogen receptor alpha inhibits the estrogen-mediated suppression of HIV transcription in astrocytes: implications for estrogen Neuroprotection in HIV dementia
  2906. Optimal dose of aprotinin for Neuroprotection and renal function in a piglet survival model
  2907. Huperzine A provides Neuroprotection against several cell death inducers using in vitro model systems of motor neuron cell death
  2908. Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and Neuroprotection
  2909. Granulocyte-colony stimulating factor is involved in low-dose LPS-induced Neuroprotection
  2910. … mouse striatum and its modulation in 1-methyl 4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson’s disease phenotype and nicotine-mediated Neuroprotection
  2911. Neuroprotection with delayed calpain inhibition after transient forebrain ischemia
  2912. Activation of NF-κB p65/c-Rel dimer is associated with Neuroprotection elicited by mGlu5 receptor agonists against MPP+ toxicity in SK-N-SH cells
  2913. Neuroprotection in glaucoma using calpain-1 inhibitors: regional differences in calpain-1 activity in the trabecular meshwork, optic nerve and implications for …
  2914. Neuroprotection of ethanol against cerebral ischemia/reperfusion induced brain injury through GABA receptor activation
  2915. Cyclic adenosine monophosphate response element-binding protein phosphorylation and Neuroprotection by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP)
  2916. Use of induced hypothermia for Neuroprotection : indications and application
  2917. Neuroprotection by herbal formula FBD and its active compounds
  2918. Neuroprotection and neurotrophism effects of liquiritin on primary cultured hippocampal cells
  2919. Basal ganglia Neuroprotection with anticonvulsants after energy stress: a comparative study
  2920. Regulation of interleukin-1β by the interleukin-1 receptor antagonist in the glutamate-injured spinal cord: endogenous Neuroprotection
  2921. It’s all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke Neuroprotection
  2922. Magnesium sulfate for Neuroprotection : what do we do now?
  2923. Bis (7)-tacrine, a promising anti-Alzheimer’s dimer, affords dose-and time-dependent Neuroprotection against transient focal cerebral ischemia
  2924. Quantitative evaluation of chaperone activity and Neuroprotection by different preparations of a cell-penetrating Hsp70
  2925. Combinatorial-approached Neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is …
  2926. Potential of choroid plexus epithelial cell grafts for Neuroprotection in Huntington’s disease: what remains before considering clinical trials
  2927. Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated Neuroprotection
  2928. Use of endovascular clamping as Neuroprotection during carotid stenting in the presence of a critical ipsilateral stenosis of the external carotid artery.
  2929. Neuroprotection and enhanced neurogenesis by extract from the tropical plant Knema laurina after inflammatory damage in living brain tissue
  2930. Aprotinin confers Neuroprotection by reducing excitotoxic cell death
  2931. Sirt1’s complex roles in Neuroprotection
  2932. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic Neuroprotection
  2933. NMDA preconditioning and Neuroprotection in vivo: delayed onset of kainic acid-induced neurodegeneration and c-Fos attenuation in CA3a neurons
  2934. … a novel anilidoquinoline derivative, 2-(2-methyl-quinoline-4ylamino)-N-(2-chlorophenyl)-acetamide, in Japanese encephalitis: correlation with in vitro Neuroprotection
  2935. Activation of the extracellular signal‐regulated kinases 1 and 2 by glial cell line‐derived neurotrophic factor and its relation to Neuroprotection in a mouse model of …
  2936. Co-application of ischemic preconditioning and postconditioning provides additive Neuroprotection against spinal cord ischemia in rabbits
  2937. Neonatal hypertonia: II. Differential diagnosis and proposed Neuroprotection
  2938. Sulfhydryl oxidation: A potential strategy to achieve Neuroprotection during severe hypoxia?
  2939. PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] confers MAO-B independent Neuroprotection in ER stress-induced cell death
  2940. Neuroprotection by neurotrophic factors and membrane depolarization is regulated by calmodulin kinase IV
  2941. Implication of pituitary adenylate cyclase-activating polypeptide (PACAP) for Neuroprotection of nicotinic acetylcholine receptor signaling in PC12 cells
  2942. Neurolological disorders and Neuroprotection after heart surgery
  2943. Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats: Relations to administration time and doses
  2944. Ischemic postconditioning induces Neuroprotection via up-regulation of endogenous antioxidant enzyme activities: experiment with rabbits
  2945. Moderate alcohol consumption, apolipoprotein E, and Neuroprotection
  2946. Acetaminophen confers Neuroprotection during early cerebral ischemia-reperfusion
  2947. A secretory phospholipase A 2-mediated Neuroprotection and anti-apoptosis
  2948. Sevoflurane preconditioning induced delayed Neuroprotection against focal cerebral ischemia in rats
  2949. Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not Neuroprotection
  2950. Delayed administration of a potent cyclin dependent kinase and glycogen synthase kinase 3 β inhibitor produces long-term Neuroprotection in a hypoxia-ischemia …
  2951. … inducer of cellular glutathione and NAD (P) H: quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic Neuroprotection
  2952. Melatonin and its therapeutic potential in Neuroprotection
  2953. Flow reversal for proximal Neuroprotection during endovascular management of critical symptomatic carotid artery stenosis coexisting with ipsilateral external carotid …
  2954. HIF‐1 alpha is an essential effector for purine nucleoside‐mediated Neuroprotection against hypoxia in PC12 cells and primary cerebellar granule neurons
  2955. … strychnine-sensitive glycine receptors modulate N-methyl-d-aspartate–evoked acetylcholine release from rat spinal motoneurons: A possible role in Neuroprotection
  2956. Targeting β2-adrenoceptors for Neuroprotection after cerebral ischemia: is inhibition or stimulation best?
  2957. 5th Annual Global College of Neuroprotection and Neuroregeneration
  2958. Neuroprotection against staurosporine by metalloporphyrins independent of antioxidant capability
  2959. … of some urea and thiourea derivatives of naphtha [1, 2-d] thiazol-2-amine as anti-Parkinsonian agents that cause Neuroprotection against haloperidol-induced …
  2960. Anesthetic drugs and sustained Neuroprotection in acute cerebral ischemia: can we alter clinical outcomes?
  2961. Neuroprotection of microglia conditioned media from apoptotic death induced by staurosporine and glutamate in cultures of rat cerebellar granule cells
  2962. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and Neuroprotection
  2963. The impact of astrocyte mitochondrial metabolism on Neuroprotection during aging
  2964. Hsp70 and Neuroprotection [J]
  2965. Does postmenopausal estrogen use confer Neuroprotection ?
  2966. Research progress of protein kinase C in Neuroprotection
  2967. Nitrous oxide: From neurotoxicity to Neuroprotection ?
  2968. p42/44 MAPK is an essential effector for purine nucleoside-mediated Neuroprotection of hypoxic PC12 cells and primary cerebellar granule neurons
  2969. Effective delivery of Pep-1-cargo protein into ischemic neurons and long-term Neuroprotection of Pep-1-SOD1 against ischemic injury in the gerbil hippocampus
  2970. Neuroprotection in stroke.
  2971. Neuroprotection in Parkinson’s disease: analysis though group of experts’ methodology
  2972. Current trends in glaucoma: what about Neuroprotection ?
  2973. Anesthetic-induced Neuroprotection : a review
  2974. LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring Neuroprotection in experimental focal cerebral ischemia in the rat
  2975. Modulation of innate immunity by copolymer‐1 leads to Neuroprotection in murine HIV‐1 encephalitis
  2976. Neuroprotection for Parkinson’s disease: clinically driven experimental design in non-human primates
  2977. 6th Global College of Neuroprotection and Neuroregeneration, annual meeting
  2978. Management of acute stroke: Neuroprotection
  2979. Advancement of therapies for Neuroprotection in multiple sclerosis
  2980. Neuroprotection from diazinon-induced toxicity in differentiating murine N2a neuroblastoma cells
  2981. Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: common pleiotropic effects in reno-, cardio-and Neuroprotection
  2982. Exploratory analysis about Neuroprotection after ischemic stroke.
  2983. La Neuroprotection est-elle à portée de main?
  2984. Neuroprotection : is it close to us?
  2985. Surgical strategies for Neuroprotection during ascending aortic and arch surgery
  2986. Sustained delivery of NT‐3 from lens fiber cells in transgenic mice reveals specificity of Neuroprotection in retinal degenerations
  2987. Perioperative strategy of Neuroprotection
  2988. Glaucoma Neuroprotection –how far is it from a dream to reality
  2989. Preconditioning with+ Gz acceleration (head-to-foot inertial load) produces Neuroprotection against transient focal cerebral ischemia in rats
  2990. Neuroprotection by tosyl-polyamine derivatives through the inhibition of ionotropic glutamate receptors
  2991. Antioxidant therapy and Neuroprotection in the newborn
  2992. Neuroprotection of antipsychotic olanzapine [J]
  2993. Perinatal brain damage: from pathogenesis to Neuroprotection
  2994. Neuroprotection of venlafaxine and fluoxetine [J]
  2995. Cannabinoids and Neuroprotection
  2996. Selective over expression of EAAT2 in astrocytes enhances Neuroprotection from moderate but not severe hypoxia-ischemia
  2997. Neuroprotection against ischemic brain injury by knockdown of hematopietic progenitor kinase 1 expression
  2998. The Neuroprotection of kappa opioid receptor agonist BRL52537 is partly through enhancing endogenous GABA function
  2999. Neuroprotection in Glaucoma
  3000. Endogenous Neuroprotection
  3001. Targeting immunophilins for Neuroprotection
  3002. brain damage from soman-induced seizures is greatly exacerbated by dimethyl sulfoxide (DMSO): Modest Neuroprotection by 2-aminoethyl diphenylborinate (2-APB) …
  3003. Neuroprotection in epilepsy: the role of antiepileptic drugs
  3004. The role of Neuroprotection in schizophrenia
  3005. Potential mechanisms of Neuroprotection induced by low dose total-body γ-irradiation in C57 mice administered with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine …
  3006. Neuroprotection with hypothermia for hypoxic ischemic encephalopathy in term newborn: review of the learning
  3007. Kynurenines and Neuroprotection
  3008. Neuroprotection , Neuronal Remodelling, and Anxiety-Like Behavior: The Role of the Teneurin and Teneurin C-Terminal Associated Peptide (TCAP) System in the …
  3009. Neuroprotection using hypothermia after perinatal asphyxia in full-term neonates
  3010. Antioxidants: promising Neuroprotection against cardiotoxin-4b-induced cell death which triggers oxidative stress with early calpain activation
  3011. 11 Adenosine Neuromodulation and Neuroprotection
  3012. Neurodegeneration and Neuroprotection in the epileptic brain
  3013. The future of Neuroprotection in glaucoma therapeutics
  3014. Effect of VEGF-B on Neuroprotection in mouse retinal ganglion cells
  3015. Neuronal and astrocytic mitochondrial dynamics as vulnerability factors and targets for Neuroprotection
  3016. Neuroprotection of sevoflurane against the ischemia injury in hippocampal slices of rat
  3017. Neuroprotection : Pharmacological Approaches
  3018. Neuroprotection of phenolic alkaloids from Menispermum dauricum versus melatonin against oxygen-glucose-serum-deprivation-mediated injury*☆
  3019. Ocular delivery of TUDCA provides Neuroprotection in a mouse model of retinal degeneration
  3020. Neuroprotection against surgically induced brain injury
  3021. Neuroprotection of GST, an extract of traditional Chinese herb, against ischemic brain injury induced by transient brain ischemia and reperfusion in rat hippocampus
  3022. Neuroprotection of recombinant human erythropoietin via modulation of N-methyl-D-aspartate receptors in neonatal rats with hypoxic-ischemic brain injury
  3023. Diagnosis and treatment strategy for Neuroprotection with combined tcm and western medicine in the early stage of Parkinson’s disease
  3024. Lewy body formation in Parkinson’s disease: neurodegeneration or Neuroprotection ?
  3025. Neuroprotection Against Neurodegenerative Diseases: Development of a Novel Hybrid Neuroprotective Peptide Colivelin
  3026. Neurodegeneration and Neuroprotection in multiple sclerosis
  3027. α-Synuclein, CSPα, SNAREs and Neuroprotection in vivo
  3028. Experimental studies on hypoxic preconditioning-induced Neuroprotection against focal ischemic injury of mice and its p38 MAPK mechanism
  3029. Neuroprotection by angiotensin receptor blockers?
  3030. Neuroprotection –DO AEDS PROTECT THE brain ?(NO)
  3031. Intraoperative neuromonitoring, Neuroprotection and preventive carotid endarterectomy in patients with increased risk for development of cerebral ischemia indicated …
  3032. D. Neuroprotection in the PICU
  3033. Preclinical versus clinical Neuroprotection
  3034. Antenatal Magnesium Sulfate for Neuroprotection Before Preterm Birth?
  3035. Deprenyl and its metabolites in Neuroprotection
  3036. Akt activation mediates estrogen-induced Neuroprotection against beta amyloid
  3037. Valproic acid-mediated Neuroprotection and neuroregeneration in optic nerve injury is associated with CREB-induction and activation of pERK1/2
  3038. IGF-I and Neuroprotection
  3039. Advantages of MRI study of normobaric hyperoxia therapy in stroke Neuroprotection
  3040. The Underlying Mechanism (s) of Fasting Induced Neuroprotection After Moderate Traumatic brain Injury
  3041. The time‐dependency of post‐conditioning for Neuroprotection against global cerebral ischemia and reperfusion injury in C57BL/6 mice
  3042. Application of induced hypothermia for Neuroprotection after cardiac arrest: a systematic review
  3043. Neuroprotection of Extraction of Gastrodia Elata for Status Epilepticus Induced by Li-Pilocarpin
  3044. Neuroprotection and Glaucoma.
  3045. Experimental Study of Different Perfusion Methods and Neuroprotection during Deep Hypothermic Circulatory Arrest [J]
  3046. The PERG as a Useful Tool in Demonstrating Functional Neuroprotection in the Mouse
  3047. Neuroprotection in spinal cord injury
  3048. Molecular mechanisms of Neuroprotection in the anoxia tolerant freshwater turtle
  3049. A Model of Sporadic Parkinson’s Disease: Herbicide Induced Parkinson’s Disease in Rat and Neuroprotection by Water Soluble CoQ10
  3050. Non-Amyloid Approaches to Neuroprotection
  3051. CRMP-2 were involved in hypoxic preconditioning-induced Neuroprotection against cerebral ischemic injuries of mice
  3052. Neuroprotection Effect of Aspirin on Neuron Apoptosis Following Chronic Spinal Cord Compressive Injury in Rats [J]
  3053. Neuroprotection against hyperhomocysteinemia-induced selective oxidative stress in brain regions of rats with folic acid or Dioscorea alata supplementation.
  3054. Abstract P28: Early Antioxidant Treatment Does Not Provide Additive Neuroprotection with Delayed Hypothermia after Asphyxic Cardiac Arrest in Newborn Pigs
  3055. … MOLECULAR CHAPERONE HSP90 IN THE HIPPOCAMPAL CA1 NEURONS―A POSSIBLE MECHANISM OF Neuroprotection BY ANGIOTENSIN RECEPTOR …
  3056. Neuroprotection Effect of Fufang Shexiang Injection in Neonates with Hypoxic Ischemic Encephalopathy
  3057. Neuroprotection of Lidocaine by Injecting into Cisterna Magna in a Rabbit Model of Subarachnoid Hemorrhage [J]
  3058. Strategies for ischemic Neuroprotection : learning from mice
  3059. Neuroprotection by DJNKI1 following seizure activity.
  3060. Clinical Neuroprotection and secondary neuronal injury mechanisms
  3061. Downstream signaling of reactive oxygen species, protein kinase C epsilon translocation and delayed Neuroprotection in sevoflurane preconditioned rats following …
  3062. Neuroprotection via activation of glutamate dehydrogenase against cerebral ischemia and reperfusion
  3063. Neuroprotection Against Ischemia-Reperfusion Injury in the Rat Retina by Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Type 1 Receptor Blocker
  3064. Identification of protein markers of Neuroprotection from radiation